The role of extracellular human immunodeficiency virus type 1 viral protein R in neuropathogenesis by Ferrucci, Adriano
 
 
 
The role of extracellular human immunodeficiency virus 
type 1 viral protein R in neuropathogenesis  
 
A Thesis 
Submitted to the Faculty 
of School of Biomedical Engineering, 
Science and Health Systems 
Drexel Universiy 
by  
Adriano Ferrucci 
In partial fulfillment of the 
requirements for the degree 
of 
Doctor of Philosophy 
June 2011 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright 2011 
Adriano Ferrucci. All Rights Reserved. 
iii 
 
 
 
 
DEDICATION 
 
 
 
To my Family 
 
 
iv 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
 
I would like to thank my Pygmalion, Dr. Brian Wigdahl for his guidance 
and support, who had the courage to take me on board and convert a “street 
flower-seller” into a more educated and respectable person.  I sincerely 
appreciate my other thesis committee members, Dr. Fred Allen, Dr. Peter Lelkes, 
Dr. Elizabeth Papazoglou, and last but not least Dr. Olimpia Meucci, for their 
support and invaluable advice.  I would like to thank professors of the 
Department of Microbiology and Immunology (who have adopted me) for their 
kindness and helpful advice; in particular Drs. Simon Cocklin, Laura Steel, Peter 
Katsikis, Fred Krebs, Julio Martin-Garcia, Sonia Navas-Martin, Pooja Jain, Zafar 
Kahn, Michael Nonnemacher and Vanessa Pirrone. 
A special thanks to those people who shared either their graduate school 
experience or their space, including past members of the lab; in particular 
Anupam Banerjee (now Dr. Banerjee), Bryan Irish (when will he be Dr. irish?), 
John Pitcher, Viraj Sanghvi (now Dr. Sanghvi), Saifur Rahman (now Dr. 
Rahman), Katerina Alexaki (now Dr. Alexaki), Yujie Liu (now Dr. Liu), Kenneth 
Thompson and Betty Condran. 
I truly appreciate throughout this interminable marathon the love and 
support of my family: my parents and my sister, who never abandoned me 
although an ocean was dividing us, and my grandparents also my greatest 
v 
 
 
 
supporters. A personal acknowledgment goes to all my friends close and far, who 
have been close or closer to me throughout these years: all my friends in Italy 
(Matteo, Pedro, Leo, Sandro, Matteo, Andrea, Venish, Ale) who have contributed 
to re-make me feel at home in every trip back to the crib. All those friends in the 
city of brotherly love who have positively contributed outside the lab to maintain a 
mens sana in corpore sano: Ramy, Frederico, Hasim, Thiago, Mohammed, 
Yousef, Ahmed, Anupam, Ramin, Jaad, Angel, Jose, Maometto, Zack, Viraj, Saif, 
All Khanzira, Herb, Giuseppe, all the volley-ballers and Joga Bonito footballers in 
the legendary evergreen Buckley Field. 
A special mention and my heartfelt thanks to the following people (not in 
order of importance): Dr. Olimpia Meucci with her helpful and almost motherly 
suggestions to my work, as well as her presence in those harsh and difficult 
moments; Dr. Simon Cocklin, a priceless help in science-related and non topics; 
Dr. Laura Steel, and Dr. Anupam Banerjee, a friend inside and outside the lab. 
I truly acknowledge the value of all those people who did not believe in me 
for the entire or part of my long journey in my thesis project as they made me 
much stronger and more mature: there is no hurdle that may not be overcome! 
I’d like to thank all the people I asked advice to on the 10th and 11th floor in 
the New College Building, whose names I might have clearly forgotten, but not 
their faces and whoever will read this page knowing that his/her name should 
have been acknowledged but have not … sometimes this is what aging does, but 
you were definitely in my thoughts! 
vi 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES .................................................................................................xi 
LIST OF FIGURES ..............................................................................................xii 
LIST OF ABBREVIATIONS .................................................................................xv 
ABSTRACT ....................................................................................................... xxii 
Chapter I: Human immunodeficiency virus viral protein R as an extracellular 
protein in neuropathogenesis ................................................................................ 1 
 1.1. Abstract .............................................................................................. 2 
 1.2. Introduction.......................................................................................... 3 
 1.3. Extracellular Vpr: active secretion or nonspecific release? ................. 8 
 1.4. Extracellular presence of other HIV-1 proteins.................................. 13 
 1.5. Source of extracellular Vpr in the brain ............................................. 14 
 1.6. Impact of extracellular Vpr on cells in the periphery.......................... 20 
 1.7. Effects of extracellular Vpr on neurons.............................................. 27 
 1.8. Effects of extracellular Vpr on astrocytes .......................................... 35 
 1.9. Conclusions ....................................................................................... 39 
 1.10. List of References............................................................................ 43 
Chapter II: Materials and Methods ..................................................................... 56 
 2.1. Materials ............................................................................................ 57 
 2.2. Cell lines and primary astrocytes maintenance................................. 58 
 2.3. Plasmid construction and site-directed mutagenesis ........................ 59 
 2.4. Western immunoblot hybridization .................................................... 62 
vii 
 
 
 
 2.5. Transient transfection and preparation of conditioned media............ 64 
 2.6. ATP and Glutathione assays ............................................................. 66 
 2.7. Purification of recombinant Vpr ......................................................... 68 
 2.8. Immunofluorescent and deconvolution microscopy........................... 69 
 2.9. Caspase detection assay .................................................................. 71 
 2.10. Human cytokine array...................................................................... 72 
 2.11. Isolation of RNA and qRT-PCR microarray ..................................... 72 
 2.12. GAPDH activity assay ..................................................................... 74 
 2.13. Statistical analysis ........................................................................... 74 
 2.14. List of References............................................................................ 75 
Chapter III: Extracellular HIV-1 Vpr affects metabolism of an astrocytic cell line by 
reducing ATP and GSH levels and compromising the antioxidant reservoir....... 76 
 3.1. Abstract ............................................................................................ 77 
 3.2. Introduction........................................................................................ 78 
 3.3. Results ............................................................................................ 87 
  3.3.1. Detection of HIV-1 Vpr as an extracellular protein............... 87 
  3.3.2. U-87 MG astroglioma cells express the GFAP marker........ 91 
  3.3.3. Determining extracellular HIV-1 Vpr-induced effects on  
   astroglioma metabolism...................................................... 94 
  3.3.4. Replenishment of ATP and GSH pool level by treatment with 
   anti-HA antibody ................................................................. 98 
   
viii 
 
 
 
  3.3.5. Determining the presence of the cystine/glutamate antiporter 
   system in U-87 MG astroglioma cells ............................... 101 
  3.3.6. Determining NAC effects with respect to extracellular Vpr- 
   induced oxidative stress.................................................... 105 
  3.3.7. Effects of recombinant HIV-1 Vpr on astrocytic 
   metabolism........................................................................ 111 
  3.3.8. Extracellular Vpr alters astrocytic GSH/GSSG balance..... 116 
  3.3.9. Effects of extracellular Vpr on ROS production ................. 119 
 3.4. Discussion ....................................................................................... 122 
 3.5. List of References............................................................................ 126 
Chapter IV: Extracellular human immunodeficiency virus Vpr effects on the 
oxidative stress pathway in primary human astrocytes ..................................... 132 
 4.1. Abstract .......................................................................................... 133 
 4.2. Introduction...................................................................................... 135 
 4.3. Results .......................................................................................... 140 
4.3.1. Primary human fetal astrocytes lose the GFAP marker after 
in vitro passages ............................................................... 140 
  4.3.2. Kinetics of extracellular Vpr-induced ATP and GSH 
   declines............................................................................. 143 
  4.3.3. Induction of oxidative stress by extracellular Vpr............... 146 
  4.3.4. Secretion of cytokines in extracellular Vpr-treated 
   astrocytes.......................................................................... 156 
ix 
 
 
 
  4.3.5. Extracellular Vpr impairs the glycolytic pathway............... 159 
  4.3.6 Extracellular Vpr activates caspases 3 and 7 ................... 166 
 4.4. Discussion and Conclusions............................................................ 170 
 4.5. List of References............................................................................ 177 
Chapter V: General Discussion ......................................................................... 186 
5.1. Results I: Extracellular Vpr induces declines in both ATP and GSH in 
both an astrocytic cell line (U-87 MG) and in primary human fetal 
astrocytes (HFA), along with increased intracellular accumulation of 
reactive oxygen species (ROS) and oxidized glutathione (GSSG), 
which shifts the balance towards lower GSH/GSSG ratios ............. 187 
 5.2. Conclusions I ................................................................................... 189 
5.3. Results II: Extracellular Vpr effects on decreases ATP and GSH pools 
are not directly correlated and are driven by impairment of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity, thus 
affecting glycolysis and ATP production, ultimately leading to 
caspase-dependent apoptosis......................................................... 190 
 5.4. Conclusions II .................................................................................. 191 
5.5. Results III: The effects of astrocyte exposure to exogenous Vpr 
reverberate on increased induction of the oxidative stress pathway, 
along with altered secretion of pro-inflammatory cytokines and 
chemoattractants ............................................................................. 192 
 5.6. Conclusions III ................................................................................. 193 
x 
 
 
 
 5.7. Additional discussion concerning the dissertation research ............ 193 
 5.8. Modeling HIV-1 Vpr-induced events leading to progression of 
neurologic disease in late-stage HIV-1-infected patients................. 197 
5.9. Most pressing questions to be addressed ....................................... 208 
5.10. Future studies to address these questions ................................... 211 
5.11. Significance and innovation of this research................................. 213 
5.12. List of References ......................................................................... 216 
VITA ................................................................................................................. 223 
 
 
xi 
 
 
 
 
LIST OF TABLES 
 
 
 
Table 1.1. Effects of extracellular Vpr on cells in the periphery and the CNS..... 41 
Table 4.1. Summary of the genes up- and down-regulated in extracellular Vpr-
exposed human fetal astrocytes........................................................................ 150 
xii 
 
 
 
LIST OF FIGURES 
 
 
 
Figure 1.1. Role of Vpr in the viral life cycle .......................................................... 7 
Figure 1.2. Possible routes of entry of soluble Vpr from the periphery to the 
central nervous system ....................................................................................... 18 
Figure 3.1. Synthesis of the tripeptide glutathione (GSH) from its amino acid 
components is driven by two ATP-dependent reaction …………………………...84 
Figure 3.2. Vpr is expressed in different intra- and extra-cellular 
compartments ..................................................................................................... 90 
Figure 3.3. U-87 MG astrocytic cells express the GFAP marker......................... 93 
Figure 3.4. HIV-1 Vpr-containing conditioned medium induces a decline in ATP 
and GSH levels in U-87 MG cells ....................................................................... 97 
Figure 3.5. Addition of anti-HA antibody to target extracellular 6His-HA Vpr 
rescued U-87 MG astrocytes from decreased ATP and GSH levels................. 100 
Figure 3.6. U-87 MG astroglioma cells possess the cystine/glutamate antiporter 
system............................................................................................................... 104 
Figure 3.7. U-87 MG astroglioma cells possess a functional Xc– system.......... 107 
Figure 3.8. N-acetyl-cysteine (NAC) partially rescued GSH-depleted U-87 MG 
cells ................................................................................................................... 110 
Figure 3.9. GST-6His-HA-Vpr protein was successfully purified from transformed 
Bl21 DE3 RIPL bacteria .................................................................................... 113 
xiii 
 
 
 
Figure 3.10. Extracellular Vpr induced a significant decline in ATP and GSH 
intracellular concentrations................................................................................ 115 
Figure 3.11. Extracellular Vpr impairs astrocytic antioxidant pool levels by 
reducing the GSH/GSSG ratio .......................................................................... 118 
Figure 3.12. Exposure of U-87 MG astrocytic cells to extracellular Vpr induced 
accumulation of reactive oxygen species (ROS)............................................... 121 
Figure 4.1. Primary humand fetal astrocytes (HFA) lose the characteristic GFAP 
intracellular astrocytic marker after three passages in culture .......................... 142 
Figure 4.2. Primary HFA exposed to extracellular Vpr manifest an initial drop in 
ATP levels followed by a decline in GSH concentration.................................... 145 
Figure 4.3. Heat map of the genes differentially expressed in extracellular Vpr-
exposed human fetal astrocytes........................................................................ 148 
Figure 4.4. Immunoblot assay confirmed down-regulation at the protein levels of 
two of the genes in extracellular Vpr-exposed human fetal astrocytes ............. 155 
Figure 4.5. Extracellular Vpr-treated primary HFA display a different pattern of 
cytokine secretion.............................................................................................. 158 
Figure 4.6. Exposure of primary HFA to extracellular Vpr or Vpr R73,80A induces 
irreversible decline of both ATP and GSH metabolites through a pathway that 
does not involve binding to ANT........................................................................ 162 
Figure 4.7. Extracellular Vpr and Vpr R73,80A impair GAPDH activity............. 165 
Figure 4.8. Extracellular Vpr applied to HFA induces activation of caspase-3   
and -7 ................................................................................................................ 169 
xiv 
 
 
 
Figure 5.1. Paradigm of HIV-1 extracellular Vpr action on astrocytes .............. 199 
Figure 5.2. Overall model of HIV-1 extracellular Vpr action on astrocytes........ 204 
Figure 5.3. Exposure to Vpr promotes increased levels of extracellular ATP by 
astrocytes .......................................................................................................... 207 
 
 
 
xv 
 
 
 
LIST OF ABBREVIATIONS 
 
1,3-BPG: 1,3-bisphosphoglycerate 
A: alanine 
Ac-DEVD-CHO: N-acetyl-L-α-aspartyl-L-α-glutamyl-N-(2-carboxyl-1-formylethyl)-
L-valinamide 
AIDS: acquired immunodeficiency syndrome 
ANT: adenine nucleotide translocator 
Apo: apolipoprotein 
Arg: arginine 
ATP: adenosine triphosphate 
BBB: blood–brain barrier 
BMVEC: brain microvascular endothelial cells 
BSA: bovine serum albumin 
BSO: buthionine sulfoximine 
C-: carboxyl- 
CA: capsid 
CaCl2: calcium chloride 
cART: combinatorial antiretroviral therapy 
CCL: chemokine (C-C motif) ligand 
cDNA: complementary DNA 
CFVF: cell-free virus-free 
xvi 
 
 
 
CM: conditioned media 
CMV: cytomegalovirus 
CNS: central nervous system 
CPT: camptothecin 
CSF: cerebrospinal fluid 
Ct: threshold cycle 
CXCR: chemokine receptor 
CYGB: cytoglobin 
Cys: cysteine 
Cys-Gly: cysteinyl-glycine 
Cys2: cystine 
DAPI: 4',6-diamidino-2-phenylindole 
Δψm: mitochondrial membrane potential 
ddH2O: distilled deionized water 
DEVD: aspartate glutamate valine aspartate (tetrapeptide) 
DGKK: diacylglycerol kinase kappa subunit 
DNA: deoxyribonucleic acid 
dNTP: deoxyribonucleotide 
DOX: doxorubicin 
DMEM: Dulbecco’s Modified Eagle’s Medium 
DTT: dithiothreitol 
DUOX: dual oxidase 
xvii 
 
 
 
E–: envelope-deficient 
EDTA: ethylenediaminetetraacetic acid 
ELISA: enzyme-linked immunosorbent assay 
FBS: fetal bovine serum 
Fig.: figure 
G3P: glyceraldehyde 3-phosphate 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase 
GFAP: glial fibrillary acidic protein 
γ-GT: gamma-glutamyl transpeptidase 
Glu: glutamate 
Gly: glycine 
gp120: glycoprotein 120 
GPx: glutathione peroxidase 
GR: glutathione reductase 
GSH: reduced glutathione 
GSSG: oxidized glutathione 
GST: glutathione S-transferase 
HA: haemagglutinin 
HAD: HIV-1-associated dementia 
HBS: HEPES buffered solution 
HEK: human endothelial kidney 
HFA: human fetal astrocytes 
xviii 
 
 
 
HIF: hypoxia-inducible factor 
His: histidine 
HIV-1; human immunodeficiency virus type-1 
HRP: horseradish peroxidase 
IDV: integrated density value 
IL: interleukin 
IP: immuno-precipitation 
IPTG: isopropyl β-D-1-thiogalactopyranoside 
JNK: c-Jun N-terminal kinase 
kDa: kiloDalton 
lac: lactose 
LPS: lipopolysaccharide 
LTR: long terminal repeat 
µg: microgram 
µl: microliter 
MA: matrix 
MAPK: mitogen-activated protein kinase 
MCP-1: monocyte chemoattractant protein 1 
MDMs: monocyte-derived macrophages 
MEN: menadione 
mg: milligram 
MIF: macrophage migratory inhibitory factor 
xix 
 
 
 
ml: milliliter 
mM: millimolar 
MPTP: mitochondrial permeability transition pore 
mRNA: messenger RNA 
MT: metallothionein 
N-: amino- 
NAC: N-acetyl-cysteine 
Nef: negative regulatory factor 
NEM: N-ethylmaleimide 
NETN: NaCl, EDTA, Tris, NP-40 buffer 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 
NIH: National Institute of Health 
NK: natural killer 
nM: nanomolar 
NOS: nitric oxide synthase 
OS: oxidative stress 
NL4-3: plasmid CXCR4 strain (Nathaniel Landau) 
PAI: plasminogen activator inhibitor 
PARP: poly ADP ribose polymerase 
PBMC: peripheral blood mononuclear cells 
PBR: peripheral-type benzodiazepine receptor 
PBS: phosphate buffered saline 
xx 
 
 
 
PCR: polymerase chain reaction 
pg: picogram 
PIC: pre-integration complex 
PKC: protein kinase C 
PMSF: phenylmethylsulfonyl fluoride 
PR: protease 
Pro: proline 
PTPC: permeability transition pore complex 
PVDF: polyvynilidene fluoride 
PXDNL: peroxidasin homolog (Drosophila)-like 
qRT-PCR: quantitative real-time polymerase chain reaction 
R: arginine 
R–: Vpr-deficient 
Rev: regulatory expression of viral protein 
RIPA: radioimmunoprecipitation assay 
RIPL: arginine isoleucine proline leucine 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
RPM: revolution per minute 
RT: reverse transcriptase 
SCARA: scavenger receptor class A 
SDS-PAGE: sodium dodecyl sulphate-polyacrilamide gel electrophoresis 
xxi 
 
 
 
Ser: serine 
Serpin: serine protease inhibitor 
SSC: saline-sodium citrate 
Tat: trans-activator of transcription 
TCA: tricarboxylic cycle 
tGSH: total glutathione 
TLR: Toll-like receptor 
tPA: tissue-plasminogen activator 
trp: triptophan 
VDAC: voltage-dependent anion channel 
Vpr: viral protein regulator 
WB: western blot 
w/v: weight/volume 
 
xxii 
 
 
 
ABSTRACT 
The role of extracellular human immunodeficiency virus type 1 
viral protein R in neuropathogenesis 
 
Adriano Ferrucci 
Brian Wigdahl, PhD 
 
 
 
 
 
Human immunodeficiency virus type 1 (HIV-1), the etiological agent of 
acquired immunodeficiency syndrome (AIDS), is treatable by antiretroviral 
therapy but may not be eradicated due to presence of long-lived cellular 
reservoirs in specific tissues such as the central nervous system (CNS). HIV-1 
enters the CNS early after infection, although the most severe symptoms of 
progressive neurocognitive impairment manifest during late stage disease, 
including inflammatory conditions such as excessive molecular oxidation and 
decreased intracellular glutathione (GSH), the main cellular antioxidant. In the 
context of neuropathogenesis, both directly infected cells as well as inflammatory 
cytokines and secreted viral proteins play a pivotal role in disease progression. 
Among the latter is Vpr, a virion-associated protein, which functions both in post-
xxiii 
 
 
 
entry steps and during the HIV-1 life cycle. Vpr has been detected as a virion-
free protein in the serum and cerebrospinal fluid of HIV-1-infected patients, and 
has the ability to enter cells. This leads to formation of mitochondrial permeability 
transition pores, which affect membrane potential and ATP translocation. 
Additionally, late-stage disease patients manifest increased extracellular Vpr 
levels in the blood. These premises led us to investigate the role of extracellular 
Vpr in inducing oxidative stress and its contribution to disease progression. We 
focused our attention on astrocytes, as the intimate regulators of neuronal fate, 
and found that extracellular Vpr induces declines in ATP and GSH levels, along 
with increased production of reactive oxygen species (ROS) and decreased 
GSH/GSSG ratio. These events are driven by Vpr-induced impairment of 
GAPDH activity and possibly glycolysis. Exposure to Vpr increased secretion of 
IL-6, IL-8, MCP-1 and MIF-1, with possible increased chemotaxis of cells from 
the periphery. Several genes of the oxidative stress pathway were dysregulated 
in response to extracellular Vpr exposure, which may cause a vicious cycle and 
further decrease intracellular GSH levels. In conclusion, we propose a model of 
HIV-1 disease progression wherein increased levels of extracellular Vpr, as 
within the CNS of late-stage HIV-1-infected patients, contribute to impair 
astrocytic functionality and affect the astrocytic-neuronal network, essential for 
brain homeostasis. This dissertation provides new insights to the field with 
respect to the conditions observed in late-stage patients. 
 Chapter I 
 
Human immunodeficiency virus viral protein R as an  
extracellular protein in neuropathogenesis 
 
Adriano Ferrucci, Michael R. Nonnemacher, and Brian Wigdahl 
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1.1 Abstract 
 Numerous studies published in the last two decades have identified the 
viral protein R (Vpr) as one of the most versatile proteins in the life cycle of the 
human immunodeficiency virus type 1 (HIV-1).  In this regard, more than a 
thousand molecules of Vpr are present in extracellular viral particles.  
Subsequent to viral entry, Vpr participates in early replicative events by assisting 
in viral genome nuclear import, and, during the viral life cycle, by shuttling 
between the nucleus and the cytoplasm to accomplish its functions within the 
context of other replicative functions.  Additionally, several studies have 
implicated Vpr as a pro-apoptotic protein, because it promotes formation of 
permeability transition pores in mitochondria, which in turn affect transmembrane 
potential and adenosine triphosphate synthesis. Recent studies have identified 
Vpr as a virion-free protein in the serum and cerebrospinal fluid of patients 
infected with human immunodeficiency virus whose plasma viraemia directly 
correlates with the extracellular concentration of Vpr.  These observations 
pointed to a new role for Vpr as an additional weapon in the HIV arsenal, 
involving the use of an extracellular protein to target and possibly inhibit the 
functionality of bystander cells not infected with human immunodeficiency virus to 
enable them to escape immune surveillance. In addition, extracellular Vpr 
decreases adenosine triphosphate levels and affects the intracellular redox 
balance in neurons, ultimately causing their apoptosis.  In this review chapter we 
discuss the role of Vpr as an extracellular protein and its downstream effects on 
cellular metabolism, functionality, and survival, with particular emphasis on how 
Chapter 1 3 
extracellular Vpr-induced oxidative stress might aggravate HIV-1-induced 
symptoms, thus affecting pathogenesis and disease progression. 
1.2. Introduction 
 From the discovery and early structural and functional studies (Cohen et 
al., 1990a; Cohen et al., 1990b; Ogawa et al., 1989) to the present, the virion-
associated viral regulatory protein, viral protein R (Vpr), has been assigned a 
number of roles throughout the viral life cycle.  Numerous reviews (Ayyavoo et 
al., 1997a; Bukrinsky and Adzhubei, 1999; Majumder et al., 2009; Morellet et al., 
2009; Romani and Engelbrecht, 2009) have elegantly analyzed and summarized 
the body of literature regarding the functional properties of Vpr.  Because Vpr is a 
virion structural protein packaged during viral budding from infected cells (Cohen 
et al., 1990a; Yuan et al., 1990), its journey through numerous intra- and 
extracellular pathways and environments remains of great interest to those 
studying the human immunodeficiency virus (HIV) pathogenic process and 
engaging in the quest to prevent and treat diseases associated with viral 
infection.  In this regard, Vpr is delivered into the newly infected cell along with 
the viral genome and a number of other virion proteins subsequent to fusion of 
the viral envelope with the plasma membrane.  Within this intracellular 
cytoplasmic context, Vpr acts as an early protein by interfacing with the pre-
integration complex (Hrimech et al., 1999), which is composed of the viral 
genome and other viral proteins, to facilitate continued reverse transcription and 
genomic access to the nucleus. In addition to its immediate-early role in the 
cytoplasm, Vpr has also been shown to localize to the nucleus (Di Marzio et al., 
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1995; Lu et al., 1993), where it may function as a transcriptional regulatory 
protein participating in the production of early viral transcripts following 
integration of the proviral genome (Agostini et al., 1996; Felzien et al., 1998; 
Sawaya et al., 2000; Sawaya et al., 1998; Subbramanian et al., 1998; Wang et 
al., 1995).  As a shuttling protein (Sherman et al., 2001), Vpr is also able to exit 
the nucleus to participate in other aspects of the viral life cycle (Sherman et al., 
2003). In this regard, Vpr interacts with the p6 Gag protein product during the 
process of incorporation into newly formed and budding virions (Bachand et al., 
1999; Huang et al., 1995; Kondo et al., 1995; Paxton et al., 1993).  Vpr also 
associates with a number of different cellular proteins, thereby halting the cell 
cycle at the G2-M phase (Chowdhury et al., 2003; He et al., 1995; Mahalingam et 
al., 1998), a function that has been proposed to occur independently of (Ayyavoo 
et al., 1997a; Goh et al., 1998) or as an event leading to apoptosis (Fukumori et 
al., 2000).  The Vpr-induced pro-apoptotic phenotype may also play an important 
role in immune escape (Ayyavoo et al., 1997b).  Indeed, cell cycle arrest 
coincides with the peak of viral transcription (Goh et al., 1998), and Vpr has been 
shown to induce apoptosis of the infected cell. These two events promote 
increased viral production and release, thus facilitating the production of 
infectious extracellular virus, the demise of the infected cell, and evasion from 
immune surveillance. Additionally, within the context of cell cycle arrest and 
apoptosis, Vpr is able to either actively or passively gain access to the 
extracellular compartment, thereby functioning as an extracellular soluble protein 
(Figure 1.1). This role is particularly significant because cell- and virion-free 
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extracellular Vpr causes detrimental effects to uninfected bystander cells.  
Furthermore, patients infected with HIV type 1 (HIV-1) develop antibodies against 
Vpr immunodominant peptides (Herzenberg et al., 1997; Reiss et al., 1990; 
Richardson et al., 2003), which could suggest that Vpr is either recognized in the 
extracellular environment by the immune response of the host or is presented as 
a processed peptide to the immune system within the context of the viral life 
cycle.  Nonetheless, despite more recent evidence concerning the role of Vpr as 
an extracellular protein, its role in the extracellular milieu is not fully understood. 
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Figure 1.1.  Role of Vpr in the viral life cycle. Vpr, located within HIV virions 
(1), enters cells and is released into the cytoplasm when the virion is uncoated 
(2).  After reverse transcription of the viral RNA genome (3), Vpr forms the 
preintegration complex (PIC) (4) along with other viral proteins (primarily 
integrase [IN] and matrix [MA]).   Vpr subsequently facilitates the transport of the 
PIC to the nucleus through the nuclear pore complex (NPC) in the nuclear 
membrane (5). Once the PIC gains access to the nucleus, the reverse 
transcribed HIV proviral DNA serves as a substrate for the viral-encoded 
integrase and is incorporated into cellular chromosomes.  Subsequently, Vpr has 
been shown to act as a transcription factor by binding to the HIV promoter of the 
newly integrated proviral genome as well as to promoters of other cellular genes, 
driving synthesis of both viral and cellular gene transcripts (6).  Due to the 
presence of a nuclear export signal, Vpr can also be exported from the nucleus 
to the cytoplasmic environment (7).  Within the cytoplasm, Vpr interacts with 
cellular proteins (8a) and with the Gag C-terminus protein (p6)/Gag protein (8b), 
thereby being incorporated into nascent virions, which then bud out of the 
surface of the infected cell (9).  During later stages, Vpr functions as a 
nucleocytoplasmic shuttling protein to continue to function within the viral life 
cycle (10) and halts cell cycle progression. This activity is believed to increase 
viral transcription to guarantee a large number of viral RNA genomes in order to 
drive the particle assembly process. Represented in light green and light blue at 
the cell surface are CD4 and CXCR4/CCR5, the receptor and coreceptors, 
respectively. LTR = long terminal repeat; RT = reverse transcriptase.
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Figure 1.1. 
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1.3.  Extracellular Vpr: active secretion or nonspecific release? 
 Although numerous studies over the years have outlined and discussed 
the detrimental effects of Vpr as a virus- and cell-free protein in the extracellular 
milieu, the process of Vpr secretion from specific producer cell populations has 
only recently been investigated (Xiao et al., 2008).  In this study, which 
represents the first evidence of Vpr secretion from cells, the authors evaluated 
the Vpr phenotypes from three different cell types: human endothelial kidney 
(HEK) 293T cells, Jurkat T cells (a proleukocytic cell lineage), and peripheral 
blood mononuclear cells (PBMC).  All of these cell populations were assayed for 
the presence of Vpr in the virus- and cell-free extracellular compartment 2 days 
after transfection, which is thought to be similar to the time required in an infected 
cell for Vpr to be transcribed or translated from the integrated provirus thereby 
modeling acute in vivo viral replication.  In a similar manner, this line of evidence 
has been validated in 293T cells within the context of this thesis study (Chapters 
3 and 4).  However, when the results from these studies are analyzed, a number 
of caveats  require consideration.  First, cells were transfected, not infected, so 
distinctive pathways and proteins could play intracellular roles that would differ 
from those played in infected target cells. Second, because Vpr is known to 
confer a pro-apoptotic phenotype in both infected and transfected cells, the 
secretory process might be the result of excessive cell death, which in turn would 
be responsible for the release of detectable amounts of Vpr into the extracellular 
space.  In addition, secretion was evaluated at about 40 hours post-transfection, 
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which corresponds to the peak of viral particle production; therefore, secretion of 
Vpr could be driven by high concentrations of Vpr in the cytoplasm late in the 
transfection process. Indeed, Vpr is known to shuttle between the nucleus and 
the cytoplasm; thus excessive transcription and translation of intracellular Vpr 
could overload or hijack the secretory (classical or nonclassical) pathway for its 
own use, thereby leading to a “passive nonspecific secretory” process. Because 
Vpr is found in the extracellular environment, its ability to hijack the secretory 
process could represent an additional weapon in the viral arsenal to induce 
detrimental effects during specific stages of disease progression. Furthermore, 
transfection of cells could mimic a scenario of active infection with abundant 
production of virions and proteins as transcription driven by the HIV-1 promoter is 
increased. Because Vpr has been shown to play a role in halting the cell cycle at 
the G2/M phase, a time at which viral production is maximal, it would be 
interesting to define the timing of these events with respect to Vpr secretion.  In 
other words, Vpr-induced arrest at the G2/M phase could facilitate enhanced viral 
production, which in turn could augment Vpr secretion. However, it should be 
emphasized that these studies were performed in HEK 293T cells, which have 
little relevance to the pathogenesis of HIV infection. 
 Previous intracellular fractionation studies (Lu et al., 1993) have also 
identified Vpr in cytosolic as well as plasma membrane fractions derived from 
PBMCs, which suggests that Vpr may function in more than just the nuclear and 
cytosolic compartments.  Vpr may function within cellular membranes or be 
exported to the extracellular environment where it may impact other extracellular 
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signaling pathways or other secondary bystander target cells.  In this regard, the 
kinetics of Vpr secretion have not yet been defined.  This information could have 
great impact on our understanding of the functional properties of Vpr. Relevant to 
these observations, it has been demonstrated that Vpr needs most of the other 
viral proteins in order to be secreted. Recent studies have also shown that Vpr 
was secreted as a dimer (Chapter 3; Zhao et al., 1994), with additional studies 
reevaluating its role in viral pathogenesis (Fritz et al., 2008; Venkatachari et al., 
2010).  Nevertheless, none of the studies published thus far regarding Vpr 
secretion have examined the functional properties of the secreted form of the 
protein. Based on results from studies obtained with immunoprecipitated 
extracellular media performed in immunoblot assays, it is not possible to 
determine whether the secreted Vpr protein is in its native, misfolded, or 
denatured form.  Thus, conclusions concerning the functional properties of 
extracellular Vpr must remain conservative when one evaluates the downstream 
effects of extracellular Vpr on target cells and draws conclusions concerning the 
functional properties of this important virion protein, because no studies have 
actually investigated the structural nature of extracellular Vpr.  Nonetheless, a 
recent report has evaluated the difference between the consequences of native 
and denatured extracellular Vpr on target cells (Sherman et al., 2002).  This 
study concluded that Vpr requires proper folding in order for the extracellular 
protein to cause detrimental effects on secondary target cells.  If one looks 
collectively at the studies concerning how Vpr affects cellular viability, one would 
conclude that, if extracellular Vpr is the cause of the observed effects in the 
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periphery and central nervous system (CNS), then the protein is most likely 
properly folded.  Nevertheless, a well-designed study clearly establishing a direct 
correlation between proper folding of extracellular Vpr and its induction of 
downstream effects on target cells has yet to be performed in a convincing 
manner. 
 The presence of extracellular Vpr in both the serum and cerebrospinal 
fluid (CSF) of HIV-1-infected patients was initially reported by two studies (Levy 
et al., 1994; Levy et al., 1995); the concentration of extracellular Vpr was found to 
increase with disease progression and to augment viral particle release from 
infected PBMCs.  Additionally, latent HIV-1-infected cell lines exposed to 
extracellular Vpr reactivated viral transcription from the latent state and 
subsequently induced the release of newly synthesized infectious viral particles 
(Levy et al., 1995).  Evidence suggesting the secretory nature of Vpr also comes 
from two recent studies (Hoshino et al., 2007; Jones et al., 2007), wherein Vpr 
was found as a free extracellular protein in the serum of patients infected with 
HIV-1. In one of these reports, the concentration of extracellular Vpr in the 
plasma of a number of patients infected with HIV-1 (with different viral loads) was 
estimated by a qualitative immunoblotting assay to be 5-10 ng/ml (Hoshino et al., 
2007).  Although a better and more quantitative assessment is needed, this effort 
represents the first to determine the extracellular Vpr concentration in circulation. 
Furthermore, this study showed the extracellular Vpr concentration in the serum 
to be directly proportional to HIV-1 viral load in the plasma, which validates the 
concept that increased secretion of Vpr occurs in the context of higher viral 
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replication. Consistent with these observations, Vpr has been detected by the 
ELISA assay in the plasma of Vpr transgenic mice at concentrations between 10 
to 22 pg/ml (Balasubramanyam et al., 2007). These data suggest that Vpr is 
released in at least two different host species, which may indicate that the 
cellular processes required for Vpr secretion are conserved across species as a 
result of critical roles they play in cellular physiological processes. Nevertheless, 
in contrast to in vitro studies in HEK 293T (Xiao et al., 2008) wherein Vpr was 
released only when most of the other viral proteins were present (except for the 
envelope and Nef proteins), transgenic mice carrying a Vpr gene driven by a 
cytomegalovirus promoter secreted (or released) Vpr into the extracellular 
medium without the presence of other viral genes. The discovery of extracellular 
Vpr in the plasma of Vpr transgenic mice suggests either that, in mice, Vpr is 
secreted without the aid of any other viral proteins or that the process of Vpr 
secretion is forced by overabundant production of the viral protein that saturates 
the intracellular compartment, thereby resulting in enhanced secretion.  However, 
the concentration of HIV-1 Vpr in the blood of Vpr transgenic mice is lower than 
that in patients infected with HIV-1 by at least two orders of magnitude, which 
could suggest that the presence of other components of the viral genome is 
required for more robust secretion. In another study (Jones et al., 2007), 
extracellular Vpr was detected in a different type of transgenic mice expressing 
Vpr driven by the c-fms (M-CSF receptor) promoter, which drives the expression 
of the Vpr gene only in cells of the monocytoid lineage.  One might conclude that 
peripheral promonocytic cells or CNS microglia, perivascular cells, or 
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parenchymal cells, all of which support transcription from the c-fms promoter, 
may be completely or in part responsible for the observed in vivo release of 
extracellular Vpr.  Despite measurements in the serum of both humans and mice, 
the extracellular concentration of Vpr in the CNS compartment has not yet been 
quantitated (Levy et al., 1994). 
1.4.  Extracellular presence of other HIV-1 proteins 
Other HIV-1 proteins are also secreted or released from either infected or 
transfected cells after exposure to the relative expression plasmids. This could 
either represent an active process that would methodically increase the 
pathogenic potential of the virus leading to spread of infectivity to a wide variety 
of tissues or a passive release from HIV-1-infected cells, which are constitutively 
expressing viral proteins. One of the first proteins found to be secreted was the 
envelope glycoprotein gp120 (Hallenberger et al., 1993), along with the larger 
gp160 protein, especially within the CNS (Kanmogne et al., 2002).  As a secreted 
extracellular protein, gp120 has been shown to stimulate the release of 
neurotoxic factors (Giulian et al., 1993) and impair astrocytic uptake of glutamate 
by reducing expression of its transporter (Vesce et al., 1997; Wang et al., 2003). 
HIV-1 Tat, primarily known as the major transactivator protein of viral gene 
expression, is also secreted from cells.  Indeed, initial studies have shown that 
Tat is secreted both after transfection with a Tat-expressing plasmid and during 
acute infection when viral production is maximal and the rate of cell death is 
minimal (Ensoli et al., 1993), which suggests a mechanism different from cell 
death based on the timing of Tat secretion. Indeed, Tat exploits the secretory 
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pathway to reach the extracellular environment (Chang et al., 1997) due to its 
intracellular shuttling ability (Stauber and Pavlakis, 1998).  As an extracellular 
protein, Tat may be taken up by specific receptor-bearing cells, thus being able 
to promote cell growth and HIV-1 gene expression (Ensoli et al., 1993). In 
addition, not only are T cells (unlike monoblastoid cells) capable of taking up 
extracellular Tat, but the viral transactivator protein is also able to induce 
programmed cell death (Vendeville et al., 2004; Yang et al., 2003). 
HIV-1 Nef, known predominantly for its role in viral replication and 
pathogenesis, has also been shown to be secreted, both by infected and 
transfected cells, into vesicles (Campbell et al., 2008) that may fuse with virions 
or uninfected bystander cells, thereby entering the cellular cytoplasm to cause 
downstream cellular signaling (Macreadie et al., 1998).  Exposure to extracellular 
Nef causes apoptosis in different cell types, especially HIV-1-infected CD4+ T 
cells (James et al., 2004). 
1.5.  Source of extracellular Vpr in the brain 
 The presence of a soluble form of Vpr in the extracellular milieu of patients 
infected with HIV-1 raises several questions: (1) Is Vpr secreted through an 
active classical or nonclassical secretory pathway?  (2) Is extracellular Vpr 
passively released from apoptotic cells(Hanson et al.)(Hanson et al.)(Hanson et 
al.)(Hanson et al.)(Hanson et al.)? (3) Is extracellular Vpr the result of a necrotic 
process involving some HIV-1-infected cells? (4) Do decaying virions contribute 
to seeding Vpr in the extracellular compartment? (5) Does Vpr diffuse out 
nonspecifically as a result of a “slippery process” based on a lack of an 
Chapter 1 15 
interaction with the Gag p6 protein, which is known to be fundamental for 
incorporation of Vpr into budding virions? (6) Could Vpr be transmitted from cell 
to cell through the formation of virological synapses, which have been shown to 
facilitate virus transmission? 
 In general, the detection of Vpr in the extracellular milieu results from 
either active secretion or “passive diffusion” from cells undergoing programmed 
cell death.  Additionally, the detection of Vpr in the plasma and in the CSF of 
patients infected with HIV-1 certainly suggests that Vpr could go through a 
secretory process in the CNS similar to that demonstrated in the peripheral 
circulation.  It is of interest to speculate which cells within the CNS might secrete 
Vpr during the course of HIV disease; likely candidates include infected 
microglia, one of the brain-resident cells most productively infected with HIV-1, 
and perivascular macrophages at the lining of the blood–brain barrier (BBB) 
because they might seed infection directly within the CNS and contribute to the 
release of Vpr during and after brain entry.  In addition, infected cells in the 
process of crossing the BBB are a possible source of Vpr.  Under physiological 
conditions, only a limited number of activated T cells, regardless of their antigen 
specificity, gain access to the CNS during the “immune surveillance” that 
functions to clear foreign pathogens and nonself molecules (Hickey, 1999).  
Under normal conditions, blood-borne monocytes travel to healthy CNS tissues 
in low numbers (Ransohoff, 2003), but, under inflammatory conditions, 
leukocytes, through a process referred to as diapedesis, cross the BBB and 
accumulate in the perivascular area, a hallmark of CNS immune response during 
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the more severe forms of HIV-1-associated neurological disease, reviewed in 
(Williams and Hickey, 1996).  Although other blood-derived cell types might 
migrate to the CNS (B cells, neutrophils, and dendritic cells) under inflammatory 
conditions, the majority of infiltrating cells are monocyte-derived macrophages 
(MDMs) with some infiltration of CD4+ T cells.  Although the former are known to 
extravasate, especially during periods of increased inflammation, infected CD4+ 
T cells are far less prone to cross the BBB, making them a less likely candidate 
for intra-CNS Vpr secretion.  In either case, infected blood-borne cells are likely 
involved in the secretory process.  Moreover, MDMs or CD4+ T cells could also 
be responsible for secretion of other viral proteins including Tat (Chang et al., 
1997; Ensoli et al., 1993) and Nef (Ali et al., 2010; Campbell et al., 2008; Lenassi 
et al., 2010) along with the shedding of the envelope protein gp120 (Hallenberger 
et al., 1993; Hart et al., 1991; Li et al., 1994) and a complex network of 
inflammatory cytokines and chemokines after traversing the BBB.  Among brain-
resident cells, in addition to microglia, astrocytes must also be considered, 
although their loss has not been directly associated with disease progression 
(Figure 1.2). Indeed, recent reports (Churchill et al., 2006; Churchill et al., 2009) 
have re-evaluated the role astrocytes play in neuropathogenesis.  The facts that 
they represent the most abundant cell type within the CNS and are susceptible to 
HIV-1 infection make them a potential source of secreted Vpr with the CNS. 
Although the loss of neurons represents one of the pathological hallmarks of the 
more severe forms of HIV-associated neurocognitive impairment, they are 
refractile to HIV-1 infection and therefore an unlikely source of Vpr in the CNS. 
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Figure 1.2.  Possible routes of entry of soluble Vpr from the periphery to 
the central nervous sytem. Within the periphery, lymphocytes (green) and cells 
of the monocyte-macrophage (blue) lineage are the major cellular carriers of HIV-
1, although the number of infected undifferentiated monocytes is low.  After 
traversing the blood–brain barrier (BBB), monocytes differentiate into short-lived 
monocyte-derived macrophages (MDMs) capable of seeding infection along with 
the Vpr released throughout the CNS.  Lymphocytes are also able to traverse the 
BBB after antigen presentation by local infected perivascular phagocytic cells, 
thus representing a source for Vpr release once activated.  Among brain-resident 
cells, microglial cells (red/maroon) represent the primary susceptible and 
permissive cellular target for HIV-1, possibly capable of releasing/secreting newly 
synthesized Vpr protein on activation in response to the presence of pathogens 
within the CNS. Resting microglia are only capable of supporting low levels of 
viral transcription and are therefore not a main source of Vpr.  Brain 
microvascular endothelial cells (BMVEC) (orange) are also infected by HIV-1 and 
therefore may be responsible for disseminating Vpr into the CNS.  Astrocytes 
(yellow) are the most abundant cells in the CNS; however their frequency of 
infection and level of permissivity is likely lower than cells of the monocyte-
macrophage lineage.  During late stages of HIV-1 disease, the number of HIV-
infected astroglial cells increases, thus seeding infection and participating in Vpr 
release.  Neurons (pink) are thus far not known to be infected by HIV-1. 
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 Another potential source of soluble Vpr within the CNS is represented by 
molecules released in the peripheral lymph nodes or circulation with intra-CNS 
activity achieved after crossing the BBB.  Although this possibility would seem 
less likely on the basis of pharmacological considerations alone, it cannot be 
ruled out. During the course of HIV disease, viral infection has been associated 
with functional and physical alterations in the BBB (Andersson et al., 2001; 
Dallasta et al., 1999; Eugenin et al., 2006; Liu et al., 2002; Wang et al., 2008), 
which compromise its integrity, thereby possibly allowing otherwise impenetrable 
compounds to gain access to the finely controlled CNS environment. 
 Although several researchers have investigated the effects of extracellular 
Vpr on native cell populations within the brain, primarily neurons, we may only 
speculate insofar as the source of Vpr. It is likely that a combination of different 
sources could participate in Vpr release to the extracellular space (whether active 
or passive), which represents one of the several functions accomplished by this 
pleiotropic viral protein. It has also been proposed that soluble virus- and cell-free 
extracellular Vpr could be more active in increasing transcriptional activity than 
endogenously expressed Vpr (Levy et al., 1994).  This hypothesis, if proven in in 
vivo studies, could explain why Vpr has evolved to gain access to the 
extracellular environment. It might represent a trigger to reactivate viral 
expression from latently HIV-1-infected cells (especially cells of the monocytoid 
lineage; (Varin et al., 2005) or from persistently infected cells, such as astrocytes.  
Indeed, several different cell types are susceptible to increased viral production 
when exposed to extracellular Vpr.  Cells acutely infected with HIV-1 show a 
Chapter 1 20 
higher peak in release of viral particles when co-cultured with extracellular Vpr; 
on the other hand, cells chronically infected with HIV-1, which under normal 
conditions show undetectable levels of viral synthesis, display a characteristic 
bell-shaped curve in virion production when exposed to extracellular Vpr (Levy et 
al., 1995). This finding clearly underscores the importance of extracellular Vpr, 
especially in the milieu of chronically infected cells, because it might potentially 
trigger reactivation of viral production. Another important relevant observation is 
the corresponding detection of increased levels of extracellular Vpr with disease 
progression, especially in patients with AIDS (Hoshino et al., 2007), which could 
represent an important component of the pathological process associated with 
viral replication and reactivation during the late stages of disease. 
1.6.  Impact of extracellular Vpr on cells in the periphery 
 Many recent studies have examined the impact of purified recombinant 
preparations of Vpr on different target cell populations to evaluate the 
downstream effects of this viral protein on functional properties and viability.  One 
of the first reports of Vpr as an extracellular protein (Levy et al., 1994) was 
unique in that it demonstrated the ability of this viral accessory protein to 
increase viral replication and viral particle release, thus allowing increased 
production of viral progeny and the spread of infection to other organ systems 
(Levy et al., 1994; Levy et al., 1995; Nakamura et al., 2002; Sherman et al., 
2002).  In addition, one of the first studies to use synthetic Vpr showed that the 
viral protein could be internalized and localized both to the cytoplasm and the 
nucleus (Henklein et al., 2000).  Because endogenously expressed Vpr is known 
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to localize to the nucleus and nuclear envelope (Kamata and Aida, 2000; 
Sherman et al., 2001; Waldhuber et al., 2003), the ability of endocytosed 
extracellular Vpr to display a similar localization pattern might be the result of 
interaction with intracellular protein partners.  Comprehensive reviews of these 
experimental observations have indicated that Vpr localizes to specific 
intracellular organelles (Sherman et al., 2002). However, despite these 
interesting investigations, the phenotype resulting from extracellular Vpr 
transduction is not fully understood.  Neither the process that drives Vpr 
internalization (either by receptor-mediated invagination or receptor-independent 
endocytosis) nor the cause of this event has been investigated, leaving a 
multitude of unresolved questions: (1) Is Vpr actually endocytosed or is it a 
process caused by the excessive presence of Vpr in conditions reproduced in 
vitro? (2) Is Vpr internalized by a receptor-mediated mechanism? (3) Why is Vpr 
internalized? (4) Is Vpr internalization part of the “viral plan” to escape immune 
surveillance or is it a completely “nonspecific event”? (5) Are there any 
differences in function between internalized Vpr and endogenously expressed 
Vpr? (6) Is Vpr taken up by any cell type, or is it the result of a cell-dependent 
process? (7) Are there any cells resistant to Vpr uptake? (8) Is it possible that 
Vpr signals through a yet unknown surface receptor(s)? 
 Vpr enters a number of different cell types, including PBMCs (Sherman et 
al., 2002). This biological activity likely involves the hydrophobic structure of Vpr 
within its three alpha helices centered in the middle of the protein (Morellet et al., 
2003), which could potentially confer the Vpr transducing property.  Indeed, 
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studies have identified the third helix as being responsible for the Vpr transducing 
activity (Taguchi et al., 2004).  Moreover, it was shown that a chimeric protein 
containing the C-terminal half of Vpr possesses higher transfection efficiency in 
several human and nonhuman cell lines than its native counterpart.  This 
experimental approach facilitates delivery of any desired DNA to the nucleus 
through a yet unknown pH-independent pathway (Heinzinger et al., 1994; Kichler 
et al., 2000). Therefore the Vpr C-terminal moiety, which includes the third alpha 
helix, has the ability to transduce the plasma membrane, likely based on high 
affinity interactions with plasma membrane-bound proteins or phospholipids 
(Coeytaux et al., 2003). Consequently, Vpr not only displays a high affinity for 
nucleic acids (Zhang et al., 1998); it is also capable of carrying DNA molecules to 
the nucleus, where plasmids could then be transcribed in order to express any 
desired gene in transfection-based experimentation (Mizoguchi et al., 2005). 
 The ability of Vpr to cause internalization and cell death when added 
externally was initially proven in a variety of yeast strains and attributed to a 
peptide (HFRIGCRHSRIG) located at the end of the third alpha helix (Macreadie 
et al., 1996; Macreadie et al., 1995). The transducing ability was then 
demonstrated using CD4+ T cells, the primary cellular target of HIV-1 (Sattentau 
et al., 1986).  Indeed, extracellular Vpr gains access to the cellular cytoplasm 
through a CD4-independent mechanism and penetrates lymphocytes, with 
ensuing rapid reduction in mitochondrial transmembrane potential, formation of 
apoptotic bodies, and DNA fragmentation, with cell death realized as an end 
point (Arunagiri et al., 1997).  In addition, extracellular Vpr impairs T-cell 
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activation and proliferation after antigen-specific priming because it inhibits 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated 
activation, which blocks production of cytokines indispensable for suppression of 
viral replication, compromising the host immune response.  Extracellular Vpr has 
also been shown to induce apoptosis in the absence of TCR-mediated activation, 
thus promoting apoptosis of uninfected bystander T cells.  In contrast, in the 
presence of TCR-mediated activation, extracellular Vpr halts the expected 
induction of apoptosis, hence sparing HIV-1-infected cells, which could function 
as long-lived viral reservoirs (Ayyavoo et al., 1997b).  In addition, endogenously 
synthesized Vpr (Andersen et al., 2006; Andersen et al., 2005; Jian and Zhao, 
2003; Nonaka et al., 2009; Sabbah et al., 2006; Stewart et al., 1997; Stewart et 
al., 2000), virion-associated Vpr (Arokium et al., 2009), and soluble extracellular 
Vpr (Goh et al., 2004; Hoshino et al., 2007; Jones et al., 2007; Mishra et al., 
2007) have been shown to induce cell cycle arrest and apoptosis, which possibly 
points to a conserved pro-apoptogenic property of Vpr regardless of the origin of 
or delivery source into the cellular environment.  However, researchers have 
recently reported an anti-apoptotic property specifically for endogenously 
expressed Vpr (Conti et al., 2000; Conti et al., 1998; Fukumori et al., 1998; 
Matarrese et al., 2000; Zhu et al., 2003).  This apparent controversy raises the 
possibility that endogenously expressed Vpr acts either as a promoter or an 
inhibitor of apoptosis on the basis of its intracellular concentration or location.  
Indeed, during acute infection (modeled in vitro by transient transfection 
experimentation), productive synthesis of Vpr is obtained, which induces cell 
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cycle arrest and apoptosis.  In contrast, during chronic or latent infection 
(simulated in vitro by low Vpr-expressing stably transfected clones), a lower 
quantity of intracellular Vpr is produced, which does not seem to be sufficient to 
induce apoptosis but instead promotes cell survival through a regulated balance 
of pro- and anti-apoptotic factors (bcl-2 and bax) (Cheng et al., 1996). This 
observation represents an interesting hypothesis to explain the differential 
cellular fate observed during the progression of HIV-1 disease.  During acute 
infection (when synthesis of viral proteins is high and the concentration of Vpr is 
therefore elevated), cells (especially CD4+ T lymphocytes) undergo extensive 
apoptosis, which is followed by a long period of cell survival, limited cell turnover, 
and limited viral gene expression and synthesis (Conti et al., 1998).  Although the 
intracellular levels of Vpr may explain why cells are either prone or resistant to 
apoptosis, the intrinsic molecular switch mechanism is not understood.  Similar to 
Vpr expressed endogenously, extracellular Vpr concentrations likely regulate 
cellular fate towards either programmed cell death or survival.  This idea is in line 
with studies reporting that increased extracellular Vpr concentration is correlated 
with HIV disease progression (Levy et al., 1994; Levy et al., 1995). 
 Pro-apoptotic biological activity of Vpr is particularly important when 
considering antigen-presenting cells, primarily dendritic cells, and macrophages, 
which could potentially be shut down on engulfment of extracellular Vpr in order 
to eliminate it from the extracellular environment.  Therefore, the cells 
responsible for Vpr clearance could undergo the damaging downstream effects 
caused by Vpr, thus becoming detrimental to the host.  In this regard, a recent 
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study has demonstrated how dendritic cells infected with a Vpr-containing virus 
demonstrated a reduced ability with respect to antigen presentation by inhibiting 
transcription of essential co-stimulatory molecules and impairing expression of 
cytokines indispensable for immune activation (Majumder et al., 2005).  A similar 
study performed by treating predifferentiated cells of monocytic origin with 
recombinant Vpr showed impairment of the differentiation process even in the 
presence of maturation signals, because the co-stimulatory receptors (CD80 and 
CD86) were not expressed in a high enough concentration on the plasma 
membrane (Muthumani et al., 2005). This event, in turn, abolishes maturation of 
these cells into professional antigen-presenting cells.  In a similar study, it has 
been shown that extracellular Vpr-treated dendritic cells not only promote 
excessive production of the inflammatory cytokine TNF-α but also dysregulate 
the CD8+ T-cell proliferation pathway, leading to their death, thus diminishing the 
reservoir of cytotoxic cells capable of mounting an adequate immune response to 
the virus (Majumder et al., 2007).  This study shows how the effects of 
extracellular Vpr are important not only to the cells directly exposed to the viral 
protein but also to the downstream cell populations, whose interactions are finely 
tuned by the immune system.  In addition, activation of CD8+ T cells has been 
shown to be directly impaired after treatment with extracellular Vpr, thereby 
profoundly suppressing their cytotoxic activity and compromising T cell-mediated 
immunity (Muthumani et al., 2002). 
 Extracellular Vpr also impacts cells of the monocytic lineage, another cell 
population targeted by HIV-1.  Vpr activates the three branches of the MAPK 
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pathway through phosphorylation of p38, extracellular-signal-regulated kinases 
(Re et al.) and c-Jun N-terminal kinases (JNK), with subsequent downregulation 
of the anti-apoptotic proteins Bcl-2 and c-IAP1.  These events, in turn, induce 
mitochondrial permeabilization and cytochrome c release through a caspase 
cascade process, which leads to the cleavage of poly ADP ribose polymerase 
(PARP) in the nucleus and subsequent apoptosis (Mishra et al., 2007).  Studies 
have demonstrated how extracellular Vpr activates the MAPK pathway and 
promotes viral transcription in both promonocytic cells and fully differentiated 
macrophages (Varin et al., 2005).  More recently, the same cells have been 
shown to actively produce IL-6, a pro-inflammatory cytokine, by signaling through 
the Toll-like receptor (TLR)-4 and the MyD88 adaptor, which in turn requires the 
NF-κB pathway (Hoshino et al., 2010) and phosphorylation of C/EBPβ.  
Additionally, extracellular Vpr induces oxidation of phospholipids, thus having 
negative effects on the intracellular redox balance. Considering the fact that 
MDMs are antigen-presenting cells, the effects caused by extracellular Vpr are 
particularly abrupt because the immune system begins to lose the capability of 
defending the host against pathogenic agents.  Moreover, if HIV-1-infected 
MDMs are taken into account, the effects are amplified because viral particles 
are synthesized intracellularly, thereby increasing viral load, and extracellular Vpr 
arrests their differentiation (Levy et al., 1993), halting their ability to present 
antigens. Although the aforementioned studies clearly identify Vpr as being 
involved in antigen presentation by dendritic cells, further studies are needed to 
determine how extracellular Vpr influences antigen presentation by MDMs and 
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corrects antigen uptake and processing by both dendritic cells and MDMs.  
Furthermore, natural killer (NK) cells (important in the lysis and removal of HIV-1-
infected cells) exposed to recombinant Vpr show impaired function, with reduced 
target cell killing activity and interferon-γ production (Majumder et al., 2008).  The 
plethora of effects that extracellular Vpr displays on a multitude of cells in the 
peripheral circulation is of particular importance not only in lymph nodes, where 
antigens are presented to effector cells, but also within the context of HIV-1-
associated neuropathogenesis in the brain, because antigen-presenting cells are 
able to traverse the BBB where they localize and process pathogens present 
within the CNS.  Because Vpr is found in the serum of patients infected with HIV-
1 (Hoshino et al., 2007; Levy et al., 1994), these studies could explain the 
inability of the immune system to maintain an adequate response against the 
virus during the course of the disease. 
1.7.  Effects of extracellular Vpr on neurons 
 One of the first lines of evidence demonstrating the ability of extracellular 
Vpr to alter neuronal function was published over a decade ago.  This study 
demonstrated that extracellular Vpr induced formation of cation-selective pores in 
lipid bilayers in vitro (Piller et al., 1996).  They proposed that the positively 
charged Vpr C-terminus interacted with the physiological negatively charged 
intracellular environment to promote formation of channels.  This process, in turn, 
altered physiological ionic currents and gradients across the plasma membrane, 
which is of critical importance in excitable cells like neurons.  Additional studies 
using patch-clamp experimentation demonstrated the “association” of Vpr with 
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the plasma membrane, thus impairing trans-membrane potential by induction of a 
large influx of sodium (Piller et al., 1998).  Recent studies have also proposed 
that neurons are capable of internalizing Vpr (Henklein et al., 2000; Rom et al., 
2009).  These two observations have pointed to the roles that extracellular Vpr 
plays as it enters neurons through a yet unknown mechanism.  Vpr entry into 
cells has been shown to cause ionic imbalance between the intra- and 
extracellular environment subsequent to transduction of the plasma membrane.  
Vpr-induced inward current is especially deleterious to neurons because it alters 
ionic concentration and electrochemical balance, which leads to their dysfunction 
and consequentlal death (Jones et al., 2007; Kitayama et al., 2008; Piller et al., 
1996; Piller et al., 1998).  Extracellular Vpr clearly interferes with neuronal 
physiological function by entering the neurons and subsequently altering 
metabolism and axonal growth (Kitayama et al., 2008). This process is of great 
importance in neuronal plasticity and memory loss, which could explain and 
correlate the increased detection of extracellular Vpr in patients with AIDS and 
neurocognitive impairment as a direct effect of extracellular Vpr on neurons.  
However, all extracellular Vpr-induced depolarizing effects were both time- and 
dose-dependent and irreversibly compromised neuronal viability.  On the basis of 
these observations, it is plausible to hypothesize that Vpr may influence neuronal 
ability to conduct action potentials over long distances, which could explain the 
observed in vivo alterations in neuronal functionality.  Indeed, because the 
presence of an excessive amount of EC Vpr in the CSF correlates positively with 
disease progression (Levy et al., 1994; Levy et al., 1995), it is logical to speculate 
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that Vpr might play a fundamental role either in causing neurocognitive 
impairment or in accelerating the symptoms already present in patients with late-
stage HIV-1 disease. Nevertheless, despite in vitro evidence of the effects of 
extracellular Vpr on neurons, the outcomes that the presence of this protein in 
the extracellular compartment induces in vivo remain to be determined because 
only mouse models have been used to examine this question. 
  Further studies have also attributed the apoptotic-inducing phenotype to 
the C-terminal domain of Vpr (Sabbah and Roques, 2005).  This truncated form 
of Vpr possesses higher apoptotic ability than the full-length Vpr, possibly due to 
the fact that the N-terminus domain of Vpr, which did not show any induction of 
apoptosis, could partially mask the pro-apoptotic domain of the protein. In 
another study, the effects of recombinant purified Vpr on a neuronal cell line and 
on primary purified neurons of both rat and human origin were investigated 
(Jones et al., 2007). Only human fetal neurons exposed to lower concentrations 
of recombinant Vpr were vulnerable.  At increased concentrations of extracellular 
Vpr, all neurons examined were susceptible to cell death.  The pro-apoptotic 
phenotype of Vpr was evident as early as 3 hours post-treatment and was 
caused by release of cytochrome c into the cytoplasm.  Excessive accumulation 
of cytoplasmic cytochrome c then promoted increased expression of caspase 3 
and p53 and a decrease in phosphorylation of Akt.  Additionally, the incomplete 
reversal of Vpr effects by co-treatment with anti-Vpr antibodies suggests the 
possible existence of other non-Vpr-induced indirect effects. Indeed, in the same 
study, a more relevant model of an in vivo scenario was used by treating 
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astrocytes with recombinant Vpr and then exposing neurons to the resulting 
astrocytic-conditioned media.  Although high concentrations of Vpr were used to 
observe any significant effect on neuronal viability, only a modest and not 
statistically significant reversal of neuronal loss was obtained when neurons were 
co-treated with anti-Vpr antibody. This observation suggested the possibility that 
a Vpr-induced effect on astrocytes may indirectly affect the functional properties 
of neighboring neurons.  In this regard, increased IL-6 transcript levels were 
found in Vpr-treated astrocytes.  If the corresponding protein were secreted into 
the extracellular environment, the resultant inflammatory cytokine storm would 
likely impair the survival of the neighboring neuronal population. A similar trend 
was noticed when conditioned media from recombinant Vpr-treated monocytic U-
937 cells was employed to cultivate a neuronal cell line (Jones et al., 2007). This 
observation might provide an explanation for the in vivo symptoms observed in 
patients infected with HIV-1 in that monocytes exposed to a low concentration of 
extracellular Vpr could represent a harmful source of inflammatory molecules that 
could cause neuronal damage after traversing the BBB.  Although this study was 
conducted using a monocytoid cell line and would thus need further confirmation 
with primary monocytes, the results represent the first evidence suggesting that 
some of the damage observed in the CNS of patients infected with HIV-1 might 
be caused by an indirect mechanism induced by Vpr.  Additional studies are 
required to address the following questions: (1) Are the inflammatory molecules 
secreted by monocytes after traversing the BBB the result of exposure to Vpr in 
the peripheral blood or in the CNS? (2) Are the production and secretion of these 
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cytokines/chemokines affected by the differentiation process monocytes undergo 
after crossing the BBB? (3) (Hanson et al.)(Hanson et al.)Because Vpr is known 
to affect the differentiation process of monocytic cells would both uninfected and 
HIV-1-infected monocytes be able to cross the BBB in the presence of pathogens 
within the CNS?  In this regard, soluble Vpr present in serum of HIV-1-infected 
individuals could arrest the differentiation process by decreasing surface 
expression of costimulatory molecules, possibly halting transmigration of 
additional monocytic cells.  This process could represent an additional viral 
mechanism to enhance active replication of the virus within the CNS, thereby 
minimizing immune surveillance such that viral infection could spread to new 
areas of the CNS.  In this scenario, the effects of extracellular Vpr in the 
peripheral circulation would impact the CNS, which could potentially explain why 
the virus needs a sufficient build-up of extracellular Vpr in the serum during late-
stage HIV-1 disease to promote any detrimental effect in the CNS, providing a 
reason why severe neurocognitive impairment is mostly observed during the later 
stages of disease. 
 A number of experimental observations could be combined to develop a 
more relevant model of the BBB, wherein all cell types (monocyte-derived 
macrophages, astrocytes, and neurons) would be included to model more 
accurately CNS damage caused by Vpr toxicity and by other viral proteins as well 
as the accumulation of other cellular neurotoxic mediators. This model would 
also include interactions involving brain microvascular endothelial cells (BMVEC), 
which are found at the lining between the capillaries and the brain environment. 
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One recent study showed how BMVEC are negatively affected by extracellular 
Vpr, including induction of excessive TNF-α production that eventually leads to 
programmed cell death (Acheampong et al., 2002). 
 More recently, exogenous Vpr has been shown to induce formation of 
reactive oxygen species (ROS) in neurons (Rom et al., 2009; Sabbah and 
Roques, 2005) and in other cell types, including MDMs and microglia (Hoshino et 
al., 2010; Rom et al., 2009). This observation underscores either the cell-
independent induction of oxidative stress by Vpr or the presence of membrane-
bound receptors widely expressed in several cell types that are capable of 
inducing a cascade of events leading to intracellular oxidation.  ROS are 
chemically reactive oxygen-containing molecules produced under physiological 
conditions as a consequence of numerous intracellular biochemical and 
metabolic processes that are promptly disposed of to maintain a reduced 
intracellular environment.  However, excessive accumulation of intracellular ROS 
has been shown to activate the oxidative stress pathway because the cellular 
antioxidant machinery may not readily remove them.  This situation generally 
results in the production of abundant quantities of peroxides and free radicals, 
which affect neuronal function, and, when the oxidative-inducing stimulus is kept 
for an extended period of time, ultimately leads to cell death through DNA 
damage.  Extracellular Vpr-induced damage has also been proven to occur in 
microglial cells, the most common HIV-1-infected cells within the CNS (Michaels 
et al., 1988), wherein the enhanced expression of hypoxia-inducible factor-1 and 
the subsequent increase in viral transcription and virion production have been 
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observed (Deshmane et al., 2009).  In addition, promotion of oxidative stress 
causes viral activation in microglial cells, which leads to increased viral particle 
release and possibly Vpr.  Therefore, extracellular Vpr may induce a vicious 
cycle: Not only does it directly affect neurons, but it also induces viral production 
and release of Vpr in microglia, which also impacts neuronal function. 
 Another feature attributed to extracellular Vpr centers on the induction of 
the loss of adenosine triphosphate (ATP), the major source of intracellular energy 
(Rom et al., 2009) in neurons. This observation, in conjunction with the 
aforementioned Vpr-promoted accumulation of ROS species, points to a direct 
effect of Vpr on mitochondria, the intracellular organelles involved in disposal of 
ROS and exchange of ATP/ADP with the cytoplasm. Indeed, previous studies 
have demonstrated that Vpr can rapidly decrease mitochondrial membrane 
potential when added exogenously to different cell types or to isolated 
mitochondria (Jacotot et al., 2000); this process, in turn, was shown to induce 
formation of the permeability transition pore complex (PTPC) (Vieira et al., 2000), 
which comprises the voltage-dependent anion channel (VDAC) on the outer 
mitochondrial membrane and the adenine nucleotide translocator (ANT) on the 
inner mitochondrial membrane.  These effects suggest a direct interaction 
between Vpr and domains of the PTPC including both the ANT and VDAC 
proteins (Jacotot et al., 2001; Sabbah et al., 2006).  Formation of PTPC induced 
by Vpr promotes the formation of mitochondrial conductance channels, with 
subsequent release of cytochrome c and apoptosis-inducing factor into the 
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cytoplasm (Roumier et al., 2002), which translocates to the nucleus, thus 
promoting DNA fragmentation and programmed cell death. 
 Neurons accumulate an excessive amount of calcium ions under certain 
physiological circumstances, which affects calcium secretion and interneuronal 
communication (Rom et al., 2009).  This response has been directly attributed to 
Vpr-induced downregulation of a plasma membrane-bound calcium transporter 
(plasma membrane calcium ATPase), responsible for the removal of calcium ions 
from cells.  This result, which needs confirmation in primary neurons, is of 
particular interest because calcium plays a role as an intracellular messenger (in 
all cell types) and regulates several different neuronal developmental processes, 
such as migration into the CNS, plasticity of dendrites and filopodia, membrane 
excitability, and neurotransmitter release (Ryglewski et al., 2007).  Alteration of 
any of the aforementioned activities by Vpr has potential deleterious downstream 
effects on neuronal survival, which impacts processes such as memory loss, thus 
leading to neurocognitive impairment. 
 Studies of neurons exposed to extracellular Vpr demonstrated the 
complete spectrum of effects that this viral protein has on this cell population, 
from intracellular transduction to impairment of calcium signaling and decreased 
levels of ATP storage. This latter observation needs further examination in 
primary neurons because a reduction in intracellular ATP levels could be due 
either to abundant energy consumption or to excessive neuronal release.  In this 
regard, neuronal axons firing action potentials are known to secrete ATP, which 
functions as a neurotransmitter (Ishibashi et al., 2006), and alteration of its 
Chapter 1 35 
extracellular concentration and associated gradient may disrupt interneuronal 
signaling. 
1.8.  Effects of extracellular Vpr on astrocytes 
 As outlined in the previous section, numerous studies have evaluated the 
detrimental effects that soluble Vpr exerts on neurons of both mouse and human 
origin, thereby affecting neuronal survival in a dose-dependent manner, starting 
at concentrations similar to those found in vivo in patients infected with HIV-1 (of 
the order of pM).  More recently, cells of the astrocytic lineage have been used to 
evaluate the effects of exogenous Vpr in order to make correlations with the in 
vivo neurodegenerative symptoms observed in patients with late-stage HIV-1 
infection (Huang et al., 2000; Jones et al., 2007; Noorbakhsh et al., 2010).  
Astrocytes have been selected as an experimental focal point because they are 
the most abundant cell population, because of their proximity to the BBB and to 
the neurons within the CNS, and becasue their plasticity allow them to change 
shape in response to nearby neuronal activity (affecting complex neuronal 
connections) and enwrap several different neuronal synapses.  The synaptic cleft 
becomes compartmentalized, resulting in more rapid uptake of ions and 
neurotransmitters, especially glutamate, ATP, and D-serine, thereby controlling 
homeostasis and eliminating otherwise neurotoxic molecules.  Astrocytes are 
glial fibrillary acidic protein-positive cells, important in transmission and 
modulation of action potentials because they control calcium concentration in the 
neuronal synaptic cleft and facilitate release of neurotransmitters from 
presynaptic termini.  Because glutamate uptake by astrocytes (the major cell type 
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responsible for this process) is finely regulated by a balanced transport of ions 
(mainly Na+, K+, and H+), this neurotoxic amino acid is quickly taken up and able 
to trigger aerobic glycolysis (Pellerin and Magistretti, 1994) as well as release of 
neuroprotective factors such as lactate, glutathione, and cysteine (Garg et al., 
2008).  These molecules are of critical importance for neuronal survival, with 
lactate taken up and converted into pyruvate for use in the tricarboxylic acid 
cycle, whereas glutathione is extracellularly cleaved into cysteine, which is 
subsequently taken up and used as a fuel molecule to resynthesize glutathione 
within neurons, thus promoting a reduced intracellular environment.  Given the 
fundamental role astrocytes play in providing precursors to neurons (Dringen et 
al., 1999), any toxic compound or molecule present within the CNS first directly 
affects astrocytic functions, which in turn impacts neuronal metabolism and fate.  
A number of investigative groups including our own have recently initiated 
studies to determine how extracellular Vpr affects astrocytic functions.  One of 
the main areas of exploration centers on how Vpr impairs calcium signaling in 
astrocytes (Noorbakhsh et al., 2010), as previously proven in neurons (Rom et 
al., 2009), which suggests another conserved feature between the two different 
cell types.  Calcium is fundamental in intercell communication, particularly among 
excitable (neurons) and nonexcitable (astrocytes) cells within the CNS; reviewed 
in (Scemes and Giaume, 2006).  Disruption of calcium concentrations and influx 
affects not only calcium-dependent intracellular pathways (such as the CREB 
pathway) but also intercellular calcium waves, which are used by astrocytes to 
transmit signals to adjacent non-stimulated cells, thus creating an astrocytic 
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network capable of reflecting local changes to a more macroscopic level.  
Although recent reports have demonstrated the ability of recombinant Vpr to 
transduce different cell types, there is no evidence yet for Vpr uptake by 
astrocytic cells.  Whether Vpr enters cells or exerts its effects by signaling 
through yet unidentified receptors on the plasma membrane, this toxic viral 
protein has been shown to activate p53 leading to apoptosis through induction of 
the caspase cascade in primary astrocytes (Noorbakhsh et al., 2010).  In the 
same study, it was shown that transgenic mice expressing Vpr in cells of the 
monocytoid lineage displayed decreased glial fibrillary acidic protein 
immunostaining within both the cortex and the basal ganglia, symptoms of 
increased astrocytic cell death.  The authors of these studies suggested that 
programmed cell death in astrocytes could be directly attributed to direct 
secretion of Vpr or release of Vpr-induced cytokines by MDMs traversing the 
BBB or by microglial cells. Additionally, the increased presence of excitatory 
molecules (including glutamate and L- and D-serine) was detected within the 
brain along with decreased production of transcripts of the excitatory amino acid 
transporters (EAAT1 and EAAT2), the major glutamate transporters expressed 
primarily within astrocytes (Noorbakhsh et al., 2010). The evidence provided 
therein could point to an association between the increased levels of glutamate 
found within the brain and the late-stage symptoms of HIV-associated 
neurocognitive impairment as an effect of exogenous Vpr.  In this regard, 
extracellular glutamate may not be efficiently cleared out by astrocytes, either 
because of diminished expression of EAAT transporters or their decreased 
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activity, as a result of a saturation event, for instance, direct formation of a 
EAAT/Vpr complex, or possibly steric hindrance factors.  In either scenario, the 
net local effect is an excessive build-up of extracellular excitatory glutamate, 
which affects neuronal activity, both directly and indirectly through astrocytic 
dysfunction.  Extracellular glutamate is indeed taken up by astrocytes and 
subsequently converted into the less neurotoxic glutamine. Glutamine in turn is 
released and taken up by presynaptic neurons, where it is reconverted into 
glutamate, which is used as a neurotransmitter to propagate excitatory stimuli, 
thus completing the cycle.  An excessive concentration of extracellular glutamate 
generates a steeper gradient, not only becoming neurotoxic but also generating 
more rapid and dramatic influx and efflux waves.  Because glutamate uptake is 
finely regulated through both the cysteine-glutamate exchanger and the sodium-
potassium ATPase pump (Garg et al., 2008), a glutamate imbalance also impairs 
cysteine and ionic gradients.  Nonetheless, blood-borne monocytes traffic to the 
brain following brain injury and, on differentiation into tissue macrophages, 
express EAAT transporters, thus becoming competent in clearing extracellular 
glutamate (Rimaniol et al., 2000).  This finding may represent a double-edged 
sword because it could provide an adaptive mechanism that MDMs develop as 
the disease progresses to promptly eliminate abundant extracellular glutamate 
while undermining the survival of CNS-resident cells such as HIV-1-infected 
monocytes that might also cross the BBB, thus reseeding viral infection in the 
brain. 
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 In a recent study, it was shown that neurons treated with conditioned 
media from Vpr-stimulated U-373 MG cells (an astrocytic cell line) underwent cell 
death and that they could not be rescued by the addition of anti-Vpr antibody to 
the extracellular medium (Jones et al., 2007). This observation points again to an 
indirect effect induced by Vpr because Vpr-treated astrocytes might take up 
extracellular Vpr and release proinflammatory cytokines, leading to a reduction in 
neuronal viability. This study shows how any toxic effect observed in astrocytes, 
although not performed under cocultivation conditions, is transmitted to neurons.  
1.9.  Conclusions  
 Future studies will need to provide convincing evidence with respect of the 
secretion or nonspecific release of the HIV-1 Vpr.  Additional studies are also 
required to delineate specific cell types involved in this “secretory process” and 
the important parts of the viral life cycle that are necessary for the process of 
secretion to occur.  It will be very important to evaluate and weigh the cellular 
sources of exogenous Vpr within the periphery and the possible route(s) of entry 
of soluble Vpr into the CNS, as these studies might prove useful in drug design 
aimed at blocking Vpr translocation. Once Vpr enters the CNS, its detrimental 
effects could be implemented on all resident cells, similar to those observed in 
the periphery (Table 1). Of particular interest are also the downstream effects on 
astrocytes and neurons, as the intricate communication between these cell types 
is ultimately responsible for the fate of neurons, which has consequences for the 
health of patients with late-stage HIV-1 infection, by inducing neurocognitive 
impairment.  Nonetheless, the mechanisms used during HIV-1-induced 
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neurovirulence are not understood and need further investigation. The causes of 
HIV-1 disease progression are multifaceted as multiple events occur leading to a 
cascade of pathological consequences. It is an attractive objective to correlate 
the observed increase in ROS formation with the augmented viral load burden 
within the CNS, although the leading causes might be of various origins.  
Additionally, late stage HIV-1-infected patients have been shown to benefit from 
the treatment with antioxidant compounds such as N-acetyl-cysteine 
(Herzenberg et al., 1997), as these remedies lengthen life expectancy, but do not 
halt the ongoing oxidation phenomena, possibly due to either an irreversibility of 
the process and/or an excessive accumulation of ROS, which may no longer be 
scavenged by the weakened antioxidant cellular defense mechanisms. 
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Table 1.  Effects of extracellular Vpr on cells in the periphery and the CNS. 
 
Cell type Effects References 
Periphery   
transduction Sherman et al., 2002;  Arunagiri et al., 1997 
↓ MMP and apoptosis Arunagiri et al., 1997 
blockade of activation and 
proliferation Ayyavoo et al., 1997 
  CD4+ T 
G2/M cell cycle arrest Sherman et al., 2002 
blockade of proliferation Majumder et al., 2007 
blockade of cytotoxic activity 
Majumder et al., 2007,  
Muthumani et al., 
2002 
CD8+ T 
apoptosis Majumder et al., 2007 
transduction Varin et al., 2005; Henklein et al., 2000 
↓ MMP and apoptosis Mishra et al., 2007 
block differentiation Levy et al., 1993 
activation of MAPK pathway Varin et al., 2005 
↑ viral transcription Sherman et al., 2002; Varin et al., 2005 
↑ IL-6 production Hoshino et al., 2010 
Monocytic 
↑ phosholipids oxidation, ↑ ROS Hoshino et al., 2010 
↓ co-stimulatory molecules (CD80, 
CD86) 
Majumder et al., 2005;  
Muthumani et al., 
2005 
blockade of maturation Majumder et al., 2005 
↓ antigen presentation Majumder et al., 2005; Majumder et al., 2007 
↑ TNF-α  production Muthumani et al., 2005 
DC 
apoptosis 
Majumder et al., 2005;  
Majumder et al., 2007; 
Muthumani et al., 
2005 
↓ IFN-γ  production Majumder et al., 2008 NK 
↓ lytic activity Majumder et al., 2008 
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CNS   
↑ ROS Deshmane et al., 2009 
Microglia ↑ viral transcription, ↑ virion 
production Deshmane et al., 2009 
Ca++ signaling Noorbakhsh et al., 2010 
↑ IL-6 production Jones et al., 2007 
¯ GFAP and cascade-dependent 
apoptosis 
Noorbakhsh et al., 
2010 
↑ Glu, L- and D-serine Noorbakhsh et al., 2010 
Astrocyte 
↓ EAAT1, EAAT2 Noorbakhsh et al., 2010 
formation of membrane pores Piller et al., 1996 
transduction Rom et al., 2009 
ionic current imbalance (Ca++) 
Jones et al., 2007; 
Piller et al., 1996; 
Piller et al., 1998; 
(Rom et al., 2009) 
impairment of axonal growth Kitayama et al., 2008 
↓ MMP and apoptosis 
Jones et al., 2007; 
Piller et al., 1996; 
Piller et al., 1998; 
Sabbah et al., 2005; 
Jacotot et al., 2000 
↑ ROS Rom et al., 2009; Sabbah et al., 2005 
Neurons 
¯ATP Rom et al., 2009 
apoptosis Acheampong et al., 2002 BMVEC 
↑ TNF-α  production Acheampong et al., 2002 
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2.1. Materials 
N-acetyl-cysteine (NAC) and buthionine sulfoximine	   (BSO) were both 
obtained from Sigma-Aldrich and utilized as controls to increase or decrease 
GSH levels, respectively.  L-Glutathione was also purchased from Sigma-Aldrich 
and used to elute GST-Vpr purified proteins bound to GSH beads (GE 
Healthcare).  The 27-aa long Vpr (70-96) peptide from HIV-1 strain NL4-3 
(IHFRIGCRHSRIGVTRQRRARNGASRS) was synthetically synthesized and 
purchased from GenScript as a lyophilized powder of >95% purity.  The 3.1 kDa 
peptide was then re-suspended in 1X phosphate buffered saline (PBS) to a stock 
concentration of either 0.5 or 1 mM and used to directly treat cells.  Whole cell 
lysates for protein extraction and estimation of protein concentration were 
prepared in 0.5X radioimmunoprecipitation assay (RIPA) buffer (Pierce, Thermo 
Fisher Scientific), with the addition of a protease and phosphatase inhibitor 
cocktail (Calbiochem, EMD) and protein concentrations were calculated using the 
Bradford protein assay procedure (Pierce, Thermo Fisher Scientific).  
pcDNA™3.1 directional TOPO expression procedure (Invitrogen) was utilized to 
clone the 6His-HA-Vpr plasmid.  Doxorubicin (DOX) hydrochloride was 
purchased from Sigma-Aldrich and used as a positive control to decrease 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity levels. 
Camptothecin (CPT, BioVision) and the caspase inhibitor Ac-DEVD-CHO 
(Promega) were utilized to activate and block caspase-3 and -7, respectively.  
Total cellular RNA for the quantitative real-time polymerase chain reaction (qRT-
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PCR) assay was prepared using an RNA isolation procedure as described by the 
manufacturer (USB, Affymetrix). 
2.2. Cell lines and primary astrocytes maintenance 
The human endothelial kidney (HEK 293T) cell line (American Type 
Culture Collection, ATCC, CRL-11268) was grown in 1X Dulbecco’s Modified 
Eagle’s Medium (DMEM; Cellgro) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS, GemCell), antibiotics (penicillin and streptomycin, at a 
concentration of 0.04 mg/ml each, Cellgro), glucose (4.5 g/mL, Cellgro), sodium 
pyruvate (1 mM, Cellgro) and HEPES (10 mM, Cellgro).  The human astroglioma 
cell line U-87 MG (ATCC, HTB-14) was grown in 1X DMEM supplemented with 
10% heat-inactivated FBS, penicillin and streptomycin (at a concentration of 0.04 
mg/ml each), 0.04 mg/ml kanamycin sulfate and 7.5% sodium bicarbonate (final 
concentration 0.05%). Primary human fetal astrocytes (HFA) were purchased 
from ScienCell Laboratories (Carlsbad, CA) and maintained in astrocyte medium 
containing 1% astrocyte growth supplement, 2% FBS and 1% 
penicillin/streptomycin. They were cultured in poly-L-lysine coated culture 
vessels, and passaged when they reached a density of approximately 7,500 
cells/cm2.  All experiments employing HFA have been performed with primary 
cells passaged no more than three times.  Beyond the third passage, the HFA 
cells begin losing the astrocytic intracellular marker glial fibrillary acidic protein 
(GFAP).  All cell lines and primary HFA were maintained at 37°C in 5% CO2 at 
90% relative humidity. 
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2.3. Plasmid construction and site-directed mutagenesis 
For all studies performed in this thesis, the non-infectious HIV-1 pNL4-
3R+E– molecular clone was utilized (obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH, obtained from 
Dr. Nathaniel Landau (Connor et al., 1995; He et al., 1995)).  This clone contains 
a firefly luciferase gene in place of the Nef sequence.  In order to construct the 
6His-HA-Vpr plasmid, two single-stranded DNA sequences (sense and 
antisense) were initially synthesized (IDT Technolgies, Inc): AGCTTGCCACC 
ATGGGACATCATCACCATCACCATTACCCATACGATGTTCCAGATTACGCTT 
and the reverse complement 5’ – CCGGAAGCGTAATCTGGAACATCGTATGGG 
TAATGGTGATGGTGATGATGTCCCATGGTGGCA. The sense sequence 
incorporates a consensus Kozak sequence prior to the initial ATG transcription 
start site (in bold) to enhance the initiation of the translation process (Kozak, 
1987).  The sense sequence also contains 6-histidine (6•His) and haemagglutinin 
(HA) coding sequences underlined and double underlined, respectively.  The 5’ 
end of the antisense sequence also contains an AccIII cleavage site.  The sense 
and antisense sequences were annealed in 1X saline-sodium citrate (SSC) 
solution, boiled for 5 min and incubated for 1 h at 45ºC.  The double-stranded 
DNA sequence was subsequently digested with the AccIII restriction 
endonuclease (Promega) for 1 h at 65ºC.  The Vpr coding sequence was PCR 
amplified from the pNL4-3R+E– molecular clone using forward (5’ – CGCATC 
CGGAGAACAAGCCCCAGAAGACC) and reverse (5’ – GCAGCTCGAGCTAG 
GATCTACTGGCTCC) PCR primers, engineered to harbor an AccIII and a XhoI 
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restriction endonuclease cleavage site, respectively (underlined).  PCR reaction 
volumes were as follows: 37 µl of ddH2O, 10 µl of 5X GC buffer (Finnzymes, 
Thermo Scientific), 0.25 µl of each of the two primers, 1 µl of 10 mM dNTPs, 500 
pg of target DNA, and 1 µl of Phusion DNA Polymerase (Finnzymes, Thermo 
Scientific). PCR thermal cycling condition was set for 25 cycles composed of an 
initial denaturation (98 ºC for 10s) step, an annealing (65ºC for 15s) and an 
extension (72ºC 15s), followed by a further extension step of 5 min at 72ºC.  The 
PCR-amplified fragment was digested with AccIII at 65ºC for 1 h. The double-
stranded DNA sequence containing the 6His and HA tags along with the Vpr 
PCR-amplified fragment (both containing the compatible AccIII overhangs) were 
then ligated overnight at 4ºC with T4 DNA ligase (Promega). This double-
stranded 6His-HA-Vpr segment and the pcDNA3.1 vector were then digested 
with the respective restriction endonucleases HindIII and XhoI (Promega) in a 
one-step reaction for 1 h at 37ºC to obtain complementary single-stranded 
overhang products. Cloning of Vpr products and pcDNA3.1 vector was then 
completed by overnight ligation at 4ºC with T4 DNA ligase (Promega).  In co-
transfection studies, the pNL4-3R–E– molecular clone (with a 4 base pair 
insertion designed to knock out the Vpr coding sequence) was also utilized and 
obtained similarly to the aforementioned pNL4-3R+E–. 
The 3HA-Vpr was a kind gift of Dr. Eric Cohen (IRCM, Montreal, Canada) 
and contains three adjacent stretches of the HA tag (YPYDVPDYA) at the 5’ end 
of the Vpr ATG transcription start site and because of the multiplicity of the HA 
tags yields a higher sensitivity in extracellular Vpr studies. 
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For recombinant Vpr purification, a GST-tagged Vpr construct (a kind gift 
from Dr. Bassel Sawaya, Temple University), cloned in the pGEX-4T-1 vector 
(GE Healthcare), under the control of the tac promoter (a hybrid derived from the 
trp and lac UV5 promoters (de Boer et al., 1983)), was chemically inducible for 
high-level expression of GST-tagged recombinant proteins. Since the Vpr 
construct obtained did not contain any tag that could aid in the purification 
process, we utilized the previously described 6His-HA-Vpr DNA sequence to 
obtain a plasmid containing a GST-6His-HA-Vpr coding sequence.  Indeed, the 
presence of the 6His stretch facilitated the purification process in elution steps 
using nickel chromatography.  Additionally, the presence of a thrombin cleavage 
site (Pro-Arg↓Gly-Ser) at the 3’ end of the GST DNA sequence and 5’ end of the 
initial Vpr ATG transcription start site separated the two proteins (GST from the 
Vpr), thus yielding a 6His-HA-Vpr protein for in vitro studies.  The following PCR 
primers were utilized: 5’ – ATTCGGATCCATGGGACATCATCACC (forward) and 
5’ – GGCTTCTAGACTAGGATCTACTGGCTCC (reverse), engineered to contain 
BamHI and XbaI cleavage sites (underlined), respectively.  The cloning process 
was performed similar to that described for 6His-HA-Vpr, utilizing an initial PCR 
reaction (same volume and thermal cycling conditions as above), followed by a 
one-step restriction endonuclease digestion for 1 h at 37ºC with BamHI and XbaI 
(Promega) and a final ligation overnight at 4ºC with T4 DNA ligase (Promega). 
The Vpr mutant plasmid (6His-HA-Vpr R73,80A), wherein two arginine 
residues at position 73 and 80 have been changed to alanine, was obtained 
through two subsequent site-directed mutagenesis reactions from the previously 
Chapter 2  	  
 
	  
62
described 6His-HA-Vpr plasmid using the QuickChange Site-Directed 
Mutagenesis procedure as described by the manufacturer (Stratagene).  Initially, 
the Vpr R73A variant (arginine residue at position 73 changed to an alanine) was 
generated in a 50 µl PCR reaction, containing 39.5 µl of ddH2O, 5 µl of 10X 
reaction buffer, 10 ng of target plasmid (6His-HA-Vpr), 1 µl of dNTPs, 1.25 µl of 
each of the two reverse complement primers (5’ – GCTGTTTATCCATT 
TCGCAATTGGGTGTCGAC and 5’ – GTCGACACCCAATTGCGAAATGGATAA 
ACAGC) and 1 µl of Pfu Turbo DNA Polymerase (2.5 U/µl).  The two nucleotides 
yielding the amino acid mutation are underlined. The PCR conditions were as 
follows: 16 cycles comprised of an initial denaturation step of 30 s at 95ºC, 
followed by an annealing at 55ºC for 1 min, and a final extension step at 68ºC for 
5 min.  Subsequently, parental plasmid DNA was digested by incubation with 1 µl 
of Dpn I  (10 U/µl) for 1 h at 37ºC.  One µl of this reaction was then transformed 
by heat shock into XL1-Blue competent cells for 45 s at 42ºC to yield the final 
GST-6HIS-HA-Vpr R73A plasmid, which was utilized to generate the double 
mutant GST-6HIS-HA-Vpr R73,80A with identical conditions as described above 
using the two reverse complement primers 5’ – GGTGTCGACATAGCGCAATAG 
GCGTTACTC and 5’ – GAGTAACGCCTATTGCGCTATGTCGACACC (mutated 
nucleotides underlined). All plasmid DNAs were confirmed by sequencing 
(Genewiz, Inc). 
2.4. Western immunoblot hybridization  
Harvested cells or cell pellets were washed twice in 1X PBS and collected 
by centrifugation at 1,000 RPM. Cells were then lysed in 0.5X RIPA buffer 
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supplemented with a protease and phosphatase inhibitor cocktail and subject to 
three freeze-thaw cycles for 30s on dry ice and 5 min at room temperature. 
Lysed samples were then cleared of nucleic acids by centrifugation at 10,000 
RPM for 10 min at 4ºC and the supernatant was collected.  Protein 
concentrations were determined utilizing the Bradford Assay (Pierce), by adding 
in single wells of a transparent 96-well plate 1 µl of protein sample in 160 µl of 
ddH2O with the addition of 40 µl of Bradford reagent.  Protein concentrations 
were assessed utilizing BSA standards (0 to 10 mg/ml), with the linear range of 
the assay determined using a colorimetric plate reader and the filter set at 595 
nm.  Equal amounts of protein for all samples were run on a 10% sodium dodecyl 
sulfate–polyacrylamide gel (SDS-PAGE) and transferred to a 0.45-µm 
Immobilon-P PVDF membrane, followed by blocking with 5% (w/v) non-fat dry 
milk in 1X PBS (1 h at room temperature).  Membranes were incubated overnight 
at 4ºC with primary antibody (1:1,000 dilution, except β-actin at 1:5,000 dilution) 
in 3% (w/v) non-fat dry milk in 1X PBS. Specific protein bands were then 
detected using a horseradish peroxidase (HRP)-conjugated secondary antibody 
in a 1:15,000 dilution (Jackson ImmunoResearch Laboratories). Spotted antigen-
antibody complexes were visualized using a chemiluminescent detection 
procedure (Pierce, Thermo Fisher Scientific) on a ChemiDoc acquisition and 
analysis station (Bio-Rad Laboratories, Hercules, CA). Densitometry was 
performed with an AlphaEase FC software package (Alpha Innotech Corporation, 
San Leandro, CA) with the intensity of each specific band calculated after 
background subtraction and normalization to the intensity of a housekeeping 
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gene (β-actin or GFAP).  For stripping, membranes were incubated for 1 h at 
room temperature using the Restore Western Blot Stripping Buffer (Thermo 
Fisher Scientific) and re-blotted in 5% (w/v) non-fat dry milk in 1X PBS.  The 
antibodies utilized in the western immunoblot studies were purchased from the 
following companies: HA, GFAP, caspase-3, and PARP (Cell Signaling), β-actin 
(Sigma-Aldrich), p24 (Santa Cruz Biotechnologies, Inc.), Vpr (kind gift of Dr. 
Kopp, NIH, Bethesda, MA), GAPDH and COX IV (Genscript), and SCARA3 
(Abcam). 
2.5. Transient transfection and preparation of conditioned media 
Exponentially growing HEK 293T cells (2 x 106) were seeded in 10 ml of 
growth medium in 10-cm Petri dishes.  Transfection was performed utilizing the 
calcium phosphate method for which a solution of CaCl2 (final concentration 60 
mM) was slowly added to 20 µg of plasmid DNA. The CaCl2–DNA mixture was 
then dispensed dropwise into a solution of 2X HEPES buffered saline (HBS), pH 
7.0.  Following a 30 min incubation wherein DNA precipitates, the CaCl2–DNA–
2X HBS mixture was added dropwise onto the cell culture monolayer.  After a 5 h 
incubation, the cell culture medium was changed and the cell culture was left 
unperturbed at 37°C for 48 h.  This period of time allows HEK 293T cells to 
produce non-infectious HIV particles as an envelope-deficient (pNL4-3R–E–) 
molecular clone has been utilized.  Vpr-containing or Vpr-deficient plasmids have 
been transiently transfected in trans with the Env- and Vpr-deficient molecular 
clone (pNL4-3R–E–). Virus-containing conditioned media have thus been 
centrifuged and filtered through a 0.45-µm syringe filter to eliminate floating 
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cellular debris.  Cell-free virus-containing conditioned media have subsequently 
been slowly layered on top of a 20% sucrose gradient and ultra-centrifuged at 
28,000 RPM in an ultra-centrifuge device (Beckman) for 2 h at 4°C.  This 
procedure allows viral particles to pass through the sucrose layer and be 
collected at the bottom of the tube.  Hence cell- and virus-free (CFVF) 
conditioned media (atop of the sucrose level) was collected and either 
immediately utilized with freshly cultured U-87 MG astrocytes or stored at -30°C 
for a brief period of time before utilization.  Virions at the bottom of tubes were re-
suspended in about 80 µl of 1X PBS volume and maintained at 4°C overnight, 
after which time viral particles were collected and lysed as indicated above to 
determine whether Vpr was incorporated into virions. 
The CFVF portion of cells co-transfected with the R–E– molecular clone 
along with the 3HA-Vpr plasmid was precipitated with ice-cold acetone, as 
organic solvents are able to denature proteins by exposing more hydrophobic 
domains thereby reducing their solubility.  Samples were then incubated 
overnight at -80ºC, washed in ice-cold acetone, and centrifuged to pellet and 
concentrate proteins within the supernatant.  Pellets were then lysed in 0.5X 
RIPA buffer and subjected to immunoprecipitation (IP) with an anti-HA antibody. 
Anti-HA IP samples were captured by protein G-agarose beads and then 
resolved on a 15% SDS-PAGE as described in section 2.4.  However, given the 
low concentration of Vpr in extracellular supernatant, spotted antigen-antibody 
complexes were visualized using a more sensitive SuperSignal ECL method 
(Pierce). 
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2.6. ATP and Glutathione assays 
For all experiments involving measurement of intracellular adenosine 
triphosphate (ATP) and glutathione (GSH) concentrations, we used the CellTiter-
Glo® Luminescent Cell Viability and GSH-Glo™ Glutathione Assay (Promega; 
Madison, WI).  To determine the total protein concentration, the Biorad Protein 
Assay was utilized (Pierce, Thermo Fisher Scientific) as previously described in 
section 2.4.  Astrocytes (either U-87 MG or primary HFA) treated or untreated 
were collected by centrifugation at 1,000 RPM, 5% of the total cell population 
was used for each ATP and GSH assay, while the remainder was utilized to 
normalize to total protein concentration.  
Cells employed for the ATP measurement were then resuspended in 50 µl 
of 1X PBS and dispensed in an individual well of a 96-well opaque plate.  ATP 
standards ranging from 10 nM to 1 µM were also utilized in duplicate to 
determine the molar concentrations.  An equal volume (50 µl) of CellTiter-Glo® 
Reagent was added to both samples and standards, contents mixed, and 
incubated at room temperature for 30 min.  Luminescent signals were detected 
using a pre-calibrated Glomax® luminometer (Promega; Madison, WI) at different 
time points until each signal peaks to the maximum value.  ATP concentrations 
were calculated after noise (no cells) subtraction from the standard curve. 
Cells employed for the GSH measurement were instead resuspended in 
25 µl of 1X PBS and dispensed in single wells of a 96-well plate.  GSH standards 
ranging from 500 nM to 5 µM were also included in separate wells in duplicate.  
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Twenty five microliters of 2X GSH-Glo™ Reagent (1:1:50 of Luciferin-NT 
substrate: GST: GSH-Glo™ Reaction Buffer) was added to each well and mixed. 
After a 30-min incubation at room temperature, 50 µl of reconstituted Luciferin 
Detection Reagent was added to each sample, following a 15-min incubation. 
GSH luminescent signals were recorded similar to the procedure to obtain ATP 
readings until values peaked and GSH concentrations were determined from the 
standard curve after background subtraction.  For determination of total (tGSH) 
and oxidized glutathione (GSSG), a similar approach was followed using the 
GSH/GSSG-Glo™ Glutathione Assay (Promega; Madison, WI).  Cells cultured in 
a 96-well tissue culture opaque plate (Falcon, BD Bioscience) were harvested at 
specific time points by removal of the cell culture medium which was immediately 
lysed in 25 µl of total or oxidized glutathione lysis buffer.  For total GSH assay, 
lysis buffer was composed of 19.5 µl of ddH2O, 5 µl of passive lysis buffer 
(Promega), and 0.5 µl of Luciferin-NT.  For GSSG, an extra 0.25 µl of N-
ethylmaleimide (NEM) was added to the lysis mixture to block any reduced GSH 
molecule.  Cells treated with either the total or oxidized glutathione lysis buffer 
were then added to 25 µl of Luciferin Generation Reagent (22.9 µl of Glutathione 
Reaction Buffer, 1.5 of GST and 0.6 of 100 mM DTT).  After a 30-min incubation 
at room temperature, 50 µl of Luciferin Detection Reagent was added to each 
well and incubated for an additional 15 min, after which time luminescent signals 
were detected as previously described for the GSH-Glo™ Glutathione Assay.  In 
order to calculate reduced and oxidized glutathione concentrations from these 
readings, the following formula was used: reduced GSH = (tGSH – GSSG/2), 
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since each molecule of oxidized glutathione gives rise to two molecules of 
reduced glutathione upon breakage of the disulfide bond. GSH/GSSG ratios 
were calculated as 2•tGSH/GSSG – 1.  All results were plotted as the ratio 
compared to untreated cells. 
2.7. Purification of recombinant Vpr 
GST-6His-HA-Vpr or the R73,80A mutant were transformed into BL21 
DE3 RIPL (Stratagene) bacteria. The main obstacle with respect to Vpr 
purification centers on its solubility in buffers devoid of detergents.  Higher Vpr 
yields could be achieved in detergent-containing buffers compared to a 1X PBS 
buffer.  However, since the Vpr preparations will need to be delivered to primary 
HFA, which are sensitive to higher concentrations of detergents and ions, 
detergent-containing buffers were likely detrimental to astrocytic survival. 
Therefore the volume of bacteria was increased in order to achieve a suitable 
Vpr concentration in a limited amount of 1X PBS (calcium- and magnesium-free).  
We initially cultured Bl21 DE3 RIPL bacteria in LB broth using ampicillin as a 
selecting agent.  Expression of Vpr was induced by addition of the isopropyl β-D-
1-thiogalactopyranoside (IPTG).  However, within a few minutes post-IPTG 
induction, the GST-tagged Vpr protein starts being degraded and incorporated 
into inclusion bodies.  To minimize this process, we determined the optimal 
conditions (temperature and minutes of IPTG induction) in order to obtain a 
majority of the protein as an uncleaved full-length product.  The optimal results 
were obtained by scaling up the bacterial volume to 2 liters and inducing with 
IPTG for 15 min at 28ºC.  Cultures were then pelleted by centrifugation at 7,000 
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RPM and lysed in NETN lysis buffer, Tris pH 8.0 (20 mM), NaCl (100 mM), EDTA 
(1 mM), NP-40 (0.5%), PMSF (1 mM), and protease inhibitor cocktail (1:100).  
The lysate was sonicated until clear and subsequently purified by affinity 
chromatography using glutathione-sepharose beads (GE Healthcare), binding to 
the GST tag at the 5’ end of the 6HIS-HA-Vpr protein.  The retained protein 
solution was washed with NETN lysis buffer and release from the column in 
elution buffer (30 mM reduced GSH in 50 mM Tris⋅HCl buffer, pH 8).  Eluted 
proteins were then cleaved with thrombin (10 U/mg or 20 U/mg of total protein) 
for 2 h.  In order to specifically retain and concentrate 6His-HA-Vpr an additional 
affinity chromatography step was performed using a His spin-trap™ nickel column 
(GE Healthcare).  Due to the presence of imidazole in the eluted protein, the 
preparation was dialyzed overnight at 4ºC in 1X PBS and the protein 
concentration was determined.  The concentrations of all purified 6His-HA-Vpr 
protein preparations were in the range of 100-250 ng/µl due to low solubility in 
aqueous solutions.  The same protocol was followed to purify the recombinant 
Vpr mutant (Vpr R73,80A). 
2.8. Immunofluorescent and deconvolution microscopy  
Adherent U-87 MG astroglioma cells or primary HFA were grown on poly-
lysine-coated coverslips. Cells were then washed twice with 1X PBS prior to 
fixation in 4% paraformaldehyde for 20 min at room temperature. 
Permeabilization of plasma membranes was performed with 0.2% Triton X-100 in 
1X PBS for 5 min. Cells were then blocked in 5% goat serum, 1% BSA in 1X 
PBS (blocking buffer) and incubated overnight with primary antibody in blocking 
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buffer at 4ºC.  The day after, staining with secondary Alexa Fluor-488 (green) or 
Alexa Fluor-595 (red)-conjugated antibody (Invitrogen) was performed for 1 h at 
room temperature in the dark.  Cells were washed three times with 1X PBS in 
between each step.  Subsequently, cells were incubated in 300 nM DAPI-
containing 1X PBS to stain nuclei and accurately washed three times.  Coverslips 
were then rinsed in ddH2O to remove saline residues and mounted on 
microscope slides with pro-long anti-fade reagent (Invitrogen) to retain the 
fluorescent signal. Slides was immediately imaged with a deconvolution 
microscope (Olympus) or stored at 4ºC.  For all cell types, a minimum of 10 fields 
at 20X magnification were analyzed.  Additionally, for higher magnification, z-
section images were captured (at least 20 different planes) at a 0.2 µm distance 
for each individual channel.  Planes were then deconvolved using the nearest 
neighbor algorithm and volume images were obtained to confirm localization by 
planar view. The following primary antibodies were utilized for immuno-
fluorescent studies: GFAP (Cell Signaling), xCT (Novus Biologicals), 4F2hc 
(Abcam), and Vpr (NIH AIDS Research and Reference Reagent Program). For 
all negative control staining, the same procedure as described above was 
followed with the exception that a secondary antibody in blocking buffer was not 
added, to rule out any non-specific binding of the primary antibody. 
In order to detect intracellular accumulation of reactive oxygen species 
(ROS) due to different oxidative stress-induced stimuli, the RedoxSensor™ Red 
CC-1 dye (Invitrogen) was utilized.  Cells were fixed, permeabilized, and 
incubated with 2 µM RedoxSensor™ Red CC-1 dye in 1X PBS at 37 ºC for 10 
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min. Following three washes with 1X PBS, cells were stained with DAPI, 
mounted on slides and processed as aforementioned.  Low-level light techniques 
were employed throughout the processing steps to avoid photo-oxidation of the 
RedoxSensor™ Red CC-1 dye. 
2.9. Caspase detection assay 
Caspase-3 and -7 activities were measured using the luminescent 
Caspase-Glo® 3/7 assay (Promega), which is based on a luminogenic substrate 
containing the tetra-peptide sequence DEVD, targeted by the two caspases. 
Augmented caspase activity leads to increased cleavage of the DEVD-containing 
substrate, which is detected as an enhanced luminescent signal.  Primary HFA 
were plated at a density of 2,000 cells in individual wells of a 96-well opaque  
tissue-culture plate and either left untreated or exposed to different compounds. 
As a positive control for induction of caspase-3 and -7, HFA were exposed for 48 
h to 2 µM CPT.  In addition, HFA were also treated singularly or in combination 
with recombinant Vpr, anti-Vpr antibody, NAC, and the caspase inhibitor Ac-
DEVD-CHO.  NAC was applied to cells 24 h prior to harvesting.  At 48 h post-
exposure to each compound, cell culture medium was removed and HFA were 
carefully washed in 1X PBS to minimize the detachment of cells from the plastic. 
HFA were then lysed in situ and incubated at room temperature in the dark for 20 
min. Luminescent signals were then recorded using a Glomax® luminometer 
(Promega; Madison, WI) and plotted as fold-over untreated cells.  All values were 
subject to background correction by subtracting the luminescent values obtained 
from wells with no cells. 
Chapter 2  	  
 
	  
72
 
2.10. Human cytokine array 
Supernatant from untreated or Vpr-treated primary HFA was collected at 
72 h and employed in the detection of differentially secreted cytokines by aid of 
the Proteome Profiler™ Array (R&D Systems, Minneapolis, MN).   Supernatants 
(500 µl) from each of the two samples were incubated with a cytokine detection 
antibody cocktail and dispensed on top of each membrane.  After an overnight 
incubation at 4ºC, cytokine-antibody complexes were detected with a 
streptavidin-HRP conjugated cocktail.  Each cytokine, spotted in duplicate, was 
visualized by a chemiluminescent detection method (Pierce).  In order to 
quantitate the brightness of each spot, densitometry was performed with an 
AlphaEase FC software package (Alpha Innotech Corporation).  The integrated 
density value (IDV) of the background was subtracted to the IDV of each spot. 
Each pair of cytokines was then normalized to the untreated IDV and the ratio of 
fold over untreated calculated.  The average of each pair was then plotted with its 
standard error, and column bars with a positive or negative fold ratio represent 
cytokines up or down-regulated in EC Vpr-treated samples compared to 
untreated ones, respectively. 
2.11. Isolation of RNA and qRT-PCR microarray 
Primary HFA were either left untreated or exposed to recombinant Vpr for 
72 h.  Total cellular RNA was isolated using the PrepEase® RNA Spin procedure 
as previously described by the manufacturer (USB, Affymetrix), through a series 
of centrifugation steps to discard genomic DNA and isolate intact total cellular 
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RNA by ethanol precipitation.  RNA eluted from both samples yielded A260:A230 
and A260:A280 ratios both greater than 2 (as measured by spectrophotometry), 
indicating very pure RNA samples. In addition, fractions subjected to 
electrophoresis produced sharp and distinct bands representative of both the 
18S and 28S ribosomal RNA. 
In order to study the genes of the oxidative stress pathway that were 
differentially regulated upon treatment with extracellular Vpr, 5 µg of total RNA 
per sample were subjected to reverse transcription using the RT2 First-Strand 
procedure as described by the manufacturer (SABioscience, Frederick, MD) to 
yield complementary DNA (cDNA).  qRT-PCR was performed on cDNA samples 
using RT SYBR Green/ROX qPCR Master Mix (SABioscience, Frederick, MD). 
The reaction mixtures (25 µl) were dispensed in individual wells of a 96-well plate 
pre-spotted with primers of genes belonging to the oxidative stress and 
antioxidant defense pathway (SABioscience).  Cycling conditions were set for 40 
cycles, each consisting of 15 s at 95ºC and 1 min at 60ºC on an ABI 7300 
Thermocycler (Applied Biosystems Inc., Foster City, CA).  For each gene, a 
threshold cycle (Ct) was calculated with the built-in software.  Augmented mRNA 
levels in Vpr-treated samples were analyzed as fold over untreated (calibrator) 
and expressed in linear scale.  Using an in-house built software (SABioscience), 
genes with the highest fold expression between treated and untreated were listed 
and plotted.  For those genes with the highest fold values, protein levels were 
compared between untreated and treated samples by western immunoblotting as 
described in section 2.4. 
Chapter 2  	  
 
	  
74
 
2.12. GAPDH activity assay 
To measure GAPDH intracellular activity, we employed a fluorimetric 
assay (KDalert™ GAPDH Assay procedure performed as described by the 
manufacturer, Ambion), which measures the conversion of NAD+ to NADH by 
GAPDH in the presence of the phosphate G-3-P.  The NADH production is 
proportional to the amount of GAPDH enzyme present intracellularly.  Cells left 
either untreated or exposed to Vpr or DOX were harvested at the relative time 
point and lysed in 100 µl KDalert lysis buffer.  Whole cell lysate (10 µl) or GAPDH 
standards (ranging from 0 to 0.26 U/ml) were dispensed in triplicate in single 
wells of a 96-well opaque plate with black walls to avoid diffraction of 
fluorescence.  After addition of 90 µl of master mix solution (proprietary formula), 
the readings were taken using a FluoroMax-3 with MicroWell Plate Reader (Jobin 
Yvon•Spex, Horiba Group) set at excitation and emission wavelengths of 560 
and 590 nm, respectively.  All readings were subtracted from the background 
value (lysis buffer alone) and a standard curve was plotted.  After verifying that 
both standards’ and sample’ readings were within the linear range, graphs were 
plotted as percentage over untreated cells ± standard errors. 
2.13. Statistical analysis 
The results were statistically analyzed by a two-tailed Student’s t-test.  
Differences between groups were considered significant if p values < 0.05 were 
obtained. 
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3.1 Abstract 
Human immunodefiency virus type 1 (HIV-1)-infected patients display 
neurological complications associated with a diverse viral quasispecies within the 
central nervous system (CNS) as well as the presence of unique viral variants 
within this compartment as compared to the periphery.  Among these patients, a 
number have been reported with an increased viral load being directly correlated 
with higher a concentration of extracellular HIV-1 Vpr in the cerebrospinal fluid 
(CSF).  In a separate study, HIV-1-infected patients with a low CD4+ T 
lymphocyte count were found to display a lower concentration of glutathione 
(GSH), the main intracellular antioxidant molecule, in the same subset of cells, 
which was also related to a shorter survival rate.  Additionally, a number of recent 
studies have pinpointed HIV-1 Vpr as an extracellular protein responsible for the 
neuronal loss observed in late stage disease patients as well as an inducer of 
ATP loss.  In order to correlate all the aforementioned studies and gain a better 
understanding of the role played by extracellular Vpr in HIV-1 disease 
progression, we utilized an astrocytic cell line (U-87 MG) to determine Vpr-
induced downstream effects on cellular metabolism and oxidative stress 
induction.  We initially exposed U-87 MG astrocytes to conditioned media (CM) 
from HEK 293T cell lines transfected either in the absence or presence of HIV-1 
Vpr and found that only Vpr-containing CM induced both an ATP and GSH 
decrease.  Due to variability and lack of control in extracellular Vpr concentration 
within CM, recombinant Vpr was purified and astrocytes were directly exposed to 
the purified viral protein.  Not only were the results obtained with CM in a dose-
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dependent manner able to be reproduced, but it was also demonstrated that 
GSH decline was slightly slower than that of ATP in a time-dependent fashion. 
GSH decline is indicative of induction of oxidative stress: treatment with the 
antioxidant molecule N-acetyl-cysteine (NAC), which provides the rate limiting 
amino acid cysteine, could rescue astrocytes from Vpr-induced GSH deprivation, 
as a partial increase in GSH levels after extracellular Vpr-induced oxidation was 
observed. These lines of evidence outline how Vpr affects astrocytic metabolism 
by depriving cells of ATP and GSH.  In addition, Vpr induced augmented 
production of reactive oxygen species (ROS), due to an increase in oxidized 
glutathione (GSSG) concentration and reduction in the overall GSH/GSSG ratio.  
This event was almost entirely suppressed by treatment with an anti-Vpr antibody 
or NAC co-treatment.  These studies confirm the role of extracellular Vpr in 
impairing astrocytic metabolism by affecting both ATP and GSH pool levels. 
3.2 Introduction 
Infection with human immunodeficiency virus type 1 (HIV-1) leads to 
neurodegenerative diseases such as HIV-associated dementia (HAD) or 
neuroAIDS.  The most severe forms of HIV-1-induced neurologic disease are a 
consequence of a cascade of events that includes a massive influx of HIV-1-
infected monocytic cells across the blood-brain barrier once this barrier is 
compromised due to persistent insult during disease progression.  Neuroinvasion 
of blood-borne extravasating cells triggers a series of inter-related events with 
ensuing effects on the central nervous system (CNS) homeostasis.  Indeed, both 
CNS-resident as well as blood-borne HIV-1-infected cells contribute to the 
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release of HIV-1 particles and viral proteins, in addition to cellular mediators, 
which contribute to an overall state of inflammation involving HIV-1-infected and 
uninfected cells at the blood-brain barrier and within the CNS.  
HIV-1 infects CNS-resident cells during the early phase of infection by 
infiltrating HIV-1-infected peripheral blood cells crossing the blood-brain barrier 
(BBB) (An et al., 1999). Both peripheral blood HIV-1-infected monocytes and 
CD4+ T cells (although to a lesser extent) penetrating into the CNS play crucial 
roles in these processes. Among cells of the CNS, microglia and perivascular 
macrophages are the primary target of productive HIV-1 infection (Gonzalez-
Scarano and Martin-Garcia, 2005), whereas astroglia and oligodendroglia are 
non-productively infected. Neurons are considered to be refractive to HIV-1 
infection (Kaul et al., 2001), and their demise, a manifestation of disease 
progression, occurs through indirect mechanisms.  It is still matter of debate 
whether astrocytes are productively infected and at what level.  Early reports 
attributed to the astrocytic compartment a low level of infection involving a CD4-
independent mechanism (Harouse et al., 1991).  Nonetheless, given their high 
abundance in the CNS, they could likely represent a major viral reservoir. Recent 
studies have revalued the role astrocytes might play in late stage disease by 
demonstrating a higher frequency of HIV-1-infected astrocytes located in the 
proximity of perivascular areas correlating with increased severity of 
neurocognitive impairment (Churchill et al., 2009).  The importance of monocytes 
is also underscored by their capability to transmit HIV-1 to CD4– astrocytes by 
cell-to-cell contact (Muratori et al., 2007).  Another sign of HIV-1 disease 
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progression is astrogliosis, characterized by excessive astrocytic activation and 
proliferation followed by apoptosis (An et al., 1996).  Astroglial infection is 
characterized by an initial peak in viral production followed by a state of 
persistent infection (different from latent infection of monocyte-derived 
macrophages, MDM, or CD4+ T cells) with the presence of multiply spliced short 
transcripts (coding mainly Nef proteins), inefficient translation of structural 
proteins (gag and env), and almost undetectable levels of viral genomic 
transcripts (Brack-Werner, 1999; Brack-Werner et al., 1992; Gorry et al., 1999).  
Restriction in astrocytic infection is attributed not only to limited viral entry (Li et 
al., 2007), but also to a post-transcriptional block in the export of viral transcripts 
from the nucleus (Kleinschmidt et al., 1994).  Viral production is not entirely 
rescued by treatment with potent viral stimulators, although reactivation could be 
accomplished upon co-cultivation with uninfected CD4+ T cells (Kleinschmidt et 
al., 1994; Tornatore et al., 1994; Tornatore et al., 1991), which confirms the 
importance of cell-to-cell contact and formation of virological synapses.  During 
late stage HIV-1 disease, an increased frequency of infiltrating monocytes and 
CD4+ T cells could deliver neurotoxic factors, such as chemokines and viral 
proteins (Tat, Vpr, gp120, and Nef) (Giulian et al., 1990), which over-activate 
astroglia to secrete glutamate, increasing excitotoxicity.  In addition, HIV-1-
infected MDMs trafficking to the brain also secrete glutamate (Erdmann et al., 
2007), thus increasing the amount of glutamate to be disposed of by astrocytes, 
creating a vicious cycle.  This sequence of events contributes to astrocytic and 
neuronal dysregulation, leading to mild to severe neurocognitive impairment.  
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Indeed, another characteristic of HIV-1-infected patients in late stage disease is 
the increase in opportunistic infections, which also impairs CNS function along 
with the direct effects induced by HIV-1.  Severe cognitive and motor dysfunction 
known as HIV-associated dementia (HAD) are relatively common end-stage 
events (Childs et al., 1999; Gendelman and Persidsky, 2005; Kaul et al., 2001; 
McArthur et al., 2003), although with the introduction of combination anti-
retroviral therapy, more severe forms of neurocognitive impairment have declined 
in frequency but increased in prevalence due to an increase in HIV-1-infected 
patient longevity, while milder forms of CNS neurocognitive impairment have 
increased in frequency and prevalence (McArthur et al., 2003).  In addition, a 
diffuse intracellular oxidation has been detected, in the form of decreased 
availability of glutathione (GSH), the main cellular antioxidant and redox buffer, 
and augmented lipid oxidation, which triggers a downstream signaling cascade 
(Herzenberg et al., 1997).  GSH is a tripeptide, composed of cysteine, glutamate, 
and glycine, which is synthesized in two subsequent ATP-dependent reactions. 
Initially glutamate and cysteine, the rate-limiting amino acid, are combined 
together by action of the γ-glutamyl-cysteine synthetase (γ-GCS), forming the 
dipeptide γ-glutamyl-cysteine (γ-GluCys), which is used as a substrate by the 
glutathione synthetase (GSH-S) to create the end product GSH.  As a thiol, GSH 
functions as an electron donor thus detoxifying reactive oxygen species (ROS) 
by the activity of glutathione-S-transferase (GST), which covalently binds GSH to 
xenobiotics or other toxic compounds.  However, the GSH sulphydryl group could 
also bind to another GSH molecule yielding a homodimer referred to as oxidized 
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glutathione (GSSG), which is no longer able to covalently bind to oxidizing 
agents.  Reduced glutathione molecules are continuously restored from oxidized 
glutathione by the action of the glutathione reductase, which transfers reduced 
equivalents from NADPH.  A decline in reduced GSH could be the result of 
different processes.  Indeed, increased intracellular oxidation leads to augmented 
levels of GSSG, thus reducing the GSH/GSSG ratio, which is maintained 
elevated under physiological conditions.  In addition, GSH could be consumed by 
GST, through the generation of glutathione-S-conjugates or secreted 
extracellularly (Dringen, 2000).  GSH deficits could be generally counteracted by 
supplementation with L-cysteine.  However, due to its ease of oxidation in the 
peptidase-rich extracellular environment, addition of N-acetyl-cysteine (NAC), 
wherein a more stable acetyl group is added, may effectively provide the 
intracellular machinery with more substrate to synthesize GSH.  All cell types not 
only require GSH for their survival, but also a fully efficient glutathione detoxifying 
system to promptly scavenge both exogenously applied peroxides or 
endogenous ROS generated continuously during oxidative metabolism. 
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Fig. 3.1. Synthesis of the tripeptide glutathione (GSH) from its amino acid 
components is driven by two ATP-dependent reactions. (A) The antioxidant 
glutathione (GSH) is composed of the three amino acids glutamate (Glu, in 
black), cysteine (Cys, in red) and glycine (Gly, in blue). Cys possesses the thiol 
(–SH) group (circled in red) capable of covalently binding reactive oxygen 
species (ROS), hence neutralizing them, or homodimerizing with another GSH 
molecule, thus forming oxidized glutathione (GSSG), unable to bind to ROS. (B) 
Glutathione biosynthesis is accomplished in two ATP-dependent reactions, 
initially combining Glu and Cys, forming Cys-Glu by action of the gamma-
glutamyl cysteine synthetase (γ-GCS), which could be irreversibly blocked by 
buthionine sulfoximine (BSO). Subsequent addition of Gly by the glutathione 
synthetase (GSH-S) gives rise to the tripeptide GSH, which is converted into 
GSSG upon detoxification of ROS. 
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Figure 3.1 
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Within the CNS, astrocytes possess a much more efficient glutathione system of 
peroxide detoxification compared to neurons (Dringen et al., 1999), although both 
cell types are equally susceptible to oxidative stress-inducing conditions.  This 
observation is in line with the astrocytic functionality in preserving a healthy 
environment, by releasing neurotrophic factors, which guide neuronal 
development, and contribute to the metabolism of neurotransmitters.  
Furthermore, astrocytes also regulate extracellular pH and potassium levels, 
which would otherwise be neurotoxic (Volterra and Meldolesi, 2005).  Astrocytes 
are known to increase the number of mature functional synapses on neurons 
thus supporting their development and, given their strategic positions at the lining 
of the BBB, they tightly regulate the uptake of molecules from the periphery 
(Dong and Benveniste, 2001). 
Adenosine triphosphate (ATP) is the major chemical energy molecule for 
intracellular metabolism.  It is generated through phosphorylation of adenosine 
monophosphate (AMP) and cellular respiration, and employed as a phosphate 
group donor to fuel a large number of intracellular processes.  Several different 
molecules, (especially chemotherapeutic compounds) are known to be potent 
apoptotic agents, as they penetrate intracellularly and trigger a signaling cascade 
that eventual leads to programmed cell death.  Among these compounds are 
iodoacetate (IAA), menadione (MEN) and doxorubicin (DOX).  At a relatively high 
concentration, IAA and DOX have been shown to decrease both ATP and GSH 
levels, although there is not sufficient evidence to either state or rule out any 
possible cause-effect relationship between the two decreases of these 
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intracellular metabolites (Verity et al., 1991; Wolf and Baynes, 2006).  On the 
other hand, there are compounds that only affect either of the two metabolites’ 
pool levels, without affecting the other.  For instance, buthionine sulfoximine 
(BSO) severely decreases intracellular GSH levels with no effect on ATP 
concentration for in vitro exposures of up to 48 h	  (Griffith et al., 1979; Griffith and 
Meister, 1979).  On the other hand, short in vitro exposures of cells to bongkrekic 
acid (BKA) decreased ATP levels, as BKA binds to the adenine nucleotide 
translocator (ANT) protein in the inner mitochondrial membrane, thus halting the 
exchange of ATP for ADP between the mitochondrial matrix and the cytoplasm	  
(Jacotot et al., 2001). Nonetheless, under oxidizing conditions, for instance by 
treatment with MEN, the glutathione pool level is dramatically impaired, as 
witnessed by a drastic decrease in the GSH/GSSG ratio	  (Smith et al., 1987). 
Previously published studies and evidence of the alterations caused by 
extracellular Vpr to astrocytes led us to examine the role of Vpr in causing a 
decline in these two metabolites as a possible cause of the aggravation in HIV-1-
infected patients suffering from severe neurocognitive impairment in late-stage 
HIV-1 disease. 
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3.3. Results 
3.3.1. Detection of HIV-1 Vpr as an extracellular protein 
Previous studies have suggested the possibility that Vpr is secreted from 
infected cells (Levy et al., 1994; Levy et al., 1995; Xiao et al., 2008).  Soluble Vpr 
has been detected in vivo in the blood serum and CSF as a cell-free and virus-
free (CFVF) protein (Hoshino et al., 2007; Levy et al., 1994; Levy et al., 1995), 
and in vitro in the cell culture supernatant of transfected HEK 293T cells, Jurkat 
(a CD4+ T precursor cell line) and peripheral blood mononuclear cells (PBMC) 
(Xiao et al., 2008).  Based on these observations, we proceeded to reproduce 
these results in HEK 293T cells to verify the presence of Vpr in CFVF 
supernatant prepared from HEK 293T cells.  Initially the expression of 
intracellular Vpr was examined by transfection of HEK 293T cells (as described 
in section 2.4).  As shown in Fig. 3.2.A (lanes 3 and 4), the expression of both 
the 6His-HA-Vpr and 3HA-Vpr constructs expression was detected.  
Subsequently, it was determined whether the Vpr protein was found in the 
extracellular medium of transfected cells, using the non-infectious Vpr-deficient 
pNL4-3.Luc.R–E– molecular clone as a result of passive release. In this regard, 
293T cells were co-transfected with the NL4-3R–E– molecular clone and/or with 
the HA-Vpr plasmid (as described in section 2.4). Western immunoblotting 
confirmed the presence of the capsid p24 protein only in those samples 
transfected with the molecular clone, along with incorporation of 3HA-Vpr 
molecules within purified pelleted viral particles (Fig. 3.2.B).  The CFVF 
extracellular medium of only those cells co-transfected with both 3HA-Vpr and 
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the molecular clone resulted in the presence of extracellular Vpr (Fig. 3.2.C), as 
previously reported (Xiao et al., 2008). Nevertheless, unlike Xiao and coworkers, 
cleavage of Vpr was not detected; however, a slower-migrating complex around 
35-40 kDa was detected, which might represent dimerization of Vpr. 
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Fig. 3.2. Vpr is expressed in different intra- and extra-cellular 
compartments. (A) Intracellular expression of the two types of HA-tagged Vpr 
proteins in HEK 293T cells.  Whole cell lysates of 293T untransfected, 
transfected with an empty vector (pcDNA) or with various Vpr plasmids.  In lane 3 
and 4, pcDNA-3HA-Vpr or our faster-migrating constructs (6His-HA-Vpr) have 
been transfected, respectively.  Whole cell lysates were run on a 15% SDS-
PAGE and probed with anti-HA antibody. As a loading control, membrane was 
stripped and probed with anti β-actin antibody. (B) Expression of p24 capsid 
protein and incorporated 3HA-Vpr within virions collected 48 h post-transfection 
from the supernatant of 293T cells transfected with the different constructs. (C) 
After ultracentrifugation at 28,000 RPM, CFVF supernatant was collected and 
acetone precipitated.  Subsequently, immunoprecipitation (with anti-HA antibody) 
followed by western immunoblotting was performed.  Only the sample co-
transfected with Vpr and the other viral proteins display Vpr in the CFVF and 
possibly presence of a dimer. 
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Figure 3.2 
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3.3.2. U-87 MG astroglioma cells express the GFAP marker  
Cells of the astrocytic lineage express the typical glial fibrillary acidic 
protein (GFAP) intracellular marker, an intermediate filament protein.  U-87 MG 
cells, a grade III astroglioma cell line (Bjorndal et al., 1997), were utilized as a 
physiologically relevant astrocytic model, since this cell line shows many of the 
morphologic features associated with cells of the astrocytic lineage.  For this 
purpose, GFAP intracellular expression was examined in U-87 MG cells utilizing 
immunofluorescence (as described in section 2.7).  Control cells, incubated 
without primary anti-GFAP antibody but with secondary antibody, did not result in 
the detection of any protein (Fig. 3.3.A).  When U-87 MG cells were incubated 
with primary anti-GFAP and Alexa Fluor-488 conjugated secondary antibody, it 
was demonstrated that U-87 MG constitutively express GFAP intracellularly (Fig. 
3.3.B).  A higher magnification (40X) of stained U-87 MG indicates the presence 
of GFAP throughout the intracellular compartment in all cells within the 
population (Fig. 3.3.C). 
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Fig. 3.3. U-87 MG astrocytic cells express the GFAP marker. U-87 MG 
astroglioma cells have been fixed, permeabilized, blocked, and incubated with 
primary anti-GFAP antibody.  Subsequently, cells have been incubated in the 
absence (A) or presence (B) of anti-GFAP primary antibody.  First, second, and 
third columns represent DAPI, FITC, and PHASE channels, respectively, 
whereas the fourth column is the superimposition of the DAPI and FITC 
channels.  All images (20X) are cross sectional fields and are representative of 
the entire cell population. Bars = 10 µm. (C) A higher magnification image (40X) 
of U-87 MG astroglioma cells with the blue-stained nucleus (DAPI) and uniformly 
distributed GFAP (FITC) throughout the intracellular environment is shown. Bar = 
10 µm. 
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Figure 3.3 
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3.3.3. Determining extracellular HIV-1 Vpr-induced effects on 
astroglioma metabolism 
HIV-1 Vpr has been reported to be toxic when added to mixed neuronal 
cell cultures (Huang et al., 2000; Sabbah and Roques, 2005).  Since we detected 
Vpr within the extracellular compartment of transfected HEK 293T cells and as a 
further evidence of its presence therein, U-87 MG cells were exposed to different 
conditioned media (CM) obtained from either 293T cells untransfected, 
transfected with the Vpr-deficient NL4-3R–E– molecular clone or the 6His-HA-Vpr 
plasmid in trans with the NL4-3R–E– molecular clone, and a kinetic analyses with 
respect to time was performed with regard to intracellular glutathione (GSH) 
levels, using a luciferase-based GSH detection assay (Fig. 3.4).  A significant 
decrease in the reduced form of GSH amount was detected in U-87 MG cells 
treated with Vpr-containing CM (light grey bar) starting at 12 h post-treatment 
and was detected for the duration of the treatment up to 48 h (Fig. 3.4.A).  On the 
other hand, Vpr-deficient CM failed to show any decrease in intracellular GSH 
levels (dark grey bars). As a positive control, U-87 MG cells were treated with 
butathione sulfoximine (BSO), which has been shown to irreversibly inhibit γ-
glutamylcysteine synthetase and GSH synthesis.  U-87 MG cells treated for 24 h 
with BSO displayed a ten-fold decline in GSH levels.  Since GSH is synthesized 
in two ATP-dependent reactions from its constituent amino acids (cysteine, 
glutamate, and glycine) and due to recent evidence demonstrating EC Vpr-
induced ATP reduction in neurons (Rom et al., 2009), we proceeded to study 
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variations in total ATP levels of U-87 MG exposed to Vpr-containing or Vpr-
deficient CM.  Only Vpr-containing CM (light grey bars) showed a reduction in 
ATP levels (about 30% at 24 h post-treatment), which became statistically 
significant 48 h post exposure (50% decrease, Fig. 3.4.B).  Our results confirm 
previously published studies (Rom et al., 2009), although with a more limited 
magnitude, primarily due to a low concentration of extracellular Vpr in the tissue 
culture CM. 
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Fig. 3.4. HIV-1 Vpr-containing conditioned medium induces a decline in 
ATP and GSH levels in U-87 MG cells. (A) Temporal kinetic analysis of 
extracellular Vpr-induced alteration of intracellular GSH levels.  CM from HEK 
293T cells transfected with different constructs have been applied to U-87 MG 
and 24 h and 48 h post-treatment only cells cultured with EC Vpr-containing CM 
manifested a drop in GSH levels in a timely fashion (light grey).  On the contrary, 
untreated cells (black bars) or conditioned media from Vpr-deficient transfected 
293T (dark grey) did not alter GSH levels.  As a positive control, U-87 MG cells 
treated with BSO (100 µM for 24 h), an irreversible inhibitor of γ-glutamylcysteine 
synthetase, induced a 90% decrease in GSH concentration (red bar).  (B) ATP 
levels similarly decline only in Vpr-containing CM at 24 h post-treatment. * P-
value < 0.01 (student paired T-test). 
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Figure 3.4 
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3.3.4. Replenishment of ATP and GSH pool level by treatment with 
anti-HA antibody 
It was hypothesized that the observed decreases in GSH and ATP pool 
levels induced by Vpr-containing 293T conditioned media could be attributed to 
the presence of extracellular Vpr.  Hence, U-87 MG cells were exposed to Vpr-
containing or Vpr-deficient 293T conditioned media in the absence or presence 
of anti-HA antibody, targeting the N-terminus tag of Vpr.  The rationale was to 
neutralize or partially block Vpr present within the extracellular medium, thus not 
allowing any downstream signaling leading to the observed declines in GSH and 
ATP.  Due to the initial lack of specificity of in-house produced anti-Vpr 
antibodies (provided by collaborators), an antibody against the N-terminal HA tag 
was utilized to block Vpr and prevent its translocation or downstream signaling 
effects, which caused the observed decreases in astrocytic metabolism. The anti-
HA antibody was previously used for IP/WB (Fig. 3.2.C) and proven to detect 
extracellular Vpr protein. Indeed, U-87 MG cells exposed to Vpr-containing 
conditioned media in the presence of anti-HA antibody demonstrated almost a 
total recovery of glutathione levels (Fig. 3.5.A), and ATP levels (Fig. 3.5.B). 
These observations point to a Vpr-direct induction of intracellular GSH decline, 
either through translocation from the extracellular compartment or by signaling 
through membrane-associated receptors, which could generate a cascade of 
signaling events leading to ATP and GSH decreases.  Overall, anti-HA antibody 
treatment of U-87 MG cells exposed to Vpr-containing conditioned media showed 
an amelioration of Vpr-induced effects. 
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Fig. 3.5. Addition of anti-HA antibody to target extracellular 6His-HA-Vpr 
rescued U-87 MG astrocytes from decreased ATP and GSH levels.  (A) Vpr-
containing CM induced reduction in GSH levels, which was almost entirely 
recovered upon treatment with anti-HA antibody directed against the N-terminus 
tag of Vpr.  Anti-HA antibody added to Vpr non-containing CM does not induce 
any effects on GSH concentrations as shown by the red bars. (B) Similarly, Vpr-
containing CM-treated U-87 MG display reduced levels of ATP compared to Vpr-
deficient CM treated cells.  Addition of the anti-HA antibody resulted in almost 
complete recovery of initial ATP concentration values. * P-values < 0.05 (student 
paired T-test). All experiments are performed 48h post-exposure. 
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Figure 3.5 
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3.3.5. Determining the presence of the cystine/glutamate antiporter 
system in U-87 MG astroglioma cells 
Oxidative stress-inducing stimuli promote glutathione depletion and a 
cascade of signaling events leading to transcription of stress-response genes 
and DNA damage (Deshmane et al., 2009).  The antioxidant compound N-acetyl-
cysteine (NAC), a precursor of cysteine, may partially replenish GSH exhaustion.  
In order to evaluate whether Vpr-induced oxidative stress in astrocytes could be 
counteracted by treatment with NAC, the presence of the Xc– system, primarily 
responsible for cysteine uptake, was verified in U-87 MG astroglioma cells. The 
XC– system, a heterodimeric protein complex composed of a catalytic unit (xCT) 
and a regulatory heavy chain (4F2hc) also referred to as CD98 (Sato et al., 
1999), is the key mediator in the uptake of extracellular cystine (the oxidized form 
of cysteine) in exchange of intracellular glutamate and functions in a Na+- and 
ATP-independent manner.  As U-87 MG cells have been previously shown to 
express both subunits (Chung et al., 2005; Kim et al., 2001; Lyons et al., 2007) at 
the mRNA and protein levels, we analyzed whether the Xc– system was correctly 
localized at the cell membrane by immunofluorescence (as described in section 
2.7).  We found that both xCT and 4F2hc units are expressed at the plasma 
membrane and within the cytoplasm (Fig. 3.6.A and B), the latter possibly due to 
constitutive expression of both units of the Xc– system, which are synthesized 
and transported to the cell membrane to meet the cellular demands for nutrients 
and GSH synthesis (Lyons et al., 2007).  In addition, a magnified view (100X) of 
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both subunits showed staining predominantly at the plasma membrane (Fig. 
3.6.C). 
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Fig. 3.6. U-87 MG astroglioma cells possess the cystine/glutamate 
antiporter system.  The antiporter is composed of a light subunit xCT (A) and a 
heavy chain 4F2hc (B), which both predominantly localize at the plasma 
membrane.  Astroglioma cells abundantly synthesized both subunits for 
continuous uptake of cystine in exchange for intracellular glutamate, thus giving 
rise to a clear intracellular staining pattern.  The first column shows stained nuclei 
(DAPI), while the second column represents the TRITC/red (for xCT) or 
FITC/green (for 4F2hc) channel.  These two channels are shown in black and 
white until merged in the third column (20X magnification), wherein they are 
represented in their original color of staining. (C) Detailed images of the two units 
in U-87 MG cells are shown at a 100X magnification, which revealed dispersed 
intracellular presence as well as at the plasma membrane.  Scale bars = 10µm 
Chapter 3  104	  
 
	  
 
Figure 3.6 
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3.3.6. Determining NAC effects with respect to extracellular Vpr-
induced oxidative stress 
After having detected both subunits of the XC– system, their functionality 
with respect to taking up cystine for glutamate was determined.  Activity of the 
XC– system could be indirectly quantitated by measuring the synthesis of the 
downstream product (glutathione), which relies primarily on high affinity cystine 
uptake by the Xc– system.  In order to verify the functionality of the 
cysteine/glutamate antiporter system, U-87 MG astrocytes were treated with 
extracellular 5 mM NAC (more resistant to oxidation than cysteine) and GSH 
levels were measured 24 h post-exposure.  NAC-treated cells displayed a 
statistical significant increase of 80% of the original untreated GSH levels (Fig. 
3.7).  This increase was specific and due to NAC uptake, as untreated cells 
demonstrated unvaried levels of GSH.  Functionality of the XC– system has been 
previously reported for astroglioma cell lines.  Indeed, gliomas are known to 
secrete abundant amounts of glutamate through the XC– system (Lyons et al., 
2007), the reason for which they can expand and survive in an otherwise 
excitotoxic and neurotoxic environment.  As a positive control, U-87 MG cells 
were also treated with the GSH-decreasing compound BSO, which irreversibly 
promotes a decrease in GSH.  Indeed, addition of NAC to the cell culture 
medium of U-87 MG cells previously treated with BSO did not rescue GSH 
intracellular levels (Fig. 3.7, first bar from the right). 
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Fig. 3.7. U-87 MG astroglioma cells possess a functional Xc– system.  Cells 
were cultured in the absence or presence of known compounds capable of either 
decreasing (BSO) or increasing (NAC) the intracellular GSH concentration.  Initial 
treatment with BSO (100 µM) induces about a 10-fold decrease in GSH 
concentration. Cells treated for 24 h with NAC (5 mM) displayed a 70-80% 
increase in intracellular GSH.  On the other hand, intracellular GSH content of 
cells pre-treated with BSO and subsequently with NAC were not rescued due to 
the irreversibility of BSO action on γ-GCS. * P-values < 0.05; ** P-value < 0.001 
compared to untreated cells, respectively (student paired T-test). N-acetyl-
cysteine = NAC. 
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Figure 3.7 
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After having verified the functionality of the XC– system in U-87 MG cells 
through indirect measurement of the downstream product GSH, we sought to 
determine whether NAC treatment could counteract Vpr-induced intracellular 
oxidation.  NAC exerts its anti-oxidant effect by donating an electron through its 
thiol group, thus scavenging free radicals produced under conditions of oxidative 
stress.  U-87 MG cells treated either with Vpr-deficient or Vpr-containing 
conditioned media were then exposed to 5 mM NAC for 24 h prior to harvest.  
Cells assayed for glutathione content displayed a statistical significant restoration 
of GSH pool levels back to 80% of initial values (Fig. 3.8). This observation 
underscores how EC Vpr-induced decline in glutathione metabolism could be 
partially rescued after the addition of an antioxidant compound.  Nevertheless, 
complete reversal of the oxidative phenotype could not be achieved, although 
NAC pre-treatment was not attempted. 
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Fig. 3.8. N-acetyl-cysteine (NAC) partially rescued GSH-depleted U-87 MG 
cells.  U-87 MG cells treated for 48h with either Vpr-deficient or Vpr-containing 
CM display a no effect or decrease in intracellular GSH concentrations, 
respectively.  Co-treatment of U-87 MG cells exposed to Vpr-containing CM with 
NAC for 24 h partially recovered cells from oxidative stress induction. * P-value = 
0.001 of untreated compared to Vpr-treated U-87 MG. ** P-value < 0.05 
compared to U-87 MG exposed to Vpr-containing CM without NAC (student 
paired T-test). 
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Figure 3.8 
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3.3.7. Effects of recombinant HIV-1 Vpr on astrocytic metabolism 
After having demonstrated a direct role of Vpr in the impairment of cellular 
metabolism, we proceeded to reproduce the previously reported observations 
through employment of recombinant Vpr. GST-6His-HA-Vpr protein was 
expressed from bacteria lysates (Fig. 3.9.A) and is present both as a full-length 
(39 kDa, top bands) as well as an intracellularly cleaved protein (~27 kDa, 
second band), as a result of Vpr-induced cytotoxicity (Kaminska et al., 2007). 
Upon thrombin cleavage and nickel chromatography, only the full-length Vpr 
displays binding ability to the column (Fig. 3.9.B).  The presence of the GST tag 
enhanced Vpr solubility (concentration in the order of units of mg/ml).  However, 
upon cleavage of GST and post-elution from the His spin column, Vpr was not 
retained within the soluble aqueous portion, yielding low final concentrations. 
Notwithstanding in the final eluted portion (figure 3.9.B lane 18) only full-length 
6His-HA-Vpr and no cleaved forms was retained in the His spin column. 
To summarize and further extend our previous studies employing Vpr-
containing HEK 293T conditioned medium, U-87 MG cells were exposed to 
extracellular recombinant Vpr and assayed for intracellular ATP and GSH levels. 
Vpr induced a statistical significant drop in ATP concentrations as early as 24 h 
post-treatment (30% decline), decreasing about two-fold after 48 h and to 20% of 
the initial values after 72 h of exposure (Fig. 3.10, red line). Similarly, GSH 
declines at all time points, with a statistical significant decrease to 40% of the 
initial values after 72 h (Fig. 3.10, blue line). 
Chapter 3  112	  
 
	  
 
Fig. 3.9. GST-6His-HA-Vpr protein was successfully purified from 
transformed Bl21 DE3 RIPL bacteria. Samples collected during the purification 
process were run on a 10% SDS-PAGE. A) Initial purification of GST-6His-HA-
Vpr protein by lysis (lane 1), sonication (lane 2) and affinity chromatography 
through GSH-agarose beads after a single step (lane 3). Three subsequent 
eluates are shown (lane 4-6). B) Two different concentrations of thrombin 
protease (10 U or 20 U per mg of protein) were added to cleave GST-conjugated 
Vpr and subsequently purified by nickel chromatography using His-Spin columns 
targeting the 6-histidine tag at the N-terminus of the Vpr recombinant protein. 
Samples treated with 10 U/mg thrombin are shown in blue (lane 2-6 and 12-15), 
whereas those cleaved with 20 U/mg thrombin are in black (lane 7-11 and 16-
19). ft = flow-through His-Trap column, w = wash. 
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Figure 3.9 
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Fig. 3.10. Extracellular Vpr induced a significant decline in ATP and GSH 
intracellular concentrations.  U-87 MG astroglioma cells exposed to 5 µg/ml of 
extracellular Vpr shows a time-dependent ATP decline up to 4-fold compared to 
untreated cells after 72 h exposure (red line).  In a similar time-dependent 
manner, the GSH concentration decreased about 2.5-fold after 72 h (blue line). * 
P-values < 0.05 compared to untreated cells (Student paired T-test). 
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Figure 3.10 
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3.3.8 Extracellular Vpr alters astrocytic GSH/GSSG balance 
Different oxidative stress-inducing compounds not only affect intracellular 
levels of total GSH, but also, and more importantly, the concentration of reduced 
GSH. These events coincide with an increased concentration of oxidized 
glutathione (GSSG) and a decrease in the ratio of reduced over oxidized 
glutathione (GSH/GSSG), an indicator of intracellular health.  Since extracellular 
Vpr induces a statistically significant decrease in reduced GSH (Fig. 3.10), we 
sought to determine whether this decline was due to a reduction in the 
GSH/GSSG ratio as a consequence of increased formation of GSSG.  In a 
similar experiment as the one shown in Fig. 3.10, U-87 MG astrocytic cells were 
exposed to Vpr and the GSH/GSSG ratio assayed at different time points (as 
described in section 2.5).  We found that, while untreated U-87 MG cells 
maintained a constant ratio, extracellular Vpr induced a significant drop in 
GSH/GSSG ratio, due to an abundant production of oxidized glutathione (Fig. 
3.11). 
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Fig. 3.11. Extracellular Vpr impairs astrocytic antioxidant pool levels by 
reducing the GSH/GSSG ratio.  U-87 MG astroglioma cells in either the 
absence or presence of 5 µg/ml of Vpr were assayed for reduced and oxidized 
glutathione levels and GSH/GSSG ratios calculated at different time points.  
While untreated cells maintain constant levels of reduced and oxidized 
glutathione (GSH/GSSG stable), Vpr-treated cells show a time-dependent 
decrease in the GSH/GSSG ratio. 
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Figure 3.11 
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3.3.9. Effects of extracellular Vpr on ROS production 
To further demonstrate extracellular Vpr ability to impair intracellular 
antioxidant defense mechanisms, we proceeded to determine whether exposure 
to extracellular Vpr induced formation of reactive oxygen species (ROS).  Indeed, 
ROS products are natural byproducts of intracellular metabolism; however, if not 
properly and timely disposed of by the cellular machinery, they accumulate within 
the mitochondria and lysosomes, thus initiating intracellular signaling with 
damaging effects.  Using a photo-oxidizable molecule (RedoxSensor™ Red CC-
1), which is taken up by cells through a non-endocytic pathway, U-87 MG cells 
were treated with different compounds and cells were stained for ROS 
intracellular accumulation.  Untreated cells did not display any photo-oxidation of 
the ROS-susceptible dye (Fig. 3.12.A); on the other hand, BSO-treated U-87 MG 
cells exhibited abundant accumulation of ROS (Fig. 3.12.B), which is 
symptomatic of an excessive state of intracellular oxidation.  As previously shown 
(Fig. 3.7), NAC treatment is not capable of rescuing BSO-induced ROS buildup 
(Fig. 3.12.C) as this process is irreversible. When cells were exposed to 
recombinant Vpr, they display an intensive ROS staining, which manifest 
increase accumulation of ROS (Fig. 3.12.D).  However, treatment of U-87 MG 
with an anti-Vpr antibody abrogated Vpr-induced formation of ROS (Fig. 3.12.E).  
Similarly, addition of NAC (5 mM) for 24 h, after a primary exposure to EC Vpr, 
rescued U-87 MG astrocytic cells from induction of oxidative stress (Fig. 3.12.F). 
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Fig. 3.12. Exposure of U-87 MG astrocytic cells to extracellular Vpr induced 
the accumulation of reactive oxygen species (ROS).  Untreated U-87 MG 
cells displayed no staining with the ROS-sensitive RedoxSensor™ Red CC-1 dye 
(A). On the contrary, U-87 MG cultured for 48 h with the inhibitor of γ-GCS 
butathione sulfoximine (BSO, 100 µM) accumulated ROS intracellularly (B), 
which can not be rescued by treatment with 5 mM NAC (C). Extracellular Vpr (5 
µg/ml) applied to U-87 MG cells similarly induced accumulation of ROS (D), 
which is blocked upon treatment of astrocytic cells with either anti-Vpr antibody 
(E) or addition of 5 mM NAC (F) for 24 h.  In all images, the first column shows 
stained nuclei (DAPI), while the second represents the FITC/green 
(RedoxSensor™ Red CC-1 dye) channel.  These two channels are shown in 
black and white until merged in the third column.   All magnifications are at 20X. 
Scale bars = 10 µm. Polyclonal anti-Vpr antibody was obtained through the NIH 
AIDS reagent bank. 
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Figure 3.12 
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3.4. Discussion 
The studies reported in this Chapter have been driven by the increasing 
evidence accumulated over the past decade, wherein HIV-1 Vpr has been 
reported to be present as a soluble protein within the blood serum and the CSF 
of HIV-1-infected patients (Hoshino et al., 2010; Hoshino et al., 2007; Levy et al., 
1994; Levy et al., 1995), and accumulates within these compartments with an 
increasing concentration as disease progresses toward the later stages. As an 
extracellular protein, HIV-1 Vpr has been shown to negatively affect brain-
resident cell survival, especially neurons and astrocytes, which are the most 
sensitive cell type to local insult and are gradually lost as HIV-1-infected patients 
advance towards acquired immunodeficiency syndrome (AIDS).  As a result, the 
studies presented in this Chapter aimed at improving our insight into the role of 
HIV-1 Vpr in neurodegeneration and investigated the impact of Vpr on the most 
abundant brain-resident cell population: the astrocyte. We initially demonstrated 
the presence of extracellular Vpr in the conditioned media of HEK 293T cells 
transfected with Vpr and other viral proteins. Subsequently, utilizing an 
astroglioma cell line (U-87 MG) we proceeded to expand the knowledge of this 
cell population with respect to how it is negatively affected by extracellular Vpr 
treatment.  To this end, these cells were exposed to different conditioned media 
either devoid or containing extracellular HIV-1 Vpr. We observed a reduction in 
ATP and glutathione (GSH) concentrations, almost entirely blocked by treatment 
with anti-Vpr antibody, which led us to directly attribute these effects to the 
presence of extracellular Vpr.  To rule out any effect of HIV-1 Vpr due to the 
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presence of possible Vpr-induced secreted cytokines and/or chemokines, we 
proceeded to demonstrate that EC HIV-1 Vpr was capable of decreasing the 
intracellular ATP pool level using different preparations of purified recombinant 
HIV-1 Vpr protein.  In addition, extracellular Vpr was shown to similarly induce a 
reduction in GSH concentration, the main intracellular antioxidant molecule, 
essential to scavenge and reduce oxidant compounds produced during cellular 
metabolism. We also demonstated that ATP and GSH concentrations are 
reduced in half at 48 h post Vpr exposure and by 72 h the decrease is about 20 
and 40% for ATP and GSH, respectively. 
Since both ATP and GSH concentrations decline during the course of 
treatment with extracellular Vpr, from the studies performed in U-87 MG two 
scenarios are possible. In one case, the glutathione decrease could be a 
consequence of ATP decline, since GSH is synthesized in two subsequent ATP-
dependent reactions. In this scenario, extracellular HIV-1 Vpr could enter into 
astrocytic cells and target the mitochondrial adenine nucleotide translocator 
(ANT) protein, which is involved in exchanging ATP molecules newly formed 
within the matrix for cytoplasmic ADP.  Indeed, it was shown that the C-terminus 
of Vpr has a high binding affinity for a loop of ANT in the intermembrane space of 
the mitochondria (Jacotot et al., 2001; Sabbah et al., 2006; Vieira et al., 2000).  
This high affinity binding would lead to a blockage in the passage of ATP to the 
cytoplasm, thus hampering ATP-dependent reactions, such as GSH synthesis.  It 
has been previously reported that EC HIV-1 Vpr enters several different cell 
types, probably through a receptor-independent mechanism.  It has been 
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substantiated that blood-borne cells (primarily monocytes and CD4+ T cells) as 
well as neurons internalize extracellular Vpr proteins when treated with 
recombinant Vpr	   (Jacotot et al., 2000; Rom et al., 2009; Sherman et al., 2002).  
This event eventually leads to the incorporation of soluble extracellular Vpr 
proteins into the intracellular environment, possibly resulting in effects similar to 
those of intracellularly synthesized Vpr in infected cells. This evidence would be 
of particular interest in the uninfected bystander cells as Vpr, known to block cell 
cycle progression and induce apoptosis, could potentially represent one of the 
causes of the massive cell death among uninfected bystander cells. 
In a second scenario, the declines in ATP and GSH would be uncoupled. 
While external stimuli causing an ATP decrease may potentially affect several 
intracellular processes, the cellular machinery tends to preserve basic metabolic 
mechanisms, thus rerouting a sufficient amount of ATP for these reactions to 
occur.  For instance, the ATP-dependent Na+/K+ pump maintains its normal 
activity even in cases where ATP levels decrease, although below a certain 
threshold it does not function properly (Dagani and Erecinska, 1987). The 
chemotherapeutic compound DOX has been shown to similarly decrease both 
ATP and GSH levels (Wolf and Baynes, 2006).  Although in this study no direct 
correlation was made between the two declines, it was shown that the ATP 
decline was due to a decreased activity of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which inhibits glycolysis and thus ATP production, 
whereas GSH reduction was concomitant to the inhibition of glucose-6-
phosphate dehydrogenase (G6PDH), which causes a decrease in NADPH, 
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responsible for GSH recycling.  In this latter case, Vpr may show similar effects 
as DOX.  Indeed, impairment of GAPDH activity and glycolysis would lead to 
decreased levels of ATP and an increased accumulation of ROS, which may not 
be disposed of in a timely manner, thus inducing a decrease in GSH 
concentrations. 
The importance of extracellular HIV-1 Vpr in the CNS during the course of 
HIV-1-associated neurologic disease is likely linked to abnormalities generated in 
the monocytic, astrocytic, and neuronal compartments. We have found that 
astrocytic metabolism is negatively affected by the presence of extracellular HIV-
1 Vpr, in that two of the most important intracellular metabolites (ATP and GSH) 
are both reduced.  Both metabolites are integral components of several different 
intracellular metabolic pathways, ATP being the main energy source driving the 
majority of energy-requiring processes and GSH scavenging excessive 
accumulation of oxidants. Additionally, given the intricate interplay between 
astrocytes and neurons, it is expectable that any insult within the astrocytic 
compartment would reverberate in a negative way to the neuronal compartment. 
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4.1 Abstract 
Although astrocytes are not the primary target of productive human 
immunodeficiency virus type 1 (HIV-1) replication within the central nervous 
system (CNS), their abundance and susceptibility to HIV-1 infection (although 
non-productive in nature) contribute to their importance. Their role is critical in 
modulating neuronal activity as any insult on the astrocytic population induced 
directly by nonproductive infection or indirectly by alterations in other CNS 
cellular compartments induced by direct HIV-1 infection (i.e. HIV-1-infected 
perivascular macrophages or microglial cells) reverberates on the neuronal 
compartment. We thus focused our attention on the outcome of exposure of 
primary human fetal astrocytes (HFA) to extracellular Vpr to gain further insight 
into the molecular mechanisms leading to astrocytic metabolic impairment.  We 
initially observed a time- and dose-dependent decrease in both ATP and 
glutathione (GSH) concentration and analyzed those genes within the oxidative 
stress pathway that were differentially regulated upon exposure to exogenous 
Vpr.  A glutathione peroxidase, a nitric oxide synthase, a diacylglycerol kinase, 
an apolipoprotein and a chemokine (CCL5) were found to be up-regulated and 
11 other genes involved in scavenging reactive oxygen species (ROS) were 
down-regulated.  Of particular interest was the down-regulation of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), a common housekeeping protein, both at 
the mRNA and protein level. This observation prompted the examination of the 
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causality between Vpr-induced ATP and GSH decreases.  Vpr is known to 
interact with the adenine nucleotide translocator (ANT) at the inner mitochondrial 
membrane, possibly blocking passage of newly synthesized ATP molecules for 
ADP in the cytoplasm.  Decreased availability of ATP could, in turn, dampen 
ATP-dependent GSH synthesis.  We challenged this model and constructed a 
mutant Vpr protein (Vpr R73,80A) with reduced binding affinity for ANT and 
demonstrated that both Vpr and Vpr R73,80A proteins decreased ATP and GSH 
levels. We attributed the observed ATP decrease to reduced GAPDH activity, 
which led us to hypothesize that Vpr impairs ATP synthesis by acting on one 
enzyme in the glycolytic pathway. This gives rise to abundant accumulation of 
ROS and a decrease in GSH concentration, thus inducing oxidative stress.  We 
also observed an aberrant secretion of pro-inflammatory cytokines, especially IL-
6 and IL-8, along with the chemoattractants MCP-1 and MIF, which could 
possibly promote increased recruitment of leukocytes and monocytes from the 
periphery. Additionally, decreased secretion of PAI-1, a fundamentally key 
cytokine in controlling the tissue plasminogen activator, could affect the 
permeability of the blood-brain barrier.  All these observations point to a role that 
extracellular Vpr plays in alteration of the oxidative stress pathway and 
chemokine secretion, which could explain some of the late-stage conditions 
observed in HIV-1-infected patients.  
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4.2. Introduction 
Oxidative stress (OS) is described as any condition wherein accumulation 
of reactive oxygen species (ROS) impairs intracellular mechanisms to promptly 
neutralize them.  OS has been implicated in several different processes, 
including neurodegenerative disorders (Baruchel and Wainberg, 1992), such as 
Parkinson and Alzheimer diseases (Abramov et al., 2003), in diabetes (Lelkes et 
al., 2001)  as well as in other pathologic conditions, like angiogenesis (Lelkes et 
al., 1998).  Glutathione (GSH), a tripeptide composed of glycine, glutamate, and 
cysteine (the latter being the rate-limiting amino acid), plays a critical role in OS 
as it is the primary player in ROS detoxification.  Most GSH is synthesized and 
resides in the cytoplasm where it is available for intracellular processes; however 
a significant amount of GSH (~10%) is also found in mitochondria (Fernandez-
Checa et al., 1997), where it is used to neutralize ROS physiologically 
synthesized in the electron transport chain. Mitochondria are not able to 
synthesize GSH, therefore they rely upon translocation of GSH from the 
cytoplasm in order to neutralize ROS produced inside the matrix (Devesa et al., 
1993).  Astrocytes, the most abundant cell type in the central nervous system 
(CNS), are terminally differentiated, non-stationary star-shaped cells, expressing 
the glial fibrillary acidic protein (GFAP) marker. Their plasticity allows them to 
change shape according to neuronal activity and by enwrapping neuronal 
synapses, not only do they take up ions and neurotransmitters, (thus controlling 
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homeostasis and disposal of neurotoxic molecules), but they also organize 
synapses into synchronously firing groups.  By extending their processes to the 
endothelial cells constituting the blood-brain barrier (BBB), astrocytes take up 
nutrients and secrete antioxidant factors, which protect the BBB from oxidative 
stress, and provide neurons with structural and metabolic support. Their role is 
important in transmission and modulation of action potentials and buffering of 
released neurotransmitters from pre-synaptic termini, especially glutamate, 
whose uptake is regulated by a balanced transport of Na+, K+, and H+ ions. 
Additionally, by taking up extracellular cysteine and glucose, they synthesize 
GSH and lactate through the process of aerobic glycolysis (Pellerin and 
Magistretti, 1994), respectively. Upon secretion, these two neuroprotective 
factors defend neurons against oxidative stress.  Hence, any causative astrocytic 
dysfunction affects the fate of neurons (Dringen et al., 1999).  The importance of 
detoxification of ROS by astrocytes is underscored by the causative impairment 
ROS may have upon glutamate uptake (Sorg et al., 1997; Trotti et al., 1996), 
which leads to activation of inflammatory pathways, and reversal of the glutamate 
cycle with subsequent accumulation in the extracellular space and neuronal 
demise (Klegeris et al., 1997; Trotti et al., 1996). Recently, it was shown how 
astroglial cells exposed to human immunodeficiency virus type 1 (HIV-1) show 
increased ROS production in culture, which is followed by telomere shortening 
and subsequent apoptosis (Pollicita et al., 2009). 
HIV-1-infected individuals are often subjected to an increased risk for 
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oxidative stress due to diminished antioxidant defense mechanisms (Perl and 
Banki, 2000; Treitinger et al., 2000) and decreases in the levels of GSH 
(Baruchel and Wainberg, 1992).  Alterations are detected in different tissues, 
including blood, and are underscored by the imbalance between reduced and 
oxidized glutathione levels (GSH/GSSG ratio).  The common effects are reflected 
by increased production of ROS with subsequent induction of intracellular 
signaling through inflammatory redox-sensitive pathways, ultimately causing 
DNA damage and positively correlating with disease progression and CD4 cell 
count (Herzenberg et al., 1997).  Several viral proteins, especially gp120 and Tat, 
have been found to induce oxidative stress (Lassiter et al., 2009). The HIV-1 
transactivator protein Tat has been shown to promote production of ROS through 
Nrf2 induction (Zhang et al., 2009) and iNOS in astroglia (Liu et al., 2002). 
Additionally, its role has been directly implicated in promoting astrocytosis, 
increasing activation of macrophages and microglial cells, T cell infiltration and 
oxidative stress through AP-1 and NF-kB-driven transcription of target genes 
(Zhou et al., 2007).  Also the viral envelope protein gp120, which is known to be 
shed from infected cells and circulating virions, have been shown to sensitize 
neurons to hydrogen peroxide-induced oxidative stress (Agrawal et al., 2009). 
Viral protein R (Vpr) has been recently shown to induce oxidative stress through 
the hypoxia-inducible factor (HIF) pathway in microglia (Deshmane et al., 2009). 
The commonality of these mechanisms is that by depleting intracellular 
antioxidant defenses the virus is able to control its own replication, as ROS 
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accumulation is able to reactivate viral production (Perl and Banki, 2000).  
Nevertheless, continuous ROS accumulation leads to the death of the infected 
cells.  In this respect, it has been shown that treatment directed at increasing 
anti-oxidative defenses might prove efficacious in delaying the onset of late-stage 
pathologies, especially associated with increased neurocognitive impairment. 
Indeed, since antioxidant mechanisms are based upon presence of thiols 
(containing a sulfhydryl group), capable of donating an electron and creating a 
disulfide bond, sulfur supplementation has proven to benefit immune functions in 
HIV-1 infection (Breitkreutz et al., 2000).  To this end, N-acetyl-L-cysteine (NAC), 
the precursor of the rate-limiting amino acid in GSH biosynthesis, was proven to 
alleviate gp120- and Tat-driven excessive oxidation in brain endothelial cells 
(Price et al., 2006), by increasing GSH levels, as well as activities of glutathione 
reductase and catalase, responsible in ROS disposal. Association between HIV-
1 and OS is of utter relevance in the CNS as resident brain cells are particularly 
susceptible to redox mechanisms. 
Vpr has been shown to interact with the adenine nucleotide translocator 
(ANT) located on the inner mitochondrial membrane (Jacotot et al., 2001; Jacotot 
et al., 2000) and for this interaction to occur at least two arginine residues (Arg73 
and Arg80) at the C-terminus domain are required (Sabbah et al., 2006).  While 
these observations were determined in cell-free isolated mitochondria or utilizing 
recombinant proteins, there is no evidence for cells treated with exogenous Vpr 
to directly interact with ANT.  It could be hypothesized that Vpr interacts with ANT 
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after transducing target cells, although several different intracellular binding 
partners have been characterized in vitro (Zhao et al., 2011).  As Vpr binds to 
ANT, this high affinity interaction could hamper the passage of ATP molecules 
from the mitochondria in exchange of ADP in the cytoplasm. This, in turn, could 
reduce the concentration of GSH as its synthesis occurs through two ATP-
dependent reactions. Nonetheless, decreases in ATP and GSH levels could be 
unrelated signaling events, or two related but uncoupled indirect events, insofar 
as decreases in ATP levels induce excessive accumulation of ROS, thus 
reducing GSH storage, as doxorubicin (DOX) does through impairment of 
GAPDH and glucose-6-phosphate dehydrogenase G6PDH (Wolf and Baynes, 
2006). Our aim in the present study was to determine the mode of action by 
extracellular Vpr in primary human astrocytes and alterations in the oxidative 
stress pathway. 
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4.3. Results 
4.3.1. Primary human fetal astrocytes (HFA) lose the GFAP marker 
after in vitro passages 
Cells of the astrocytic lineage express the typical glial fibrillary acidic 
protein (GFAP) intracellular marker, an intermediate filament protein. As 
astroglioma cell lines (especially U-87 MG and U-373 MG) constitutively express 
the GFAP intracellular marker (for reference see Fig. 3.3), primary astrocytes are 
known to differentiate towards other pathways upon in vitro cultivation.  In this 
regard, we initially verified GFAP expression within primary human fetal 
astrocytes (HFA) at each individual passage by immunofluorescent analysis. 
HFA were cultivated as reported in section 2.2 and subjected to 
immunofluorescent analysis as described in section 2.8.  HFA express high 
levels of GFAP for the first two passages (> 95%). At passage three (P3) the 
amount of GFAP+ cells is around 60%, whereas beginning with passages four 
and five (P4-P5) the loss of GFAP immunoreactivity was more pronounced and 
was dramatically reduced to only a small number of positive cells by passage 
nine (P9), at which point cells also stopped proliferating (Fig. 4.1.A).  Additionally, 
cells were collected at each passage, lysed, and subjected to immunoblotting 
assay as described in section 2.4. Western immunoblot analysis on HFA 
collected at different passages also confirmed decreased GFAP 
immunoreactivity from passage two (P2) until nine (P9) as shown (Fig. 4.1.B). 
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Fig. 4.1. Primary human fetal astrocytes (HFA) lose the characteristic GFAP 
intracellular astrocytic marker after three passages in culture. (A) HFA 
maintain an elevated intracellular GFAP staining (> 95%) for the first two 
passages in culture (P1 and P2) as shown by immunofluorescence microscopy. 
At passage three (P3) the amount decreases to around 60%. From passage four-
five (P4-P5) the number of GFAP-positive cells decrease dramatically to below 
10% of the overall cell population (P5 through P9).  After the ninth passage, HFA 
stop growing in culture and only a small number of cells displayed the astrocytic 
intracellular marker. All magnifications reported are at 20X. Scale bars = 10 µm. 
(B) Whole cell lysates (30 µg) are run on a 10% SDS-PAGE. Western 
immunoblot assay confirms the decreased abundance of GFAP from passages 6 
to 9. 
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Figure 4.1 
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4.3.2.  Kinetics of extracellular Vpr-induced decreases in the levels 
of ATP and GSH   
As U-87 MG cells have been shown to be sensitive to treatment with 
extracellular recombinant HIV-1 Vpr protein, we sought to reproduce this result 
and previously reported studies in primary HFA (Jones et al., 2007; Noorbakhsh 
et al., 2010). To this end, a kinetic analysis of ATP and GSH concentration levels 
was performed within HFA treated with different amounts of extracellular Vpr. 
HFA were incubated in the absence or presence of recombinant Vpr for 24, 48, 
or 72 h. At each time point, cells were harvested and assayed for intracellular 
ATP and GSH concentrations.  The ATP concentration was significantly 
decreased at 24 h post-exposure with the highest concentration utilized (5 µg/ml) 
and continued to decline for the two subsequent time points examined (Fig. 
4.2.A).  ATP decreased to four- to ten-fold the initial values (depending on the 
astrocytic preparation utilized) when treated with 5 µg/ml Vpr. On the other hand, 
GSH concentration showed a slightly slower kinetic response with values only 
reduced approximately two-fold by the last time point (72 h) (Fig. 4.2.B).  This 
delayed decrease could be better appreciated when ATP and GSH responses to 
Vpr treatment were plotted in the same graph (Fig. 4.2.C). This kinetic analysis 
confirmed data previously shown in the astroglioma cell line, wherein ATP 
decline was slightly more pronounced than GSH when compared to untreated 
cells. 
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Fig. 4.2. Primary HFA exposed to extracellular Vpr manifest an initial 
decrease in ATP levels followed by a decline in GSH concentration. (A) 
Kinetic analysis of intracellular ATP concentration in HFA treated with different 
concentrations of EC Vpr demonstrate that ATP decreases to half of the initial 
levels in astrocytes 48 h post-treatment and decline ten-fold at 72 h after 
exposure. (B) A similar but less dramatic decrease was observed for GSH, with a 
slower kinetic response than ATP. GSH concentration declined to 40% of the 
original values at 72 h post-treatment. * P-value < 0.05, ** p-value < 0.01. (C) As 
a comparison, only the results of two Vpr concentrations are reported (2 and 5 
µg/ml) for both ATP and GSH in order to better appreciate the different kinetic 
responses of the two metabolites to Vpr treatment. The graph is color-coded: 
cold colors represent the lowest concentration (2 µg/ml), whereas hot colors are 
for the highest (5 µg/ml). 
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4.3.3. Induction of oxidative stress by extracellular Vpr 
Extracellular Vpr induces a decrease in both ATP and GSH metabolites 
and shifts the intracellular balance towards an increased generation of ROS as 
indicated by an increased concentration of oxidized glutathione (GSSG) and a 
decrease in the GSH/GSSG ratio (Fig. 3.11 and 3.12).  These observations led 
us to gain a better insight with respect to the intracellular mechanisms involved in 
Vpr-induced oxidative stress and thus analyze the genes within the antioxidant 
defense mechanism pathways that were differentially regulated. In this regard, a 
gene array was utilized with the most potentially relevant genes of the oxidative 
stress pathway spotted in single wells of a 96-well plate (SABiosciences). HFA 
were exposed in the absence or presence of extracellular Vpr, harvested, and 
qRT-PCR was performed from total extracted RNA (as described in section 
2.11). The analysis of all genes indicated that 6 genes were found to be 
statistically up-regulated and 11 down-regulated as shown in Fig. 4.3 and Table 
4.1. 
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Fig. 4.3. Heat map of the genes differentially expressed in extracellular Vpr-
exposed HFA.  The different genes are represented as color-coded, with the 
intensity of the green indicating the level of fold under-expression, and the 
intensity of red indicating the level of the over-expressed genes (top).  At the 
bottom is represented a table of the genes, with their relative fold under- or over-
expression determination, and the relative fold induction or reduction. HFA were 
either left untreated or exposed to recombinant Vpr for 48h. 
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Table 4.1. Summary of the genes up- and down-regulated in extracellular 
Vpr-exposed HFA. The 6 up-regulated (arrow up) and 11 down-regulated (arrow 
down) genes are color-coded as represented in Fig. 4.3 (red and green, 
respectively). In the second column the fold increase/decrease compared to 
untreated cells is provided. The last column is the full name of each gene 
examined.  
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Among the up-regulated genes, glutathione peroxidase (GPX5) was of 
particular interest.  This gene functions in protecting cells and especially is 
involved in protecting enzymes from oxidative damage by the action of the 
electron donor compound GSH, and NOS2, which are two proteins known to be 
up-regulated during oxidative stress-inducing stimuli (Barhoumi et al., 2004).   
Also ApoE has received attention in recent studies as a specific genotype 
containing the ApoE ε4 allele was found to be associated with increased risk of 
HIV-1-associated dementia (HAD) (Burt et al., 2008).  The gene with the highest 
over-expression was the recently characterized peroxidasin homolog 
(Drosophila)-like (PXDNL), of which very little is known.  Its characterization 
could not be further evaluated due to the paucity of information available, 
however, it could potentially be relevant as its counterpart (PXDN) within 
Drosophila is an extracellular protein involved in peroxidative reactions and 
extracellular matrix formation.  CCL5, also known as RANTES (regulated upon 
activation, normally T-cell expressed and secreted), is a cytokine with 
chemotactic ability especially for T cells, eosinophils, and basophils (Rot et al., 
1992; Taub et al., 1993). DGKK is a newly discovered member of the 
diacylglycerol kinase (DGK) family, a group of enzymes that metabolize 
1,2,diacylglycerol (DAG) to generate phosphatidic acid (PA). It codes for the 
kappa subunit, which changes the balance of signaling lipids at the plasma 
membrane upon induction of oxidative stress stimuli (Imai et al., 2005). 
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Most of the genes found down-regulated code for proteins involved in 
scavenging ROS, such as metallothionein 3 (MT3), with the highest decrease, 
metallothionein-like 5 (MTL5), scavenger receptor class A member 3 (SCARA3) 
and cytoglobin (CYGB). These observations, if confirmed at the protein levels, 
could reveal a scenario wherein Vpr-induced excessive accumulation of ROS 
may not be counter-acted by the specific action of scavenging proteins, which 
are negatively affected either directly by Vpr or through indirect mechanisms. 
Also of particular interest was the reduction in expression of a commonly found 
housekeeping gene GAPDH. Indeed, all the results reported herein were 
analyzed without considering GAPDH among the housekeeping genes in order 
not to skew the results.  Four more housekeeping genes (B2M, HPRT1, RPL13A, 
and ACTB) were then employed in the analysis as normalizing factors, since their 
expression was found unvaried between untreated and Vpr-exposed HFA. Only 
recently, has GAPDH’s role been evaluated in apoptosis and OS possibly due to 
its nuclear translocation propensity (Dastoor and Dreyer, 2001). Additionally, 
GAPDH activity was found to decline upon exposure to the chemotherapeutic 
agent DOX, directly correlating with a decline in ATP levels. 
Subsequently, the expression of selected proteins has been examined in 
HFA in the absence and presence of Vpr by immunoblot assay.  Indeed, both 
GAPDH and SCARA3 were found to be down-regulated not only at the mRNA 
but also at the protein level (Fig. 4.4).  Normalization was performed utilizing two 
types of housekeeping proteins, namely the cytoskeletal β-actin protein and 
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cytochrome c oxidase or complex IV (COX IV), a transmembrane protein 
belonging to the electron transport chain. As shown in Fig. 4.4, both 
housekeeping proteins are not altered in astrocytes in the absence or presence 
of Vpr.  Densitometric analysis was performed as described in section 2.4, 
suggesting about a 1.4- and 10-fold reduction in GAPDH and SCARA3 protein 
expression, respectively. 
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Fig. 4.4. Immunoblot assay confirmed down-regulation at the protein level 
of two of the genes in extracellular Vpr-exposed HFA. Two of the genes 
down-regulated (GAPDH and SCARA3) were assessed at the protein level (48 h 
post-exposure) in HFA by immunoblotting in the absence or presence of 
extracellular 5 µg/ml Vpr (the concentration yielding the more pronounced 
effects).  Both β-actin and COX IV (one of the components of the mitochondrial 
transport chain) were used to normalize to total protein.  Fold expression of each 
protein within the untreated astrocytes is reported below the band and expressed 
as fold over Vpr-exposed HFA. 
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Figure 4.4. 
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4.3.4. Secretion of cytokines in extracellular Vpr-treated astrocytes 
HIV-1-induced neuropathogenesis is a concern especially among late-
stage HIV-1-infected patients, who show symptoms of neurodegeneration. 
Several studies have identified molecules likely responsible for the observed 
effects either among viral proteins or cellular cytokines whose secretion was 
induced by viral infection.  The induced late stage physiologic alterations include 
excessive neuronal loss and an abnormal increase in the number of astrocytes 
(astrogliosis).  With this in mind, we proceeded to determine whether exposure of 
primary HFA induced the secretion of cellular cytokines.  To this end, a cytokine 
array was used with the most common cytokines spotted in duplicate on a 
nitrocellulose membrane, and detection was performed using a 
cytokine/detection mixture utilizing a chemiluminescent detection system (Pierce, 
Thermo Scientific).  Treatment of HFA with extracellular Vpr increased secretion 
of IL-6, IL-8, MCP-1, and MIF, whereas it decreased secretion of serpin E1, a 
serine proteinase inhibitor (Fig. 4.6.A). Densitometric analysis showed a 
significant increase in IL-6 (8-fold), along with IL-8, MCP-1 and MIF (2-fold) (Fig. 
4.6.B).  It is noteworthy to indicate that among the cytokines spotted on the array 
there was also CCL5 (RANTES), found over-expressed at the mRNA level (Fig. 
4.3 and Table 4.1), but not significantly up-regulated between untreated or Vpr-
exposed astrocytes, as CCL5 was not detected in either conditioned media (Fig. 
4.5). 
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Fig. 4.5. Extracellular Vpr-treated primary HFA display a different pattern of 
cytokine secretion. (A) Membranes spotted in duplicate with the most common 
cytokines have been incubated with cell culture medium from either untreated or 
EC Vpr-treated HFA (5 µg/ml). Cytokines differentially expressed in the two cell 
supernatants are shown in different colored squares (IL-6 = orange; MCP-1 = 
red; MIF = blue; IL-8 = light blue; and PAI-1 = green). (B) Densitometric analysis 
of the up- or down-regulated cytokines present in the cell culture media show an 
increased secretion of IL-6 (8-fold), IL-8, MCP-1, and MIF (2-fold) and a 
decreased secretion of serpin E1 (3-fold). * P-value < 0.05, ** p-value < 0.01 
(student paired T-test). 
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Figure 4.5. 
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4.3.5. Extracellular Vpr impairs the glycolytic pathway 
As Vpr affects both ATP and GSH concentrations, and due to the 
involvement of ATP in the synthesis of GSH from its precursor amino acid, we 
investigated whether the decreases in the two metabolites were correlated with 
each other.  As previously discussed, the two arginine residues at position 73 
and 80 of Vpr show high affinity binding for the ANT (90-119) domain (Jacotot et 
al., 2000; Sabbah et al., 2006). In our in vitro setup, we sought to determine 
whether exposure to extracellular Vpr leads to an initial decrease in the level of 
ATP due to binding to ANT and a subsequent GSH decrease or whether the two 
events were independent of each other.  We initially cloned a Vpr mutant protein 
(Vpr R73,80A), wherein the ANT binding residues were knocked out using site-
directed mutagenesis (as described in section 2.3), and the recombinant protein 
was purified as described in section 2.7.  Hence, HFA were incubated in the 
absence or presence of Vpr or Vpr R73,80A and both the levels of ATP and GSH 
were assessed.  Both Vpr and Vpr R73,80A mutant induced comparable 
decreases in the levels of ATP and GSH, without any statistical difference 
between the two proteins both 24 and 48 h after exposure (Fig. 4.6).  These 
observations have suggested that a Vpr-induced mechanism other than binding 
to the ANT protein must be operative.  Indeed, in the latter case, the Vpr mutant, 
not able to bind to ANT, would freely allow exchange of ATP and ADP between 
mitochondrial matrix and cytoplasm. This study suggests that the intracellular 
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cascade of events does not involve the initially hypothesized interaction between 
Vpr and ANT and subsequent blockage of ATP passage, which, in turn, would 
generate less ATP molecules available for GSH synthesis. 
In addition, to investigate whether the Vpr-induced effects were or were 
not reversible, fresh medium was added to cells treated with either recombinant 
protein and cultivated for an additional 24 h period.  As shown in Fig. 4.6, neither 
ATP nor GSH concentrations rebound to sub-initial values upon elimination of the 
stimulus causing their decrease, which points to an irreversible effect induced by 
extracellular Vpr. 
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Fig. 4.6. Exposure of primary HFA to extracellular Vpr or Vpr R73,80A 
induces a irreversible decrease in both ATP and GSH metabolites through 
a pathway that does not involve binding to ANT.  HFA treated for 24 or 48 h 
with recombinant extracellular Vpr or Vpr R73,80A (mutant protein with reduced 
binding affinity to ANT) were assayed for intracellular levels of ATP (A) and GSH 
(B), and found to decrease in a similar manner in a time-dependent fashion. 
Upon removal of the protein in the extracellular medium after a 48 h exposure, 
neither ATP nor GSH rebound to initial values as compared to untreated 
astrocytes. Doxorubicin (DOX) was used as a positive control for ATP and GSH 
declines in both (A) and (B). 
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Figure 4.6. 
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As GAPDH was found to be down-regulated upon exposure to 
extracellular Vpr both at the mRNA and protein levels (Fig. 4.3 and 4.4), we then 
analyzed its activity using a fluorimetric assay. Cells incubated for 24 or 48 h in 
the absence or presence of recombinant Vpr or Vpr R73,80A were lysed and 
analyzed for GAPDH activity as described in section 2.12.  At both time points 
GAPDH activity was found to be lower than that in untreated cells (Fig. 4.7).  As 
a comparison, astrocytic cells were treated with two different concentrations of 
doxorubicin (DOX), which has been shown to alter intracellular ATP values by 
acting on GAPDH (Wolf and Baynes, 2006).  These observations point to either a 
direct binding of Vpr to GAPDH or an indirect mechanism through which Vpr (or 
its mutant Vpr R73,80A) affects GAPDH activity by removal of its substrate 
glyceraldehyde 3-phosphate (G3P).  An additional mechanism could involve 
suppressing the reduction of NAD+ to NADH, which occurs simultaneously with 
conversion of G3P to D-glycerate 1,3-bisphosphate (1,3-BPG). 
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Fig. 4.7. Extracellular Vpr and Vpr R73,80A impair GAPDH activity. (A) U-87 
MG astrocytic cells treated with doxorubicin (DOX) at two different concentrations 
(0.5 and 1 µM) or full-length extracellular Vpr showed decreased activity of 
GAPDH 24 h post-exposure as measured by a fluorimetric assay. (B) Both Vpr 
and Vpr R73,80A mutant proteins also induced decreased GAPDH activity 48 h 
after treatment. 
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Figure 4.7. 
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4.3.6. Extracellular Vpr activates caspases 3 and 7 
Persistence of an oxidative stress-inducing stimulus has deleterious 
effects on cellular viability as it may activate intracellular signaling pathways 
leading to cell death.  One of these is the caspase pathway, whose activation 
initiates a caspase cascade of events eventually leading to translocation of 
transcription factors to the nucleus, promoting DNA fragmentation and cell death 
(reviewed in (Riedl and Salvesen, 2007).  Since an irreversible effect was 
observed upon treatment with Vpr as demonstrated by a lack of rebound in ATP 
and GSH concentrations after removal of extracellular Vpr (Fig. 4.6), we 
proceeded to determine whether the presence of Vpr was able to activate 
caspase-3 and -7 through the use of a luminescent assay.  HFA were exposed to 
different compounds known to promote caspase-dependent cell death or 
extracellular Vpr and compared to cells that were untreated.  Camptothecin 
(CPT), an inhibitor of DNA topoisomerase I through activation of the caspase 
cascade, showed almost a 2.5-fold increase in caspase-3 and -7 activity when 
compared to untreated cells (Fig. 4.8).  Addition of a caspase inhibitor (Ac-
DEVD-CHO) abrogated the observed increase.  Similarly, exposure of HFA to 
extracellular Vpr promotes a 2-fold increase in caspase-3 and -7 activity, 
confirming previous results obtained at the mRNA levels (Noorbakhsh et al., 
2010). On the other hand, while CPT-induced effects were significantly 
decreased upon treatment with a caspase inhibitor (fifth column from the left), 
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addition of Ac-DEVD-CHO or an anti-Vpr antibody to Vpr-treated HFA only 
partially diminished the observed effects (Fig. 4.8.A, columns 7 and 8).  Western 
immunoblotting confirmed expression of cleaved caspase in Vpr-treated HFA 
(Fig. 4.8.B). Overall, these results showed how astrocytes exposed to 
extracellular Vpr initiate a series of intracellular events, commencing with a 
decreased availability of ATP and GSH, reduced GAPDH activity, and ultimately 
culminating with caspase-dependent cellular death. 
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Fig. 4.8. Extracellular Vpr applied to HFA induces activation of caspase-3 
and -7. (A) HFA have been treated with different stimuli for 48 h and assayed for 
caspase activity using the Caspase-Glo® 3/7 Assay procedure.  As a positive 
control, cells have been treated for 48 h with camptothecin (CPT, 2 µM), which 
has been shown to inhibit DNA topoisomerase I, through activation of caspase 
cascade.  Cells treated with Vpr (5 µg/ml) for 48 h similarly activates caspase-3 
and -7.  This effect was only partially recovered after treatment of HFA with anti-
Vpr antibody or a caspase inhibitor (Ac-DEVD-CHO). * P-value < 0.05 (student 
paired t-test).  Immunoblot assays revealed expression of caspase 3 in Vpr-
treated HFA (B), along with full-length PARP and cleaved lower molecular weight 
forms of PARP primarily in Vpr-treated HFA (C).  As a control, membranes were 
stripped and re-probed for the intracellular astrocytic marker GFAP. 
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Figure 4.8. 
 
 
Chapter 4  170 
 
 
 
 
4.4. Discussion and Conclusions 
During early infection, HIV-1 initially targets blood-borne cells and is also 
believed to enter the CNS, where it infects other cell types (as discussed in 
Chapter 1).  The introduction of combinatorial antiretroviral therapy (cART) has 
deeply alleviated HIV-1-associated symptoms in infected patients and profoundly 
ameliorated as well as lengthened their life span. Nonetheless, HIV-1 
compartmentalizes in different tissues of the body, evolving and giving rise to 
different genotypes (Fulcher et al., 2004; Llewellyn et al., 2006; Potter et al., 
2004), which mow poses the main impediment against eradication of the virus 
from the human host.  Of particular interest in this regard has been the CNS, 
separated from the peripheral blood through the highly specific and selective 
blood-brain barrier (BBB).  Although the BBB restricts access of antiretroviral 
drugs to the CNS, intrinsic local mechanisms maintain viral replication under 
control throughout disease progression until the later stages of disease.  Indeed, 
early infection involves an asymptomatic phase with limited CNS abnormalities, 
which progresses, eventually leading to neurodegenerative disorders of 
increasing severity, from minor cognitive motor disorders to more severe forms 
such as HAD (Shapshak et al., 2011).  Several different hypotheses have been 
proposed as co-factors associated with the worsening of the overall health of 
HIV-1-infected patients, both viral encoded proteins, pro-inflammatory cytokines, 
and excessive cellular invasion from the blood compartment (Lawrence and 
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Major, 2002), possibly as a result of increased permeability of the BBB, which is 
compromised at later stages (Dallasta et al., 1999).  Our interest focused on HIV-
1 Vpr due to the pleiotropic functions this protein performs along the viral life 
cycle.  Initially Vpr was found as a soluble extracellular and virion-free protein in 
both the blood serum and CSF of HIV-1-infected patients (Hoshino et al., 2007; 
Levy et al., 1994; Levy et al., 1995).  Within the CNS, previous studies have 
centered their attention on neurons, since late stage HIV-1-infected patients 
experience significant neuronal loss.  It was noticed that neurons exposed to 
recombinant Vpr protein are severely impaired, with inhibition of axonal 
outgrowth and eventual demise (Kitayama et al., 2008; Sabbah and Roques, 
2005).  More recent studies have investigated the response of astrocytes, due to 
their number and their morphological architecture, which tends to protect and 
encase neurons, not only providing them with nutrients, but also shielding them 
from potential insult.  Extracellular Vpr was shown to cause formation of porous 
channels at the plasma membrane (Piller et al., 1996), which causes aberrant 
inward sodium current in neurons (Piller et al., 1999; Piller et al., 1998) as well as 
rapid intracellular Ca2+-flux in astrocytes (Noorbakhsh et al., 2010). Abnormal 
concentrations of cytoplasmic Ca2+ could then lead to alteration in mitochondrial 
Ca2+ uptake, which, along with down-regulation of GAPDH within the initial 
glycolytic pathway, could impair or decrease the efficiency of oxidative 
phosphorylation (Brookes et al., 2004), thus leading to ATP decline.  In fact, in 
our studies with HFA, we initially discovered a dose-dependent decrease in ATP 
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and GSH, two of the main cellular metabolites, products of the aerobic respiration 
and antioxidant pathway, respectively. As OS is one of the common 
denominators among late-stage HIV-1-infected patients along with an increased 
concentration of extracellular Vpr, we initially hypothesized the existence of a 
correlation between the two events. In order to further investigate this 
association, we analyzed genes differentially regulated upon exposure of 
astrocytes to extracellular Vpr. Using a gene array, the expression of several 
genes involved in the oxidative stress pathway was examined at the mRNA level. 
These studies resulted in the identification of 6 genes to be up-regulated and 11 
down-regulated.  Among the former ones, of particular interest was GPX5, whose 
role is well known in lipid peroxide reduction along with that of hydrogen peroxide 
to water molecules, although GPX5 is a selenium-independent peroxidase 
(specific for the epididymis in the mammalian male reproductive tract (Chabory et 
al., 2010)), whose function in astrocytes has not yet been explored.  DGKK was 
also found to be up-regulated about 5-fold compared to untreated astrocytes. 
Upon G-protein coupled receptor activation, DGKs phosphorylate DAG into PA 
and activate protein kinase C (PKC), thus leading to phosphorylation of many 
different target proteins, such as kinases of the MAPK pathway.  If confirmed at 
the protein level, DGK up-regulation could explain the observed increased 
phosphorylation of SAPK/JNK and P38 MAP kinases (Noorbakhsh et al., 2010). 
Another interesting observation was the up-regulation of CCL5 upon exposure to 
exogenous Vpr in the gene array (about 4-fold), which was not detected in the 
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cytokine array (Fig. 4.5), which underlies a possible post-translational 
sequestering effect or dampening of protein production.  Vpr treatment also 
increased transcriptional expression of ApoE, essential in the catabolism of 
triglyceride-rich lipoproteins, which has been recently associated to increased 
risk of Alzheimer’s disease (Ma et al., 1994) and accelerated progression 
towards AIDS-defining illnesses (Burt et al., 2008). 
Most of the down-regulated genes code for ROS-scavenging proteins, 
such as MT3, CYGB, DUOX2, and SCARA3, which all confer cellular ability to 
detoxify ROS produced during intracellular metabolism. Exogenous Vpr could 
possibly induce abundant ROS production by down-regulating all these enzymes, 
thus irreversibly promoting an oxidative intracellular status.  Of particular interest 
in our study was the down-regulation (about 5-fold at the mRNA level) of 
GAPDH, a common housekeeping gene.  GAPDH’s role in oxidative stress has 
been recently evaluated and could possibly be due to its nuclear translocation 
(Dastoor and Dreyer, 2001), prevented by Bcl2 under physiological conditions, 
thus disabling its specific role in glycolysis and inducing apoptosis.  A lower 
expression of GAPDH and/or a decreased activity due to an abundant 
translocation to the nucleus, also found in diabetic retinopathy (Kanwar and 
Kowluru, 2009), could explain the observed loss in ATP production.  An 
additional study wherein bovine pulmonary artery endothelial cells were exposed 
to DOX identified a decreased activity of GAPDH, which positively correlated with 
ATP concentration (Wolf and Baynes, 2006).  GAPDH inhibition has also been 
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demonstrated after exposure of rat astrocytes to peroxynitrite (Buchczyk et al., 
2003) and nitric oxide in endothelial cells (Padgett and Whorton, 1995).  These 
observations point to a mechanism by which Vpr, acting as an oxidant-like 
compound, promotes decreases in ATP levels through inhibition of GAPDH 
activity and aberrant regulation of energy metabolism. Subsequently, GAPDH 
could promote initiation of apoptosis through nuclear translocation (Schlisser et 
al., 2010), further depleting intracellular storage levels of ATP in a vicious cycle. 
Our data suggests a role of GAPDH as an intracellular sensor of oxidation. 
We subsequently evaluated any alteration in the cytokine profile of Vpr-
exposed astrocytes as HIV-1 is known to induce secretion of pro-inflammatory 
and chemotactic cytokines. We demonstrated increased secretion of IL-6, as 
previously described in neuronal cells exposed to Vpr-treated astrocytic 
conditioned media (Jones et al., 2007) or Vpr-treated monocyte-derived 
macrophages (Hoshino et al., 2010).  Also IL-8 was found increased in medium 
of Vpr-exposed astrocytes, which has been reported in one previous study in 
both T cells and macrophages infected with Vpr-containing HIV-1 virions (Roux 
et al., 2000). Two additional studies demonstrated increased IL-8 secretion in 
primary HFA, either infected with a VSV-G pseudotyped virus (Li et al., 2007) or 
by co-infection with hepatitis C virus (Vivithanaporn et al., 2010). 
Along with the two interleukins, two other chemotactic cytokines were 
found elevated in the extracellular medium of Vpr-treated HFA; MCP-1 and MIF. 
MCP-1 or CCL2 was also found increased in astrocytes co-cultured with HIV-1-
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infected macrophages (Muratori et al., 2010), thus possibly contributing to 
increased recruitment of T lymphocytes as well as HIV-1-infected macrophages 
transmigrating through the BBB, which could reseed infection within the CNS. 
Interestingly, astrocytes treated with exogenous HIV-1 Tat secreted abundant 
MCP-1, which was also found in excess in the brains and CSF of patients with 
HAD (Conant et al., 1998), possibly pointing to a similar mechanism by both viral 
proteins in induction of MCP-1 secretion. 
MIF is up-regulated in several different inflammatory and infectious 
diseases. Peripheral blood mononuclear cells (PBMC) of HIV-1-infected patients 
have been found to release excessive amounts of MIF, which in turn has been 
shown to activate viral transcription and replication in HIV-infected CD4+ T cells 
(Regis et al., 2010). Additionally, activation of the toll-like receptor 4 (TLR4) has 
been shown to induce the secretion of MIF by mature dendritic cells (Popa et al., 
2006), macrophages (Roger et al., 2003; Yin et al., 2010), and astrocytes (Seike 
et al., 2011), and recombinant Vpr-treated macrophages have been shown to 
induce IL-6 production through TLR4/MyD88 signaling (Hoshino et al., 2010).  If 
substantiated in vitro, our data not only would confirm a similar mechanism of 
activation between monocyte-derived macrophages and astrocytes by 
exogenous Vpr, but would also explain the cause of increased MIF and IL-6 
secretions. 
PAI-1, a member of the serine protease inhibitor 1 (Serpin-1) family, is the 
primary inhibitor of tissue-plasminogen activator (tPA), widely expressed both in 
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the periphery and within the CNS, where astrocytes are the major source 
(Buisson et al., 1998).  The importance of a balanced production of tPA and PAI-
1 is vital especially in a highly regulated and selective environment such as the 
CNS, through tight junctions within endothelial cells at the lining of the BBB 
(Dohgu et al., 2011).  Therefore, a decreased presence of PAI-1 in Vpr-exposed 
astrocytes (as shown in Fig. 4.5) could potentially cause deleterious effects in 
reducing the tightness of the brain endothelial barrier, thus partially explaining the 
increased permeability and lack of selectiveness observed at the later stages in 
HIV-1-infected patients (Dallasta et al., 1999).  Altered secretion of these three 
reported cytokines (MCP-1, MIF, and PAI-1) have not been previously associated 
to treatment with exogenous HIV-1 Vpr and represent new mechanisms by which 
Vpr could exert its deleterious effects in late stage HIV-1 disease when excessive 
Vpr protein concentration is detected within the CSF of HIV-1-infected patients. 
Additionally, the observed effects on cytokine stimulation could be either a direct 
consequence of Vpr exposure or an indirect mechanism through an autocrine 
and/or paracrine manner by action of altered cytokines or a synergistic effect of 
Vpr with any of these cytokines. 
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The focus of this thesis has been to analyze the downstream effects of 
exogenous Vpr with respect to astrocytic metabolism, with particular interest in 
two fundamental metabolites: ATP and glutathione (GSH). Our studies were 
driven by the rationale that, despite the fact that the neuron is the cell type most 
abundantly lost during late stage HIV-1 disease and is sensitive to any supra-
threshold extracellular stimulus, astrocytes outnumber neurons and surround 
them to confer protection from cellular insult. With this in mind, we aimed to 
examine the effects caused by abundant extracellular Vpr in the astrocytic 
compartment, which could, in turn, reverberate to cause defects to the 
neighboring neuronal population. 
This chapter will include: results and conclusions, further discussion of the 
thesis research, the most pressing questions to be asked, and future studies to 
address the gaps in knowledge. In addition, the significance and innovation of 
this thesis research will also be discussed. A model will also be proposed 
concerning the impact of increased extracellular Vpr observed in the 
cerebrospinal fluid (CSF) of late-stage HIV-1-infected patients centered on the 
functionality of astrocytes within the CNS and Vpr-induced downstream signaling 
effects within this cell population. 
5.1. Results I: Extracellular Vpr induces declines in both ATP and GSH in 
both an astrocytic cell line (U-87 MG) and in primary human fetal 
astrocytes (HFA), along with increased intracellular accumulation of 
reactive oxygen species (ROS) and oxidized glutathione (GSSG), 
which shifts the balance towards lower GSH/GSSG ratios. 
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The following observations have been reported in Chapter III as well as 
part of Chapter IV of this dissertation. 
1. HEK 293T cells co-transfected with a Vpr-containing plasmid and HIV-1 
molecular clone induce secretion/release of soluble Vpr into the 
extracellular medium (Fig. 3.2). 
2. Exposure of the astrocytic cell line U-87 MG to Vpr-containing conditioned 
medium induced a time-dependent decrease in both ATP and GSH 
concentrations (Fig. 3.4). 
3. Exposure of U-87 MG astrocytic cells and primary HFA to extracellular 
recombinant Vpr promotes intracellular changes leading to a reduction in 
both ATP and GSH concentrations, in a dose-dependent manner (Fig. 
3.10 and 4.2); these results are similar to results obtained utilizing Vpr-
containing conditioned medium (Fig. 3.4). 
4. The observations summarized in the third point were specifically driven by 
extracellular Vpr as addition of anti-HA antibody (targeting the N-terminus 
of the 6His-HA-Vpr protein) was able to abrogate the observed effects on 
ATP and GSH decreases (Fig. 3.5). 
5. After verifying the presence of efficient cysteine-glutamate antiporters on 
U-87 MG cells (Figs. 3.6 and 3.7), application of the antioxidant molecule 
N-acetylcysteine (NAC) could partially counter-act the exogenous Vpr-
induced GSH decrease (Fig. 3.8), by supplying the rate-limiting amino acid 
cysteine. 
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6. U-87 MG astrocytes exposed to extracellular Vpr manifest an increased 
formation of ROS, which was partially blocked or counter-acted by the 
addition of anti-Vpr antibody or NAC, respectively (Fig. 3.12), confirming 
our previous results concerning partial replenishment of reduced GSH 
pool levels (Figs. 3.5 and 3.8). 
7. As a consequence, GSSG concentrations directly paralleled the increase 
in ROS formation, which, along with a decrease in reduced GSH, is 
mirrored by a decline in GSH/GSSG ratios in a time-dependent manner 
(Fig. 3.10). 
5.2.  Conclusions I 
Five basic conclusions can be drawn from the results of our initial 
experimental investigations. (1) Vpr is secreted/released only in the presence of 
the other viral proteins (except the surface envelope glycoprotein and Nef). (2) 
Recombinant Vpr reproduces the declines in ATP and GSH levels previously 
obtained with Vpr-containing conditioned media. (3) The level of GSH pools 
could be partially replenished by treatment with the antioxidant molecule NAC. 
(4) Co-treatment with antibody targeting the Vpr protein in the extracellular milieu 
blocks the downstream signaling cascade of events leading to declines in the 
pools of ATP and GSH. (5) Vpr induces an oxidative intracellular environment 
that is characterized by an excessive accumulation of ROS and altered balance 
of reduced over oxidized glutathione. Overall, these observations indicate that 
Vpr triggers intracellular signaling events, which affect astrocytic cell energy and 
antioxidative defense storage in a dose-dependent manner.  Additionally, a 
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partial relief of these conditions is obtained upon addition of the antioxidant 
compound NAC. 
5.3. Results II: Extracellular Vpr effects on ATP and GSH pools are not 
directly correlated and are driven by impairment of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) activity, thus affecting glycolysis and 
ATP production, ultimately leading to caspase-dependent programmed cell 
death. 
The following results are presented in Chapter IV of this dissertation. 
8. As Vpr was shown to interact with the mitochondrial adenine nucleotide 
translocator (ANT), a Vpr mutant protein (Vpr R73,80A) with reduced ANT 
binding affinity (Jacotot et al., 2000) was equally capable of inducing both 
ATP and GSH declines as compared to parental Vpr (Fig. 4.6). 
9. Extracellular Vpr-treated primary HFA display a reduced level of GAPDH 
both at the mRNA and protein levels (Figs. 4.3 and 4.4, Table 4.1) 
10. Exogenous parental Vpr and mutant proteins similarly induce reduced 
GAPDH activity (Fig. 4.7), a protein found to play a role in apoptosis	  
(Chuang and Ishitani, 1996). 
11. Astrocytes exposed to recombinant Vpr display an increased caspase-3 
and -7 activation, leading to caspase-3 cleavage, which in turn promotes 
nuclear DNA fragmentation (Fig. 4.8). 
12. The effects extracellular Vpr exerts on astrocytic metabolism are 
irreversible, since removal of Vpr (or its mutant) does not lead to a 
rebound in either ATP or GSH concentrations (Fig. 4.6).	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5.4. Conclusions II 
These results suggest four important and inter-related conclusions.  (1) 
Initially we proposed that Vpr exerted its downstream signaling through the 
binding to ANT, blocking the passage of ATP for ADP between the mitochondrial 
matrix and the cytoplasm, and affecting the availability of ATP for GSH synthesis. 
Utilizing a Vpr mutant protein with respect to the binding site for ANT, the results 
suggest a different pathway than we initially hypothesized and we now theorize 
that impairment may involve one of the enzymes in the glycolysis pathway 
(GAPDH).  (2) Not only was GAPDH found under-regulated at both the mRNA 
and protein levels, but its activity was also severely impaired upon treatment with 
both parental Vpr and mutant Vpr.  (3) The results induced by exogenous Vpr to 
the astrocytic population are likely irreversible since removal of Vpr promoted 
neither a complete nor a partial recovery of the two metabolite levels (ATP and 
GSH).  (4) Vpr-induced effects likely occur after a threshold is reached, after 
which irreversible induction of caspase-dependent apoptosis occurs, through 
PARP activation and nuclear fragmentation.  Overall, these results indicate that 
Vpr acts through impairment of one key enzyme in the glycolytic pathway, which 
decelerates or compromises the conversion of glucose to pyruvate.  This, in turn, 
leads to a reduced synthesis of ATP due to a lesser availability of substrate for 
the Krebs cycle and oxidative phosphorylation.  A decrease in the levels of GSH 
could be either an immediate consequence of a decrease in ATP levels (although 
not through blockage of the mitochondrial membrane-associated ANT) or a 
consequence of an increased buildup of ROS within the intracellular 
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environment.  The mode of action of Vpr resembles that of the chemotherapeutic 
drug doxorubicin (DOX), which induces both ATP and GSH reductions, through 
impairment of GAPDH and G6PDH enzymatic activities. 
5.5. Results III: The effects of astrocyte exposure to exogenous Vpr 
reverberate on increased induction of the oxidative stress pathway, along 
with altered secretion of pro-inflammatory cytokines and chemoattractants.  
The following results are presented within Chapter IV of this dissertation. 
13. Several genes belonging to the oxidative stress pathway were found to be 
down-regulated at the mRNA level after prolonged treatment with 
recombinant Vpr (Fig. 4.3 and Table 4.1). 
14. The scavenger receptor class A, member 3 (SCARA3) was confirmed to 
be down-regulated also at the protein level (Fig. 4.4). 
15. Among the genes found to be up-regulated, of particular interest was a 
specific glutathione peroxidase (GPX5) and a nitric oxide synthase 
(NOS2), both of which play important roles in scavenging ROS, avoiding 
excessive intracellular accumulation (Fig. 4.3 and Table 4.1). 
16. Elevated concentrations of IL-6 (8-fold) and IL-8 (2.5-fold) were found in 
Vpr-exposed astrocytic conditioned medium, along with the chemokines 
monocyte chemoattractant protein-1 (MCP-1) and macrophage migration 
inhibitory factor (MIF) (Fig. 4.5). 
17. Decreased secretion of serpin E1 (plasminogen activator inhibitor-1 or 
PAI-1) was also detected in the extracellular medium of Vpr-treated 
astrocytes (Fig. 4.5). 
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5.6.  Conclusions III 
We conclude that exposure to recombinant Vpr induces a cascade of 
signaling events, affecting the oxidative stress pathway thereby perturbing the 
intracellular redox environment.  Indeed, the inability to properly and timely 
eliminate the excessive ROS within the cellular environment does not favor a 
reduced intracellular milieu, thus shifting the balance towards an exaggerated 
oxidation status.  This is also reflected by the aberrant secretion of pro-
inflammatory cytokines and chemoattractants. 
5.7.  Additional discussion concerning the dissertation research 
A number of previous studies have demonstrated the impact of other viral 
proteins with respect to neuropathogenesis. HIV-1 gp120 is shed from both 
infected cells and infectious virions	  (Willey et al., 1994; York and Nunberg, 2004), 
thus contributing to the neurotoxic effects observed both in vitro in neuronal 
(Meucci et al., 1998) and astrocytic populations (Vesce et al., 1997) as well as in 
vivo models (Toggas et al., 1994).  In addition, the HIV-1 Tat protein has been 
shown to be secreted from HIV-1-infected cells (Chang et al., 1997; Ensoli et al., 
1993) and, as an extracellular soluble protein, not only enters cells but also 
contributes to bystander cell killing and neuronal dysfunction (Cheng et al., 1998; 
Vendeville et al., 2004; Yang et al., 2003).  More recently, HIV-1 Vpr has also 
been shown to be secreted (Xiao et al., 2008) and capable of entering cells of 
different origin both blood-borne or CNS-dwelling (Arunagiri et al., 1997; Jacotot 
et al., 2000; Rom et al., 2009; Sherman et al., 2002). The detection of 
extracellular Vpr in the blood serum and CSF of HIV-1-infected patients 
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corroborates these observations and has suggested a role for Vpr as an 
extracellular protein (Hoshino et al., 2007; Levy et al., 1994; Levy et al., 1995). 
Indeed, previous studies have indicated the detrimental effects caused by 
exogenous Vpr both in astrocytes and neurons (Jones et al., 2007; Kitayama et 
al., 2008; Noorbakhsh et al., 2010; Piller et al., 1998; Sabbah and Roques, 
2005). Additionally, as discussed in Chapter I, it is yet unclear whether 
extracellular Vpr induces apoptosis through cell cycle arrest or confers an 
apoptosis-protecting phenotype (Conti et al., 2000; Conti et al., 1998; Fukumori 
et al., 1998; Goh et al., 1998; Matarrese et al., 2000).  A possible explanation 
might reside in the concentrations of extracellular Vpr, which highly depend on 
the stage of disease progression (Levy et al., 1994); initially Vpr, present at low 
levels, could confer an anti-apoptotic phenotype in order to warrant adequate 
viral progeny production, although astrocytes might be sensitized to Vpr 
exposure. It is only at later stages of disease, when Vpr concentrations increase, 
that astrocytes (pre-sensitized to detrimental Vpr effects) manifest a pro-
apoptotic phenotype, inducing abundant cell death as the host immune 
surveillance system is burdened to maintain control of the infection.  Interestingly, 
late-stage HIV-1-infected or AIDS patients have been shown to bear increased 
oxidation and decreased GSH levels within the T cell compartment (Gil et al., 
2003), partly alleviated by oral administration of NAC	  (Herzenberg et al., 1997).  
Excessive oxidation and GSH deficiency have also been detected within the 
CNS, and therapeutic strategies aimed at restoring the GSH pool have revealed 
promising results (Castagna et al., 1995; Sung et al., 2001).  All these 
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observations have led us to hypothesize that a strong correlation exists between 
oxidative stress and excessive concentrations of extracellular Vpr in late-stage 
symptomatic HIV-1-infected patients.  Indeed, Vpr-induced oxidative stress has 
been recently shown in a yeast model (Stromajer-Racz et al., 2009) and in 
monocyte-derived macrophages (Hoshino et al., 2010), pointing at a conserved 
mechanism exerted by Vpr.  Of particular interest is the interplay among Ca2+, 
ATP, and ROS generation; indeed, as Vpr permeabilizes lipid bilayers inducing 
an inward current (Piller et al., 1996; Piller et al., 1998), it was shown to alter ion 
concentrations and gradients, especially Ca2+ (Acharjee et al., 2010; Noorbakhsh 
et al., 2010; Rom et al., 2009).  Ca2+ balance is vital for cell survival as an 
excessive increase in cytoplasmic Ca2+ concentrations lead to the formation of 
mitochondrial permeability transition pores (MTPT) by impairing the Krebs cycle 
and electron flow into the respiratory chain with the consequential accumulation 
of ROS (Brookes et al., 2004).  Vpr is also known to naturally target 
mitochondria, the key players in the oxidative stress pathway, by specifically 
interacting with the mitochondrial ANT (Jacotot et al., 2001; Jacotot et al., 2000) 
and altering mitochondrial membrane potential (Mishra et al., 2007). However, 
since the Vpr mutant (Vpr R73,80A) induced effects similar to parental Vpr in our 
studies, we developed an alternative model to explain the mechanism of Vpr 
action (discussed below).  Additionally, while Vpr-induced ATP decline has been 
previously described in neurons and found to impair transportation of 
mitochondria within neurites	  (Kitayama et al., 2008), the effects of ATP reduction 
have not been associated with any outcome in astrocytes.  Indeed, most of the 
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ATP would be converted to ADP and eventually to AMP by adenylate kinase; the 
AMP would then act as an allosteric activator of glycolysis (Dr. John Baynes, 
personal communication).  Interestingly, astrocytes have been shown to secrete 
ATP as a gliotransmitter, which mediates propagation of Ca2+ waves among glial 
and neuronal cells (Coco et al., 2003; Guthrie et al., 1999; Pangrsic et al., 2007), 
possibly establishing a negative feedback loop between the high Ca2+ 
concentrations and decreased ATP concentrations, paralleled by ATP release. 
The interplay between ATP and GSH metabolites is of particular 
importance: indeed, ATP decrease is not sufficient for GSH to diminish as 
treatment with iodoacetate reduces ATP but not GSH (Verity et al., 1991; Wolf 
and Baynes, 2006).  These two metabolites are not necessarily coupled and it is 
important to determine their intricate inter-relationship since different compounds 
(especially chemotherapeutic drugs) might invariably and independently reduce 
either or both the levels of ATP and GSH. 
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5.8. Modeling HIV-1 Vpr-induced events leading to progression of 
neurologic disease in late-stage HIV-1-infected patients 
The studies performed in our laboratory have focused on determining the 
downstream effects of excessive levels of exogenous Vpr within the CNS that 
could be potentially used as molecular markers to identify HIV-1-infected 
individuals more prone to developing advanced stage disease, neurologic 
disease, or in the long-term, other end-organ pathologies.  We report in this 
thesis that extracellular Vpr promotes ATP and GSH depletion in astrocytes in a 
dose-dependent manner, not by direct binding to ANT but through impairment of 
GAPDH activity. This leads to a cascade of events, which include increased 
formation of ROS, reduction in GSH and a decrease in GSH/GSSG ratios (Fig. 
5.1). It is of particular interest to determine whether Vpr-induced decrease in 
GAPDH activity is directly correlated to Vpr interaction or a consequence of ROS 
formation. With this respect, studies are under way to demonstrate whether 
elimination of ROS (through supplementation of NAC or ATP-derived 
supplements) could restore GAPDH activity and functionality, thus counter-acting 
Vpr-induced downstream effects. 
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Fig. 5.1. Paradigm of HIV-1 extracellular Vpr action on astrocytes.  The two 
hypothesized models for the toxicity of exogenous Vpr are presented.  According 
to the model on the left, a decrease in Vpr-induced intracellular ATP is due to 
direct binding of Vpr to the adenine nucleotide translocator (ANT) on the inner 
mitochondrial membrane, where Vpr might halt the physiological transport of ATP 
molecules produced during the tricarboxylic acid cycle (TCA), lowering the 
cytosolic availability of ATP, with consequences for all cellular ATP-driven 
reactions.  One of them is characterized by a decrease in reduced glutathione 
(GSH), synthesized in two ATP-dependent reactions by the initial formation of 
cysteine-glutamate (Cys-Glu) (through the action of glutamyl-cysteine synthase 
[γ-GCS]) and the subsequent formation of GSH after addition of glycine (Gly) (by 
glutathione synthetase [GSH-S]). GSH functions as an electron donor in all 
cellular redox reactions by detoxifying reactive oxygen species (ROS) produced 
as by-products of physiological cellular metabolism.  Decreased concentrations 
of reduced GSH then causes a shift towards production of oxidized glutathione 
(GSSG).  In the model presented on the right, Vpr, upon transduction of the 
plasma membrane, induces downstream effects (possibly through an increase in 
[Ca2+]i) by impairing GAPDH activity within the glycolytic pathway, leading to ATP 
decrease, excessive accumulation of ROS, and decrease in GSH as well as 
GSH/GSSG ratios. 
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 Additionally, Vpr induces secretion of the pro-inflammatory cytokines IL-6 
and IL-8, and the chemoattractants MCP-1 and MIF, along with reduced 
secretion of PAI-1, whose role is fundamental in regulating tPA and BBB 
tightness.  As a final consequence, induction of apoptosis through activation of 
the caspase cascade is achieved.  Herein we propose a model regarding the 
mode of action of exogenous Vpr with possible relevance to HIV disease 
progression (Fig. 5.2).  The model centers on the observations that the Vpr 
mutant (Vpr R73,80A) is capable of inducing decreases in the intracellular levels 
of ATP and GSH to the same extent as the parental Vpr.  This led us to 
hypothesize that Vpr does not initially exert its effects through binding to the ANT 
complex, but rather acts upon the glycolytic pathway by impairing GAPDH 
activity.  This, in turn, leads to a decreased production of ATP, observed as early 
as 24 h post-exposure and progresses until 72 h (Fig 4.2).  The decrease in the 
levels of ATP promotes the over-production of ROS, which may not be readily 
detoxified by intracellular GSH.  Similar to the effects of DOX on ATP and GSH, it 
is also possible that Vpr acts on the G6PD/NADPH pathway, hence altering 
synthesis of GSH.  Decreases in the intracellular levels of ATP and GSH 
detrimentally affect mitochondria function through membrane hyperpolarization 
(decreased Δψ) and induce a rupture of MPTP, thus leading to the opening of 
pores.  This event would expose the ANT protein (usually not exposed to the 
cytoplasmic compartments by the presence of the VDAC complex) to solutes and 
compounds within the cytoplasmic environment.  Due to Vpr binding affinity to 
specific loop regions within the ANT (Sabbah et al., 2006), this would enhance 
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the block to ATP (produced in the matrix) in exchange for ADP from the 
cytoplasm.  Nonetheless, this seems only to be a secondary event and not the 
initial cause of Vpr downstream effects since the Vpr mutant containing a 
defective ANT binding domain was still shown to induce decreases in ATP levels.  
Indeed, Vpr and Vpr R73,80A both promote a similar decrease in ATP and GSH, 
which led us to hypothesize that Vpr-ANT binding is not required to amplify the 
Vpr-induced inhibitory capability.  If the GSH decline were a direct consequence 
of Vpr binding to the ANT, which blocks passage of ATP, then the Vpr mutant 
would not reduce the levels of ATP and GSH as a result of this process, which 
was not observed in our studies. The two declines may or may not be 
associated; however, the link is not through direct binding of Vpr to ANT as 
initially hypothesized. 
It is possible to attribute Vpr downstream effects to high Ca2+ 
concentrations, which are known to impair oxidative phosphorylation and 
increase ROS buildup.  Indeed, under physiological conditions Ca2+ is beneficial 
for cell survival as it stimulates the Krebs cycle and electron flow through the 
electron transport chain, thus increasing ATP levels (Brookes et al., 2004). 
Additionally, mitochondrial transition pores are closed and ANT is in its matrix 
conformational state, whereby VDAC does not allow passage of solutes with a 
molecular weight greater than 1,500 Da (Halestrap, 2009).  Since there is no 
evidence for extracellularly Vpr-treated cells to directly promote opening of 
VDAC, which masks ANT from the cytoplasmic compartment, it seems 
reasonable to hypothesize the existence of an intermediate molecule to promote 
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pore opening.  Ca2+ ions are likely candidates, not only because Vpr has been 
shown to induce increased Ca2+ concentrations (Acharjee et al., 2010; 
Noorbakhsh et al., 2010; Rom et al., 2009), which can trigger the opening of 
MTPT (Gincel et al., 2001), but also because they can freely diffuse through the 
VDAC due to their molecular size.  These events would then induce 
mitochondrial membrane hyperpolarization and, in a vicious cycle, lead to 
programmed cell death through a caspase cascade.  Additionally, ROS buildup 
could trigger intracellular signaling and transcription of NF-κB-activated genes, 
along with viral trans-activation from persistently infected astrocytes (Fig. 5.2).  
Moreover, the dual action of ROS on both caspase-dependent apoptosis and 
transcription of NF-κB-dependent genes, including the HIV-1 long terminal repeat 
(LTR) promoter, would have to be timely synchronized for the virus to take full 
advantage of the host cell machinery before its demise. 
Increased oxidation of GSH is detrimental for neuronal survival; indeed, 
GSH is secreted into the extracellular medium and catabolized into Cys-Gly to be 
taken up by neurons as cysteine, which has been shown to trigger GSH 
synthesis (Garg et al., 2008). Decreased presence of reduced GSH within the 
astrocytes leads to diminished secretion and a reduced uptake and availability of 
GSH to the neuronal compartment, whose antioxidant pool is then indirectly 
affected. An overall schematic of the model presented in this thesis is 
represented in Fig. 5.2. 
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Fig. 5.2. Overall model of HIV-1 extracellular Vpr action on astrocytes.  As 
exogenous Vpr gains access to the intracellular environment, it induces a series 
of events. Declines in ATP and GSH (previously shown in a larger model in Fig. 
5.1) are potentially harmful as they likely increase the generation of ROS 
species, signaling transcription of oxidative-sensitive genes, along with NF-κB-
driven transcription of the HIV-1 long-terminal repeat (LTR), which could enhance 
the opportunity of viral spread from persistently infected astrocytes. GSH 
synthesized within astrocytes may also be secreted and, upon cleavage by the 
gamma-glutamyl transpeptidase (γ-GT) into Cys-Gly, may be taken up by 
neurons as Cys, thus igniting GSH production within the neuronal compartment. 
Additionally, exogenous Vpr also induces secretion of the pro-inflammatory 
cytokines IL-6 and IL-8, the chemoattractants MCP-1 and MIF, which in turn 
could facilitate migration of monocytes from the periphery.  Decreased levels of 
PAI-1 in the CNS could also reduce the integrity of the blood-brain barrier (BBB), 
allowing passage of otherwise excluded molecules to the CNS. Increased 
chemotaxis of monocytes may also enhance viral infection in the CNS, as 
uninfected as well as HIV-1-infected cells could gain access to the brain. 
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Figure 5.2. 
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Vpr was also shown to affect cell membrane stability with formation of 
pores (Piller et al., 1996; Piller et al., 1998). An indirect measurement of a 
compromised cell membrane was drawn from our initial studies in both U-87 MG 
and primary HFA, wherein an increased concentration of extracellular ATP was 
identified in cultured astrocytes exposed to Vpr (Fig 5.3), possibly due to either 
active secretory mechanisms or to leakages from the intracellular compartment 
due to damage to the plasma membrane.  Moreover, it has been recently shown 
that ATP release from astrocytes is regulated by diacylglycerol signaling 
(Mungenast, 2011, accepted for publication).  We detected up-regulation of one 
member of the diacylglycerol kinase family at the level of mRNA (Fig. 4.3 and 
Table 4.1), which, if confirmed at the protein level, could possibly explain the 
reason for the observed increase in extracellular ATP levels. Due to the 
importance of secreted ATP in intercellular communication within the CNS, an 
excessive buildup of extracellular ATP could have downstream effects in a 
paracrine as well as autocrine manner. Indeed, within the tripartite synapse, 
composed of the astrocytic extensions along with the neuronal presynaptic and 
postsynaptic components	  (Halassa et al., 2007), release/leakage of ATP into the 
extracellular environment could affect neuronal activities along with synaptic 
transmission.  The interplay between Vpr-induced increase in Ca2+ 
concentrations, reduction of intracellular ATP, and up-regulation of DGK could 
potentially be significant in an in vivo scenario in order to explain some of the 
observations in late stage HIV-1-infected patients. 
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Fig. 5.3. Exposure to Vpr promotes increased levels of extracellular ATP by 
astrocytes.  Extracellular conditioned media (50 µl, in triplicate for each time 
point) from primary HFA treated with extracellular Vpr (as described in Fig. 4.2) 
were assayed for ATP levels.  The results were plotted in a time-dependent 
response as fold over untreated cells.  Measurements were performed with a 
luminescent assay similarly to intracellular ATP concentrations (as described in 
section 2.6).  
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5.9. Most pressing questions to be addressed 
A number of studies have outlined the role that exogenous Vpr may play 
in neuronal impairment, by activation of a number of different pathways (Jones et 
al., 2007; Kitayama et al., 2008; Sabbah et al., 2006).  However, only one study 
employed conditioned media from either Vpr-exposed astrocytes or monocytic 
cells to treat a neuronal cell line and measure secretion of IL-1β and IL-6, along 
with neuronal survival (Jones et al., 2007).  In the same study, a mouse model 
was introduced with Vpr under the control of the c-fms promoter, thus allowing 
expression of Vpr only in monocytoid cells.  Recently, studies have focused also 
on the effects of extracellular Vpr on astrocytes (Noorbakhsh et al., 2010) and 
monocyte-derived macrophages (Hoshino et al., 2010) as the other two 
fundamental mediators of neuropathogenesis.  Additionally, recent evidence has 
attributed to GAPDH a role in apoptosis and oxidative stress, which, along with 
our observations, suggest a role for this protein in Vpr-induced programmed cell 
death (Dastoor and Dreyer, 2001; Wolf and Baynes, 2006). The following 
questions should be addressed moving forward with this research project: 
1. Given the observation that extracellular Vpr alters ionic current and 
especially the concentration of Ca2+, whose role is of importance in tightly 
regulating cellular health by maintaining mitochondrial balance with 
respect to ATP synthesis and ROS production, do both Vpr and Vpr 
R73,80A mutant (with reduced ability to bind to ANT) perturb Ca2+ 
intracellular concentrations? 
Chapter 5  209 
 
2. Does treatment with Vpr induce an initial Ca2+ increase prior to GAPDH 
down-regulation at both the level of mRNA and protein? 
3. Given Vpr-induced down-regulation of GAPDH activity observed as early 
as 24 h post-exposure, does Vpr exert its effects on GAPDH by direct 
binding or through intermediary proteins or a cascade of downstream 
effects? 
4. Since Vpr induces GAPDH impairment which may be involved 
mechanistically in the genesis of decreases in ATP pools, and this, in turn, 
may promote an immediate chain reaction leading to abundant ROS 
accumulation and the decrease in the levels of GSH, at what point along 
this cascade of effects is the mitochondrial membrane potential 
decreasing? 
5. Given the observation that both Vpr and Vpr R73,80A induce decreased 
concentrations of ATP and GSH, is the mode of action of Vpr and its 
mutant similar with respect to GAPDH activity? 
6. Given the observed up-regulation of diacylglycerol kinase in our gene 
array assay, is DGKK up-regulated also at the protein level?  Is its kinase 
activity increased?  Additionally, since recent evidence proposed a role for 
diacylglycerol (DAG) in ATP release, is an up-regulation in DGKK, hence 
increased conversion of DAG sufficient to justify excessive concentrations 
of ATP in the extracellular medium? 
7. Vpr has been shown to translocate through plasma membranes due to the 
presence of its three hydrophobic alpha-helices which possibly harpoon 
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onto lipid bilayers (Piller et al., 1999; Piller et al., 1996; Piller et al., 1998), 
giving rise to a series of downstream signaling events. Does Vpr 
interaction with the plasma membrane compromise its integrity thus 
allowing inward and outward flow of molecules otherwise not permitted to 
translocate across the membrane? 
8. Given the observation that parental Vpr increased secretion of the pro-
inflammatory IL-6, IL-8 and the chemoattractants MCP-1 and MIF, and 
decreased secretion of PAI-1, does Vpr R73,80A induce secretion of the 
same cytokines/chemokines? If so, does it occur to the same extent (fold 
over untreated)? 
9. Since cytokines are known to act in a paracrine as well as autocrine 
manner, what is the effect of the exposure on the aforementioned 
cytokines/chemokines, on astrocytic survival, and how does the exposure 
affect neuronal survival? 
10. Extracellular Vpr has been shown to act through the TLR4/MyD88 
pathway in monocyte-derived macrophages (MDM), which leads to viral 
reactivation and IL-6 secretion (Hoshino et al., 2010).  Moreover, in a 
independent study, MIF was shown to be secreted from astrocytes 
stimulated with LPS, which acts through the TLR4 pathway (Seike et al., 
2011). Given these separate independent observations, does exogenous 
Vpr act through the TLR4 receptor in astrocytes as previously shown in 
MDM? Is this signaling cascade’s effects then the cause of MIF secretion? 
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11. The C-terminus domain of Vpr (70-96) has been referred to as the 
mitochondriotoxic domain and has also been shown to be responsible for 
the observed downstream effects (Jacotot et al., 2000; Sabbah et al., 
2006). Are results presented herein reproducible employing just the C-
terminus domain of Vpr or does Vpr (70-96) act through a different 
pathway? 
12. Given the tightly regulated process of glutamate uptake through the Xc– 
system, XAG– system and the Na+/K+ ATPase (Garg et al., 2008) and the 
fundamental role of astrocytes in removal of glutamate from actively firing 
neurons, does exogenous Vpr impair or slow down glutamate uptake as a 
result of decreased ATP levels and aberrant ROS accumulation? 
5.10. Future studies to address these questions 
The following studies should be done to address the above questions: 
1. To measure GAPDH mRNA levels by RT-PCR and protein levels by 
immunoblotting assays, to confirm the down-regulation of the gene and 
the protein and its kinetics in primary HFA. 
2. To study the GAPDH intracellular localization pattern and its possible 
nuclear translocation associated with its decreased activity after exposure 
to Vpr.  Additionally, to perform subcellular fractionation studies in order to 
collect mitochondria, cytoplasm, and nuclei and determine location of Vpr 
and GAPDH in a time-dependent response assay by immunoblotting. 
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3. To perform immunoprecipitation and western immunoblotting (IP/WB) 
assays, to determine possible physical interactions between Vpr and 
GAPDH. 
4. To measure mitochondrial membrane potential using the MitoProbe DiIC1 
dye either by flow cytometry or immunofluorescent assay: in the former 
case a more quantitative measurement would be accomplished, whereas 
in the latter a more qualitative one would show cells with a decreased Δψm 
in green, compared to healthy cells whose mitochondria would otherwise 
stain in red. 
5. To measure plasma membrane integrity and potential through the probe 
DiOC6, along with LDH release in the cell culture supernatant to 
quantitate leakages from the intracellular environment at different time 
points. 
6. To expose primary HFA to both Vpr and Vpr R73,80A in order to evaluate 
the amount of the up-regulated cytokine/chemokines secreted (IL-6, IL-8, 
MCP-1, and MIF) by quantitative enzyme-linked immunosorbent assay 
(ELISA) and compare the levels with untreated astrocytes. 
7. To measure ATP and GSH concentration levels of primary HFA co-treated 
with Vpr and anti-TLR4 receptor antibody (or TLR4 antagonist) in order to 
determine whether Vpr signaling effects are caused by the TLR4 and the 
associated adaptor MyD88 pathway. 
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8. To assess glutamate uptake rate by primary HFA after the application of 
different amounts of L-Glu and study the residual concentrations of 
glutamate within the extracellular medium after long exposure to Vpr. 
5.11. Significance and innovation of this research 
Our hypothesis unveils a possible mechanism involved in the increased 
ROS production and viral load burden in the CNS.  We propose that the in vivo 
manifestations of intracellular oxidative stress observed in late stage HIV-1-
infected patients correlate with increased Vpr secretion as disease progresses 
towards more severe forms of neurodegeneration. We suggest that HIV-1 Vpr 
within the CNS, either actively secreted or passively diffusing out of infected cells 
(T cells, MDM, and microglia) or from CNS-resident apoptotic/necrotic cells, is 
taken up by bystander uninfected or persistently infected astrocytes, diminishing 
intracellular ATP levels and affecting the biosynthesis of GSH through 
inactivation of GAPDH.  These primary events (possibly promoted by Vpr-
induced increase in intracellular Ca2+ concentrations) alter astrocytic metabolism, 
cytokine/chemokine secretions, and intracellular signaling eventually leading to 
caspase activation, and programmed cell death.  
The model we presented herein explains the observed declines in 
intracellular ATP levels  and reduced GSH pools by HIV-1 extracellular Vpr within 
the astrocytic compartment (Fig. 5.3).  To our knowledge this study is the first 
one to relate astrocytic impairment with Vpr-induced reductions in GADPH 
activity.  Indeed, as less GAPDH is either present or active to convert G3P into 
1,3-BPG, less acetyl-coenzyme A may be available for use in the tricarboxylic 
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cycle, lowering production of ATP, with natural consequences on all cellular ATP-
driven reactions.  Decreased ATP negatively affects oxidative phosphorylation, 
thus increasing production of ROS, which, in turn, induces oxidation of 
glutathione. GSSG can then no longer act as an electron donor and hence 
induces increased accumulation of intracellular ROS in a vicious cycle. The 
model proposed herein involves the prediction of outcomes associated with other 
processes not directly measured in our research study.  For instance, an 
increase in ROS could lead to increased viral transactivation from the integrated 
proviral genome, which may restore viral gene expression or particle production 
from persistently infected astrocytes.  Reductions in ATP pools may also impair 
glutamate uptake by firing neurons, thus inducing excessive extracellular 
accumulation and excitotoxicity. Additionally, impairment of glutathione 
metabolism in an oxidizing astrocytic intracellular milieu may reduce secretion of 
neuroprotective factors (such as lactate and cysteine), on which neurons rely for 
their metabolism, thus promoting their dysfunction and death.  Reduced 
intracellular ATP levels have potential detrimental effects also on its release as a 
gliotransmitter, which may impact intercellular astrocytic and neuronal 
communications.  Vpr-induced impairment of GAPDH activity could be counter-
balanced by an increased requirement of glucose from the periphery. It is also 
interesting to notice that extracellular glutamate has been shown to stimulate 
astrocytic aerobic glycolysis, hence astrocytes could potentially exploit neuronal 
released L-Glu to compensate for the impairment within the glycolytic pathway 
caused by Vpr on GAPDH (Pellerin and Magistretti, 1994). 
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To our knowledge, current in vitro and in vivo models of 
neuropathogenesis focus more on the direct effects that viral proteins (including 
Vpr) play on neurons, neglecting their fundamental dependence upon astrocytic 
metabolism (Cheng et al., 2007; Jones et al., 2007; Kitayama et al., 2008; Piller 
et al., 1996; Piller et al., 1998). Our in vitro model may be of value in studying 
events occurring during late stage HIV-1 disease and could unveil signaling 
events intimately interrelated. Nonetheless, a more complex model would also 
entail the co-culturing of neuronal cells with primary astrocytes at a near 
physiologically relevant ratio (1:10), wherein both direct and indirect effects of 
Vpr could be studied in more depth.  Additionally, the utilization of HIV-1-infected 
monocytic conditioned media or monocyte-astrocyte co-cultivation would offer a 
more relevant in vivo scenario to study the complex network of crosstalk among 
the different subpopulations. This project will continue to unveil the intricate 
mechanism of Vpr-induced effects between relevant cells within the CNS. 
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